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Abstract: BACKGROUND: Physical exercise training may form an important part of regular care for
people with cystic fibrosis. This is an update of a previously published review. OBJECTIVES: To assess
the effects of physical exercise training on exercise capacity by peak oxygen consumption, pulmonary
function by forced expiratory volume in one second, health-related quality of life and further important
patient-relevant outcomes in people with cystic fibrosis. SEARCHMETHODS: We searched the Cochrane
Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from
comprehensive electronic database searches and handsearches of relevant journals and abstract books of
conference proceedings.Date of the most recent search: 04 May 2017.We searched ongoing trials registers
(clinicaltrials.gov and the WHO ICTRP). Date of most recent search: 10 August 2017. SELECTION
CRITERIA: All randomised and quasi-randomised controlled clinical trials comparing exercise training
of any type and a minimum duration of two weeks with conventional care (no training) in people with
cystic fibrosis. DATA COLLECTION AND ANALYSIS: Two authors independently selected studies for
inclusion, assessed methodological quality and extracted data. The quality of the evidence was assessed
using the GRADE system. MAIN RESULTS: Of the 83 studies identified, 15 studies which included
487 participants, met the inclusion criteria. The numbers in each study ranged from nine up to 72
participants; two studies were in adults, seven were in children and adolescents and six studies included
all age ranges. Four studies of hospitalised participants lasted less than one month and 11 studies were
outpatient-based, lasting between two months and three years. The studies included participants with
a wide range of disease severity and employed differing levels of supervision with a mixture of types of
training. There was also wide variation in the quality of the included studies.This systematic review
shows very low- to low-quality evidence from both short- and long-term studies that in people with
cystic fibrosis aerobic or anaerobic physical exercise training (or a combination of both) has a positive
effect on aerobic exercise capacity, pulmonary function and health-related quality of life. No study
reported on mortality; two studies reported on adverse events (moderate-quality evidence); one of each
study reported on pulmonary exacerbations (low-quality evidence) and diabetic control (very low-quality
evidence). Although improvements were not consistent between studies and ranged from no effects to
clearly positive effects, the most consistent effects of the heterogeneous exercise training modalities and
durations were found for maximal aerobic exercise capacity (in four out of seven studies) with unclear
effects on forced expiratory volume in one second (in two out of 11 studies) and health-related quality of
life (in two out of seven studies). AUTHORS’ CONCLUSIONS: Evidence about the efficacy of physical
exercise training in cystic fibrosis from 15 small studies with low to moderate methodological quality is
limited. Exercise training is already part of regular outpatient care offered to most people with cystic
fibrosis, and since there is some evidence for beneficial effects on aerobic fitness and no negative side
effects exist, there is no reason to actively discourage this. The benefits from including physical exercise
training in an individual’s regular care may be influenced by the type and duration of the training
programme. High-quality randomised controlled trials are needed to comprehensively assess the benefits
of exercise programmes in people with cystic fibrosis and the relative benefits of the addition of aerobic
versus anaerobic versus a combination of both types of physical exercise training to the care of people
with cystic fibrosis.
DOI: https://doi.org/10.1002/14651858.CD002768.pub4
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-144103
Journal Article
Published Version
Originally published at:
Radtke, Thomas; Nevitt, Sarah J; Hebestreit, Helge; Kriemler, Susi (2017). Physical exercise training
for cystic fibrosis. Cochrane Database of Systematic Reviews, 11:CD002768.
DOI: https://doi.org/10.1002/14651858.CD002768.pub4
2
Cochrane Database of Systematic Reviews
Physical exercise training for cystic fibrosis (Review)
Radtke T, Nevitt SJ, Hebestreit H, Kriemler S
Radtke T, Nevitt SJ, Hebestreit H, Kriemler S.
Physical exercise training for cystic fibrosis.
Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD002768.
DOI: 10.1002/14651858.CD002768.pub4.
www.cochranelibrary.com
Physical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
32ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
38DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
88DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Aerobic training versus no physical training, Outcome 1 Change in VO2 peak during maximal
exercise (ml/min per kg BW). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 1.2. Comparison 1 Aerobic training versus no physical training, Outcome 2 Change in FEV1(% predicted). 100
Analysis 1.3. Comparison 1 Aerobic training versus no physical training, Outcome 3 Change in health-related quality of
life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 1.4. Comparison 1 Aerobic training versus no physical training, Outcome 4 Change in mean power during WAnT
(W per kg BW). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 1.5. Comparison 1 Aerobic training versus no physical training, Outcome 5 Change in strength (Newton
metres). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 1.6. Comparison 1 Aerobic training versus no physical training, Outcome 6 Change in peak work capacity during
maximal exercise (W per kg BW). . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 1.7. Comparison 1 Aerobic training versus no physical training, Outcome 7 Annual rate of change in peak work
capacity during maximal exercise over 36 month (%). . . . . . . . . . . . . . . . . . . . . 104
Analysis 1.8. Comparison 1 Aerobic training versus no physical training, Outcome 8 Change in treadmill speed (km/h). 104
Analysis 1.9. Comparison 1 Aerobic training versus no physical training, Outcome 9 Change in treadmill exercise time
(min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 1.10. Comparison 1 Aerobic training versus no physical training, Outcome 10 Change in heart rate (beats per
min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Analysis 1.11. Comparison 1 Aerobic training versus no physical training, Outcome 11 Change in oxygen saturation
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Analysis 1.12. Comparison 1 Aerobic training versus no physical training, Outcome 12 Annual rate of change in peak VE
over 36 months (L/min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Analysis 1.13. Comparison 1 Aerobic training versus no physical training, Outcome 13 Change in FVC (% predicted). 108
Analysis 1.14. Comparison 1 Aerobic training versus no physical training, Outcome 14 Change in FEF25-75 (%
predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Analysis 1.15. Comparison 1 Aerobic training versus no physical training, Outcome 15 Change in RV/TLC (%). . 110
Analysis 1.16. Comparison 1 Aerobic training versus no physical training, Outcome 16 Change in FEV1/FVC (%
predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Analysis 1.17. Comparison 1 Aerobic training versus no physical training, Outcome 17 Change in total physical activity
(counts per min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Analysis 1.18. Comparison 1 Aerobic training versus no physical training, Outcome 18 Change in moderate-to-vigorous
physical activity (hours per week). . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
iPhysical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.19. Comparison 1 Aerobic training versus no physical training, Outcome 19 Change in total physical activity
(MJ/day). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 1.20. Comparison 1 Aerobic training versus no physical training, Outcome 20 Change in body weight (kg). 113
Analysis 1.21. Comparison 1 Aerobic training versus no physical training, Outcome 21 Change in BMI (kg/m2). . 114
Analysis 1.22. Comparison 1 Aerobic training versus no physical training, Outcome 22 Change in BMI z score. . . 114
Analysis 1.23. Comparison 1 Aerobic training versus no physical training, Outcome 23 Change in fat-free mass (kg). 115
Analysis 1.24. Comparison 1 Aerobic training versus no physical training, Outcome 24 Change in body fat (%). . . 116
Analysis 1.25. Comparison 1 Aerobic training versus no physical training, Outcome 25 Annual rate of change of ideal
weight for height (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 1.26. Comparison 1 Aerobic training versus no physical training, Outcome 26 Change in triceps skinfold thickness
(mm). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 1.27. Comparison 1 Aerobic training versus no physical training, Outcome 27 Change in armmuscle circumference
(cm). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 2.1. Comparison 2 Anaerobic training versus no physical training, Outcome 1 Change in VO2 peak during
maximal exercise (ml/min per kg BW). . . . . . . . . . . . . . . . . . . . . . . . . . 118
Analysis 2.2. Comparison 2 Anaerobic training versus no physical training, Outcome 2 Change in FEV1 (% predicted). 119
Analysis 2.3. Comparison 2 Anaerobic training versus no physical training, Outcome 3 Change in HRQoL. . . . 120
Analysis 2.4. Comparison 2 Anaerobic training versus no physical training, Outcome 4 Change in HRQoL physical
function (CF questionnaire). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 2.5. Comparison 2 Anaerobic training versus no physical training, Outcome 5 Change in peak power during
WAnT (W). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 2.6. Comparison 2 Anaerobic training versus no physical training, Outcome 6 Change in mean power during
WAnT (W). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 2.7. Comparison 2 Anaerobic training versus no physical training, Outcome 7 Change in mean power during
WAnT (W per kg BW). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Analysis 2.8. Comparison 2 Anaerobic training versus no physical training, Outcome 8 Change in lower limb strength
(Newton metres). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Analysis 2.9. Comparison 2 Anaerobic training versus no physical training, Outcome 9 Change in peak work capacity
during maximal exercise (W). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Analysis 2.10. Comparison 2 Anaerobic training versus no physical training, Outcome 10 Change in peak work capacity
during maximal exercise (W per kg body weight). . . . . . . . . . . . . . . . . . . . . . 124
Analysis 2.11. Comparison 2 Anaerobic training versus no physical training, Outcome 11 Change in lactate during maximal
exercise (mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Analysis 2.12. Comparison 2 Anaerobic training versus no physical training, Outcome 12 Change in peak oxygen saturation
during maximal exercise (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Analysis 2.13. Comparison 2 Anaerobic training versus no physical training, Outcome 13 Change in FVC (% predicted). 126
Analysis 2.14. Comparison 2 Anaerobic training versus no physical training, Outcome 14 Change in RV/TLC (%). . 127
Analysis 2.15. Comparison 2 Anaerobic training versus no physical training, Outcome 15 Change in total physical activity
(counts per min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 2.16. Comparison 2 Anaerobic training versus no physical training, Outcome 16 Change in moderate to vigorous
physical activity (hours per week). . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 2.17. Comparison 2 Anaerobic training versus no physical training, Outcome 17 Change in physical activity
(MJ/day). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 2.18. Comparison 2 Anaerobic training versus no physical training, Outcome 18 Change in weight (kg). . 130
Analysis 2.19. Comparison 2 Anaerobic training versus no physical training, Outcome 19 Change in BMI (kg/m2). . 131
Analysis 2.20. Comparison 2 Anaerobic training versus no physical training, Outcome 20 Change in fat-free mass (kg). 132
Analysis 2.21. Comparison 2 Anaerobic training versus no physical training, Outcome 21 Change in body fat (%). . 133
Analysis 3.1. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 1 Change in
VO2 peak during maximal exercise (ml/min per kg BW). . . . . . . . . . . . . . . . . . . . 134
Analysis 3.2. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 2 Change in
FEV1 (% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Analysis 3.3. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 3 Annual
change in FEV1 (mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
iiPhysical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 4 Change in
subjective health perception (CFQ-R). . . . . . . . . . . . . . . . . . . . . . . . . . 136
Analysis 3.5. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 5 Change in
Quality of Life: CFQ-R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Analysis 3.6. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 6 Change in
peak power during WAnT (W per kg body weight). . . . . . . . . . . . . . . . . . . . . . 138
Analysis 3.7. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 7 Change in
mean power during WAnT (W per kg body weight). . . . . . . . . . . . . . . . . . . . . 139
Analysis 3.8. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 8 Change in
muscle strength (all limbs) (1RM test). . . . . . . . . . . . . . . . . . . . . . . . . . 140
Analysis 3.9. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 9 Change in
muscular strength - leg press (kg; 1 RM test). . . . . . . . . . . . . . . . . . . . . . . . 140
Analysis 3.10. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 10 Change
in Muscular Strength - Chest press (kg; 1 RM test). . . . . . . . . . . . . . . . . . . . . . 141
Analysis 3.11. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 11 Change
in Muscular Strength - Latpull down (kg; 1 RM test). . . . . . . . . . . . . . . . . . . . . 141
Analysis 3.12. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 12 Change
in Muscular Strength - Biceps curl (kg; RM test). . . . . . . . . . . . . . . . . . . . . . 142
Analysis 3.13. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 13 Change
in Muscular Endurance - Number of push ups. . . . . . . . . . . . . . . . . . . . . . . 142
Analysis 3.14. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 14 Change
in Muscular Endurance - Number of sit ups. . . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 3.15. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 15 Change
in Muscular Endurance - Flexibility (cm). . . . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 3.16. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 16 Change
in Muscular Endurance - hand grip strength (kg). . . . . . . . . . . . . . . . . . . . . . 144
Analysis 3.17. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 17 Change
in peak work capacity during maximal exercise (W per kg BW). . . . . . . . . . . . . . . . . 145
Analysis 3.18. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 18 Change
in functional exercise capacity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Analysis 3.19. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 19 Change
in peak heart rate during 6MWT (beats/min). . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 3.20. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 20 Annual
change in peak heart rate (beat/min). . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Analysis 3.21. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 21 Annual
change in VE (L/min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Analysis 3.22. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 22 Change
in peak ventilation (VE) during maximal exercise. . . . . . . . . . . . . . . . . . . . . . 148
Analysis 3.23. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 23 Annual
change in lactate (mmol/l). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Analysis 3.24. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 24 Change
in RR during 6MWT (breaths/min). . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Analysis 3.25. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 25 Annual
change in RR (breaths/min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Analysis 3.26. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 26 Annual
change in RER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Analysis 3.27. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 27 Change
in oxygen saturation (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Analysis 3.28. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 28 Change
in Borg breathlessness score. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
Analysis 3.29. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 29 Annual
change in Borg breathlessness score. . . . . . . . . . . . . . . . . . . . . . . . . . . 151
iiiPhysical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.30. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 30 Change
in Borg fatigue score. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Analysis 3.31. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 31 Annual
change in Borg muscle effort. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Analysis 3.32. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 32 Change
in FVC (% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
Analysis 3.33. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 33 Annual
change in FVC (mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 3.34. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 34 Change
in RV/TLC (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 3.35. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 35 Change
in Total Energy Expenditure (k/cal). . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Analysis 3.36. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 36 Change
in the Number of Steps. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Analysis 3.37. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 37 Change
in Physical Activity (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 3.38. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 38 Change
in vigorous physical activity (hours per week). . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 3.39. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 39 Change
in body weight (kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Analysis 3.40. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 40 Change
in BMI (kg/m2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Analysis 3.41. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 41 Change
in sum of four skinfolds (mm). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Analysis 3.42. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 42 Change
in body fat (%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Analysis 3.43. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 43 Change
in fat-mass (kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Analysis 3.44. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 44 Change
in fat-free mass (kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Analysis 3.45. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 45 Change
in metabolic parameters (HbA1c (%)). . . . . . . . . . . . . . . . . . . . . . . . . . 162
Analysis 3.46. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 46 Change
in metabolic parameters (Glucose AUC). . . . . . . . . . . . . . . . . . . . . . . . . 162
Analysis 3.47. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 47 Change
in metabolic parameters (Total Insulin AUC). . . . . . . . . . . . . . . . . . . . . . . . 163
Analysis 3.48. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 48 Change
in metabolic parameters (Insulin Sensitivity Index). . . . . . . . . . . . . . . . . . . . . . 163
Analysis 3.49. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 49 Change
in Plasma Glucose (mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
Analysis 3.50. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome 50 Change
in Plasma Insulin (µU/mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
165ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
171WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
171HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
174CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
174DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
175SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
175DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
176INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ivPhysical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Physical exercise training for cystic fibrosis
Thomas Radtke1, Sarah J Nevitt2, Helge Hebestreit3, Susi Kriemler1
1Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 2Department of Biostatistics, Uni-
versity of Liverpool, Liverpool, UK. 3Paediatric Departement, Julius-Maximilians University, Würzburg, Germany
Contact address: Thomas Radtke, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84,
Zurich, 8001, Switzerland. thomas.radtke@uzh.ch.
Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.
Publication status and date: Edited (no change to conclusions), published in Issue 11, 2017.
Citation: Radtke T, Nevitt SJ, Hebestreit H, Kriemler S. Physical exercise training for cystic fibrosis. Cochrane Database of Systematic
Reviews 2017, Issue 11. Art. No.: CD002768. DOI: 10.1002/14651858.CD002768.pub4.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Physical exercise training may form an important part of regular care for people with cystic fibrosis. This is an update of a previously
published review.
Objectives
To assess the effects of physical exercise training on exercise capacity by peak oxygen consumption, pulmonary function by forced
expiratory volume in one second, health-related quality of life and further important patient-relevant outcomes in people with cystic
fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from
comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Date of the most recent search: 04 May 2017.
We searched ongoing trials registers (clinicaltrials.gov and the WHO ICTRP). Date of most recent search: 10 August 2017.
Selection criteria
All randomised and quasi-randomised controlled clinical trials comparing exercise training of any type and a minimum duration of
two weeks with conventional care (no training) in people with cystic fibrosis.
Data collection and analysis
Two authors independently selected studies for inclusion, assessedmethodological quality and extracted data. The quality of the evidence
was assessed using the GRADE system.
Main results
Of the 83 studies identified, 15 studies which included 487 participants, met the inclusion criteria. The numbers in each study ranged
from nine up to 72 participants; two studies were in adults, seven were in children and adolescents and six studies included all age
ranges. Four studies of hospitalised participants lasted less than one month and 11 studies were outpatient-based, lasting between
two months and three years. The studies included participants with a wide range of disease severity and employed differing levels of
supervision with a mixture of types of training. There was also wide variation in the quality of the included studies.
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This systematic review shows very low- to low-quality evidence from both short- and long-term studies that in people with cystic
fibrosis aerobic or anaerobic physical exercise training (or a combination of both) has a positive effect on aerobic exercise capacity,
pulmonary function and health-related quality of life. No study reported onmortality; two studies reported on adverse events (moderate-
quality evidence); one of each study reported on pulmonary exacerbations (low-quality evidence) and diabetic control (very low-quality
evidence). Although improvements were not consistent between studies and ranged from no effects to clearly positive effects, the most
consistent effects of the heterogeneous exercise training modalities and durations were found for maximal aerobic exercise capacity (in
four out of seven studies) with unclear effects on forced expiratory volume in one second (in two out of 11 studies) and health-related
quality of life (in two out of seven studies).
Authors’ conclusions
Evidence about the efficacy of physical exercise training in cystic fibrosis from 15 small studies with low to moderate methodological
quality is limited. Exercise training is already part of regular outpatient care offered to most people with cystic fibrosis, and since there
is some evidence for beneficial effects on aerobic fitness and no negative side effects exist, there is no reason to actively discourage
this. The benefits from including physical exercise training in an individual’s regular care may be influenced by the type and duration
of the training programme. High-quality randomised controlled trials are needed to comprehensively assess the benefits of exercise
programmes in people with cystic fibrosis and the relative benefits of the addition of aerobic versus anaerobic versus a combination of
both types of physical exercise training to the care of people with cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y
Physical training to improve exercise capacity in people with cystic fibrosis
Review question
We reviewed the evidence about whether physical exercise training improves low aerobic fitness, improves health-related quality of life
and slows the decline in lung function in people with cystic fibrosis (CF). This is an update of a previously published review.
Background
CF affects many systems in the body, but mainly the lungs. It causes shortness of breath and limits the amount of exercise people with
the condition can tolerate. The progress of lung disease leads to a low ability to exercise and physical inactivity, which in turn affects
health and health-related quality of life.We looked for studies where people with CF of any age did aerobic training (continuous activity
at a low to moderate intensity, such as jogging, cycling, swimming or walking) or anaerobic training (weight or resistance training or
sprinting at a high intensity for a short duration) or a combination of both compared to no training.
Search date
The evidence is current to: 04 May 2017.
Study characteristics
This review includes 15 studies with a total of 487 people with CF; the numbers in each study ranged from just nine people up to 72
people in the largest study. Two studies were in adults, seven were in children and adolescents and six studies included all age ranges.
Four studies lasted less than one month and took place while the participants were in hospital; 11 studies were outpatient-based and
lasted from two months up to three years. The studies included people with a wide range of severity of CF lung disease. There were
differing levels of supervision in the studies and a mixture of types of training.
The outcome most often reported in the studies was the change in lung function; other commonly reported outcomes included peak
oxygen consumption, health-related quality of life, change in muscle strength and change in body composition (e.g. muscle and fat).
Key results
Due to different study designs (type of exercise training, duration, etc.), we could not combine results from different studies. The short-
term studies did not show differences between treatments. The longer studies showed that physical exercise training can improve aerobic
capacity, there were some improvements in lung function and health-related quality of life, but these were not consistent across all
studies. No study reported the number of deaths; two studies reported on side effects; one study reported on pulmonary exacerbations
and another on diabetic control.
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Quality of the evidence
We included a number of small studies and thought the quality of these studies was moderate at best (only for side effects). Overall,
there was only low- to very low-quality evidence that aerobic or anaerobic physical exercise training (or a combination of both) has
a positive effect on aerobic exercise capacity, pulmonary function and health-related quality of life in people with CF. In four of the
studies the participant characteristics at the start of the studies were different between groups, despite being put into the different
treatment groups at random. It is not possible for people not to know which treatment group they are in when comparing exercise
training to no exercise. However, we do not think the fact that people knew which treatment they were receiving would affect the
results for lung function as long as the assessments were done properly. In contrast, there may be bias when the people assessing an
individual’s cardiopulmonary fitness are not blinded to which group the volunteer is in. In less than half of the included studies, the
investigators tried to prevent the outcome assessors from knowing which groups the participants were in; and in only one study was
the lead researcher blinded. The studies did not routinely measure health-related quality of life and where it was measured, different
measurement tools were used. Selective reporting of results maybe an issue, especially as most of the included studies were not listed
in trial registries, which give advance details of the outcomes being measured. We are uncertain about the effects and further better
quality studies will likely change these findings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Aerobic training compared with no physical training for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: Outpat ients
Intervention: Aerobic training
Comparison: No physical training
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No physical training Aerobic training
Exer-
cise capacity: change
in VO2 peak during max-
imal exercise (mL/ min
per kg body weight)
Follow-up: f rom hospi-
tal discharge up to 3
years
Short-term improvements in exercise toler-
ance during aerobic training were signif icant ly
greater than with no physical training at hos-
pital discharge and 1 month af ter hospital
discharge
One study showed no dif ference between
groups at 3 months and 1 study showed a
signif icant improvement in exercise tolerance
following aerobic training at 6 months com-
pared to no physical training
No signif icant longer-term dif ferences be-
tween groups were observed
NA 170
(4 studies)
⊕©©©
very low1,2,3
Pulmonary function:
change in FEV1 (% pre-
dicted)
Follow-up: f rom hospi-
tal discharge up to 3
years
There were no short-term dif ferences between
groups at hospital discharge or one month
af ter hospital discharge
Two studies showed a signif icant improve-
ment in pulmonary funct ion during and fol-
lowing aerobic training at 3 months, 6 months
and 18 months post-training compared to no
physical training
However, 1 study showed no signif icant dif -
NA 187
(5 studies)
⊕⊕©©
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f erences in annual change of pulmonary func-
t ion between groups were observed over 36
months
HRQoL: CFQ Quality of
Well-being Scale and
perceived ’posit ive ef -
fects.’
Follow-up: one month
af ter hospital discharge
up to three years
No signif icant dif f erences between the
groups were shown according to the CFQ
A signif icant improvement in HRQoL accord-
ing to the Quality of Well-being Scale was
observed in the aerobic exercise group com-
pared to the no physical training group at 1
month af ter hospital discharge, MD 0.10 (95%
CI 0.03 to 0.17)
Posit ive ef fects were reported by 43 out of
49 part icipants (not reported by treatment
group)
NA 143
(3 studies)
⊕⊕©©
low1,4
CF- related mortality
Follow-up: NA
Outcome not reported. NA
Pulmonary exacerba-
tions: number of hospi-
talisat ions and number
of days in hospital
Follow-up: up to three
years
There were no between-group dif ferences re-
ported for the mean number of hospitalisa-
t ions or mean number of days in hospital at
year 1, 2 and 3
NA 65
(1 study)
⊕⊕©©
low1,5
Diabetic control
Follow-up:NA
Outcome not reported. NA
Adverse events
Follow-up: up to two
years
One study reported that no adverse ef fects
occurred. In the other study, 1 part icipant in
the aerobic training group injured her ankle
and missed 2 days of aerobic training. One
part icipant f rom the control group developed
haemoptysis and withdrew f rom the study
NA 71
(2 studies)
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CFQ: Cyst ic Fibrosis Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; HRQoL: health-related quality of lif e;MD: mean dif ference; NA: not
applicable; VO2 peak: peak oxygen consumption.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to risk of bias: Methodological details of the studies relat ing to randomisat ion and allocat ion
concealment were unclear; one study used an inadequate method of randomisat ion and allocat ion concealment which may
have introduced bias.
2. Downgraded once due to applicability: the no physical training group of one study deteriorated more than expected, this
should be taken into account when interpret ing results.
3. Downgraded once due to applicability: in one study, the method of measuring VO2 was not validated and likely underest imates
the true VO2 peak of the study part icipants.
4. Downgraded once due to imprecision and applicability: very lim ited numerical data reported and unclear if the measures
and quest ionnaires used were validated in this populat ion.
5. Downgraded once due to imprecision: very lim ited numerical data reported.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting autosomal
recessively inherited disease in populations of Northern European
descent. The incidence of CF has been estimated as 1 in 3500
live births in the USA (CF Foundation 2009; CF Trust 2010).
The prevalence in the European countries varies widely and was
recently estimated as 0.840 per 10,000 (Farrell 2008). Although
CF is a multisystem disease, the primary cause of death is respi-
ratory failure (CF Trust 2010). Progressive respiratory disease re-
sults in an abnormal ventilatory response to exercise in CF, which
contributes to dyspnoea (shortness of breath) and is a major limit-
ing factor to exercise tolerance in this population (O’Neill 1987).
In addition, a sedentary lifestyle contributes to the progression of
physical and functional impairment in CF (Schneiderman 2014).
A consequence of this is low aerobic fitness that is associated with
reduced life expectancy (Nixon 1992).
Description of the intervention
Physical exercise training is defined as participation in a pro-
gramme of regular vigorous physical activity designed to improve
physical performance, cardiovascular function, muscle strength or
any combination of these three (Shephard 1994). There are basi-
cally two different types of physical exercise training: aerobic train-
ing or anaerobic training, but none can be considered purely ’aer-
obic’ or ’anaerobic’ with respect to energy supply. Aerobic train-
ing usually involves periods of continuous training (e.g. cycling or
running) for a length of time at a target intensity below the anaer-
obic threshold. Anaerobic training involves training (e.g. weight
or resistance training or sprinting) at a high intensity for a short
duration above the anaerobic threshold.
How the intervention might work
Physical exercise training has multiple beneficial effects. It con-
tributes to the alleviation of dyspnoea and improves exercise tol-
erance in people with CF (Cerny 2013). Physical exercise train-
ing maintains pulmonary function by improving sputum clear-
ance through a combination of hyperventilation, mechanical vi-
bration, coughing and changes in sputum rheology leading to facil-
itated and increased sputum expectoration (Dwyer 2011; Dwyer
2017; Hebestreit 2001) and possibly training of respiratory mus-
cles (Houston 2013).
Physical exercise training may also be an important part of the
management of diabetes in CF, as exercise improves glycaemic
control in type 1 diabetes mellitus by improving insulin sensitiv-
ity and reducing systemic inflammation (Galassetti 2013). Regu-
lar exercise may delay the onset of osteoporosis by preventing a
reduction in bone mineral density (Tejero García 2011). Other
postulated benefits of any physical exercise training may be de-
creased anxiety and depression, enhanced feelings of well-being
and health-related quality of life (HRQoL) (Hebestreit 2014) and
enhanced performance at work, recreational and sport activities
(ACSM 2010). It is not clear how many weeks training are re-
quired to achieve these benefits or what combination of aerobic
and anaerobic training is required. Non-adherence to prescribed
physical training may contribute to worsening signs and symp-
toms of respiratory disease, more frequent respiratory infections
and a reduced ability to perform activities of daily living and thus
ultimately have a detrimental effect on the individual’s prognosis.
Side effects of physical exercise training are extremely rare so that
exercise can be considered safe in CF (Ruf 2010).
Why it is important to do this review
This review aims to provide evidence for the inclusion of physical
exercise training in regular care for people with CF. This version of
the review is an update of previous versions (Bradley 2002; Bradley
2008; Radtke 2015a).
O B J E C T I V E S
To assess the effects of physical exercise training on exercise capac-
ity by peak oxygen consumption (VO2 peak), pulmonary function
by forced expiratory volume at one second (FEV1), HRQoL and
further important patient-relevant outcomes in people with CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT) or quasi-RCTs.
Types of participants
People with CF, of any age, and any degree of disease severity,
diagnosed on the basis of clinical criteria and sweat testing or
genotype analysis.
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Types of interventions
Any type of prescribed physical exercise training delivered to peo-
ple with CF compared to usual care. Studies which involved pure
respiratory muscle training were excluded. In a post hoc change
it was stipulated that studies must have a duration of at least two
weeks.
Types of outcome measures
Primary outcomes
1. Exercise capacity (VO2 peak reported either as L, mL per
kg body weight or fat-free mass or as per cent (%) predicted)
2. Pulmonary function (FEV1 reported either as L or %
predicted and as absolute values or change from baseline)
3. HRQoL (measured by generic or disease-specific
instruments, or both using validated instruments or patient
reports)
In a post hoc change, the fourth primary outcome ’mortality’ was
moved to secondary outcomes in line with Cochrane guidance to
limit the number of primary outcomes to three.
Secondary outcomes
1. CF-related mortality
2. Muscle strength and anaerobic exercise capacity, measured
by muscle force tests (isokinetic or non-isokinetic tests), a
Wingate Anaerobic Test (WaNT) or by a supramaximal sprint
test on a cycle ergometer measured by e.g. aerobic capacity as
power in absolute values (Watt), adjusted for body weight, fat-
mass; fat-free mass, or as % predicted), or muscle strength as kg
or Nm or anaerobic capacity as peak power, mean power and
fatigue index during a WaNT
3. Additional indices of exercise capacity (such as peak work
capacity, peak heart rate, minute ventilation, lactate and
functional capacity tests (six-and 12-minute walk tests; shuttle
tests; three-minute step test; sit-to-stand test); oxygenation;
effort and fatigue)
4. Additional indices of pulmonary function, pulmonary
diffusing capacity, ventilation inhomogeneity and respiratory
muscle strength (such as forced vital capacity, forced expiratory
flows between 25% and 75% of expirated volume, total lung
capacity, functional residual capacity, residual volume,
pulmonary diffusing capacity for carbon monoxide, pulmonary
diffusing capacity for nitric oxide, lung clearance index and
maximum inspiratory and expiratory pressures)
5. Physical activity, measured by self report (diary), validated
questionnaires or objectively with pedometers (e.g. number of
steps) or accelerometers (counts per min; time spent in different
exercise intensities, e.g. light, moderate, vigorous physical
activity)
6. Body composition, measured by weight (kg), body mass
index (kg/m² or z scores), skinfolds (mm), bioelectrical
impedance analysis or whole body air-displacement
plethysmography or dual-energy X-ray absorptiometry (e.g. fat
mass, fat-free mass in kg, % or % predicted)
7. Acute exacerbations
i) number of exacerbations
ii) time to first exacerbation
8. Antibiotic use (including oral, intravenous or inhaled
antibiotics)
9. Bone health (measured by dual X-ray energy absorptiometry
or peripheral quantitative computed tomography)
10. Diabetic control, measured by fasting blood glucose levels
(mmol/L or mg/dL), insulin levels (mmol/L or mg/dL) or
homeostasis model assessment (HOMA) or oral glucose
tolerance test (blood glucose in mmol/L or mg/dL)
11. Compliance with physical exercise training, assessed by
questionnaires, (online) diaries, or with exercise monitoring
devices such as heart rate monitors
12. Adverse events related to the exercise intervention or
exercise testing as part of intervention
Search methods for identification of studies
There are no restrictions regarding language or publication status.
Electronic searches
Relevant studies were identified from the Cystic Fibrosis and Ge-
netic Disorders Group’s Cystic Fibrosis Trials Register using the
term: exercise.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching through the abstract books of three major cystic fi-
brosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activ-
ities for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group website. Date of the most
recent search of the Group’s Cystic Fibrosis Trials Register: 04May
2017.
We searched the ongoing trials database clinicaltrials.gov (https://
clinicaltrials.gov/) using the terms: “physical activity” AND“cystic
fibrosis”. A further search was run using the terms “exercise” AND
“physical activity” AND “training” AND “cystic fibrosis”. Date of
most recent search: 01 June 2017.
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We also searched the WHO ICTRP (http://apps.who.int/
trialsearch/) using the terms: “physical activity and cystic fibrosis”.
Date of the most recent search: 09 August 2017.
Searching other resources
The reference lists of eachRCTandof review articleswere searched
for additional publications that may contain RCTs. Authors of
studies included in this review and other experts in the field were
contacted and asked for information on other published and un-
published studies.
Data collection and analysis
Selection of studies
Two authors (for the original review JB, FM; from the 2015 update
onwards SK, TR) independently assessed the titles and abstracts
of identified citations and selected the studies to be included in
the review. They excluded non-RCTs, those studies involving res-
piratory muscle training exclusively, those which did not have a
programme of exercise training and those that did not meet the
inclusion criteria, based on screening the abstracts or full text ar-
ticles. If disagreement arose on the suitability of a study for inclu-
sion in the review, the authors reached a consensus by discussion.
The authors recorded any areas of disagreement. The studies that
did not fulfil all of the inclusion criteria were excluded and their
details listed with the reason for exclusion. A third review author
solved all the discrepancies if disagreement or uncertainty of the
two authors persisted.
Data extraction and management
Each author (SK, TR) independently extracted data using stan-
dard data acquisition forms containing details about: study de-
sign (parallel versus multi-arm; single-centre versus multicentre,
participants and trial characteristics for baseline equality between
groups, details on the number of participants screened for eligibil-
ity, randomised, analysed, excluded, lost to follow up and dropped
out, method of randomisation and allocation concealment, blind-
ing of personnel and outcome assessors, use of stratification, in-
complete outcome data, selective reporting, use of intention-to-
treat analysis); the detailed intervention (aerobic training versus
no training; anaerobic training versus no training and a combina-
tion of both versus no training; duration of studies, i.e. short term
(less than one month) and long term (more than one month) and
whether the study was supervised, partially supervised or not su-
pervised); and outcome measures (continuous and dichotomous).
If disagreement arose on the quality of a study, the authors reached
a consensus by discussion. If disagreement persisted, they con-
tacted a third author. The authors recorded any areas of disagree-
ment. One author (for the original review JB, from the 2015 up-
date onwards TR) entered the data into the Cochrane software Re-
viewManager (Review Manager 2014) and a second author (from
the 2015 update onwards SK) reviewed it. The review authors
contacted the authors of the included studies in case of unclear or
missing data and information.
Assessment of risk of bias in included studies
For the original review two authors judged the methodological
quality of the review (JB, FM). From the 2015 update onwards,
two authors (SK, TR) independently assessed the risk of bias for
each included study according to the Cochrane risk of bias tool
(Higgins 2011). In particular, the authors examined details of
the randomisation method with sequence generation, allocation
concealment, degree of blinding, inclusion and exclusion criteria,
dropouts or withdrawals, intention-to-treat and detailed statisti-
cal analysis. Authors also examined for selective reporting and any
other potential sources of bias. The authors judged the risk of
bias as low, unclear or high. Unexplained dropouts or an unequal
number of dropouts across treatment groups was considered as a
potential risk of bias. Likewise, a lack of important information,
e.g. on adverse effects, missing data, statistical methods etc., was
also considered as potential risk of bias.
Measures of treatment effect
The authors have currently only been able to report continuous
outcome data and have calculated themean differences (MD)with
95% confidence intervals (CIs) where between-group differences
in themean change frombaselinewere recorded.Whendata on the
standard deviation (SD) for an individual groupwere not available,
but instead standard error (SE) of the difference was available they
used the available calculator within the Review Manager software
(Review Manager 2014). Where possible, the published standard
error of the mean (SEM) was used, or alternatively, published CIs
were taken to estimate SE. If in future updates of this review,
differentmeasurement scales are used for an outcome, e.g. different
HRQoL scales, the authors plan to analyse the data using the
standardised mean difference (SMD) with 95% CIs.
Also, if in future updates of this review, the authors are able to
present data for dichotomous outcomes, e.g. mortality or adverse
events, they plan to record the number of participants experiencing
an event and the total number of participants by group. They will
analyse the data and report the odds ratio (OR) (the odds that an
outcome will occur given a particular treatment, compared to the
odds of the outcome occurring in the absence of that treatment)
with 95% CIs.
Unit of analysis issues
The authors have not included any cross-over studies in this latest
version of the review. If future versions of this review include cross-
over studies and if data are presented in published papers from
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paired statistical analyses or if available information is available to
allow us to adjust for within-patient correlation using themethods
described by Elbourne (Elbourne 2002), we will use the generic
inverse variance method for data analysis. If appropriate data are
not presented to allow adjustment for within-patient correlation,
we will contact study investigators to request these data. If we are
unable to make the necessary adjustments, we will describe data
from cross-over studies narratively in the review.
Dealing with missing data
The review authors contacted the investigators of studies included
in this review for further study details and data and 12 inves-
tigators responded. The investigators of four studies stated that
the requested data were not available (Klijn 2004; Michel 1989;
Schneiderman-Walker 2000; Selvadurai 2002). The investigator
of a further study confirmed that the extracted data were correct
and that no further data were available (Cerny 1989). The investi-
gators of the Hebestreit study stated that they were in the process
of writing up the abstract for publication - the review authors have
now included this study in the updated review (Hebestreit 2010).
One investigator involved in the Phillips study, currently listed
under Studies awaiting classification, confirmed that the study has
been completed and the review authors updated the information
in the table (Phillips 2008). In both publications by Santana-Sosa,
the means and SEs were reported for all variables; the review au-
thors contacted the investigators for additional data (Santana-Sosa
2012; Santana-Sosa 2014). Finally, investigators of six studies pro-
vided additional raw data for this review update (Beaudoin 2017;
Hebestreit 2010; Kriemler 2013; Rovedder 2014; Santana-Sosa
2012; Santana-Sosa 2014).
Assessment of heterogeneity
Due to the low number of included studies and variability of inter-
ventions, the authors were unable to combine data for any of the
listed outcomes; however, if for future updates of this review the
authors are able to combine any data, they will measure hetero-
geneity between studies using the the Chi² test and the I² statistic
(Higgins 2003). The Chi² test measures the deviation of observed
effect sizes from the underlying overall effect. A low P value (or a
large Chi² statistic relative to its degree of freedom) provides evi-
dence of heterogeneity of intervention effects (variation in effect
estimates beyond chance). The authors will use a P value of 0.10,
rather than the conventional level of 0.05, to determine statisti-
cal significance. The I² statistic, as defined by Higgins (Higgins
2011), measures heterogeneity as a percentage where a value:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I² depends on: (i) mag-
nitude and direction of effects; and (ii) strength of evidence for
heterogeneity (e.g. P value from the Chi² test, or a CI for I²).
Assessment of reporting biases
The authors assessed relevant bias and selective reporting by com-
paring the ’Methods’ and ’Results’ sections from the included pa-
pers and trial registries, if available. They have documented this
information in the risk of bias tables and figures. If, for future
updates of the review, they are able to include and combine a suf-
ficient number of studies (n = 10), the authors will assess publica-
tion bias initially by visual inspection of a funnel plot, although
they are aware that an asymmetrical funnel plot is not necessarily
due to publication bias.
Data synthesis
The review authors used a fixed-effect model for all outcome pa-
rameters using the Review Manager software (Review Manager
2014). The authors were unable to pool studies due to the low
number of available studies, the use of different exercise types and
different study durations. For future updates, the authors will use
a random-effects model if substantial or considerable heterogene-
ity exists. The random-effects model incorporates any between-
study heterogeneity into a meta-analysis if the number of studies
is sufficient. The authors will select theMDwhen combining data
and use forest plots to compare results across studies.
Subgroup analysis and investigation of heterogeneity
If the authors are able to include a sufficient number of studies
(about n = 10) and they observe at least moderate heterogeneity
in the pooled analyses, they will undertake subgroup analyses of
children versus adults, supervised versus unsupervised training and
disease severity.
Sensitivity analysis
If the authors are able to include a sufficient number of studies (n
= 10) and in order to investigate whether heterogeneity impacted
upon the overall pooled effect estimate, the authors plan to ap-
ply random-effects modelling, and compare this with a fixed-ef-
fect model. They also plan a sensitivity analysis with and without
quasi-randomised studies and based on the quality of the studies.
The authors will exclude studies with a high risk of bias from the
analysis.
Summary of findings tables and quality of the
evidence (GRADE)
In a post hoc change in line with current Cochrane guidance, at
the 2017 update we added a summary of findings table for each
comparison presented in the review (Summary of findings for the
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main comparison; Summary of findings 2; Summary of findings
3). We selected the following seven outcomes to report (chosen
based on relevance to clinicians and consumers):
1. Exercise capacity
2. Pulmonary function
3. HRQoL
4. CF-related mortality
5. Pulmonary exacerbations
6. Diabetic control
7. Adverse events
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded evidence by
one level if they considered the limitation to be serious and by two
levels if very serious.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Please see the study flow chart for details (Figure 1). The com-
bined searches to date have identified 123 individual references
to 83 unique studies. A total of 15 studies (30 references) are in-
cluded, 51 studies (73 references) have been excluded (for further
details, see Excluded studies),13 studies (15 references) are cur-
rently awaiting assessment and four studies (five references) are
ongoing.
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Figure 1. Study flow diagram.
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Included studies
Of the 83 studies identified, 15 studies with a total of 487
participants met the inclusion criteria (Beaudoin 2017; Cerny
1989; Douglas 2015; Hebestreit 2010; Hommerding 2015; Klijn
2004; Kriemler 2013; Michel 1989; Moorcroft 2004; Rovedder
2014; Santana-Sosa 2012; Santana-Sosa 2014; Selvadurai 2002;
Schneiderman-Walker 2000; Turchetta 1991).
Trial characteristics
All included studies were of a randomised parallel group design.
The study by Beaudoin was registered as randomised cross-over
study (ClinicalTrials.gov) but results were reported as randomised
parallel group design in the final publication (Beaudoin 2017).
Thirteen studies were single-centre studies (Beaudoin 2017; Cerny
1989; Douglas 2015; Hommerding 2015; Klijn 2004; Michel
1989; Moorcroft 2004; Rovedder 2014; Santana-Sosa 2012;
Santana-Sosa 2014; Selvadurai 2002; Schneiderman-Walker
2000; Turchetta 1991) and two studies were national multicentre
studies conducted in Germany and Switzerland (Hebestreit 2010;
Kriemler 2013). The size of trials varied from a minimum number
of nine participants (Michel 1989) to a maximum of 72 partici-
pants (Schneiderman-Walker 2000). In one study the number of
participants in each group was not reported and the MD between
the treatment and control groups could not be calculated (Michel
1989).
There was wide heterogeneity in study designs with eight studies
using a supervised training approach (Cerny 1989; Douglas 2015;
Klijn 2004;Michel 1989; Santana-Sosa 2012; Santana-Sosa 2014;
Selvadurai 2002;Turchetta 1991); six studies a partially-supervised
approach (Beaudoin 2017; Hebestreit 2010; Hommerding 2015;
Kriemler 2013; Rovedder 2014; Schneiderman-Walker 2000) and
one an unsupervised training approach (Moorcroft 2004).
Four studies were of short duration (less than onemonth) andwere
carried out during hospitalisations (Cerny 1989; Michel 1989;
Selvadurai 2002; Turchetta 1991). In one study the hospital ad-
mission was for routine assessment (Turchetta 1991); in two fur-
ther studies, the hospital admission was due to an acute exacer-
bation requiring intravenous antibiotic treatment (Cerny 1989;
Selvadurai 2002); and in the fourth study, the reason for and the
duration of admission were not reported (Michel 1989). The re-
maining 11 longer-term studies (more than one month) were out-
patient-based (Hebestreit 2010; Hommerding 2015; Klijn 2004;
Kriemler 2013; Moorcroft 2004; Rovedder 2014; Santana-Sosa
2012; Santana-Sosa 2014; Schneiderman-Walker 2000). Both
Santana-Sosa studies used a two-month training period including
a one-month detraining period, during which the participants did
not engage in supervised exercise training (Santana-Sosa 2012;
Santana-Sosa 2014). Three studieswere home-based training stud-
ies lasting three months (Beaudoin 2017; Hommerding 2015;
Rovedder 2014). The Klijn study was a three-month study with a
three-month follow up (Klijn 2004). The Hebestreit and Kriem-
ler studies were both of six months duration including a six- and
18-month follow-up period (Hebestreit 2010; Kriemler 2013).
The Moorcroft study was a 12-month study (Moorcroft 2004),
the Douglas study is a 24-month intervention study (Douglas
2015) and the Schneiderman-Walker study lasted three years
(Schneiderman-Walker 2000).
Follow-up studies off training were undertaken in seven stud-
ies (Hebestreit 2010; Klijn 2004; Kriemler 2013; Michel 1989;
Santana-Sosa 2012; Santana-Sosa 2014; Selvadurai 2002).
Participants
Two studies included adults only (Beaudoin 2017; Moorcroft
2004); seven studies included children and adolescents only
(Douglas 2015; Hommerding 2015; Klijn 2004; Santana-Sosa
2012; Santana-Sosa 2014; Selvadurai 2002; Turchetta 1991)
and six studies included both adults and children (Cerny 1989;
Hebestreit 2010; Kriemler 2013; Michel 1989; Rovedder 2014;
Schneiderman-Walker 2000). Overall, the studies included par-
ticipants with a broad range of disease severity.
The vast majority of studies included participants of both sexes
(Beaudoin 2017; Douglas 2015; Hebestreit 2010; Hommerding
2015; Klijn 2004; Kriemler 2013; Moorcroft 2004; Rovedder
2014; Santana-Sosa 2012; Santana-Sosa 2014; Selvadurai 2002;
Schneiderman-Walker 2000; Turchetta 1991); however, no infor-
mation was available for two studies (Cerny 1989, Michel 1989).
Eight studies provided detailed information about the propor-
tion of male and female participants at baseline (Hebestreit 2010;
Hommerding 2015; Kriemler 2013; Rovedder 2014; Santana-
Sosa 2012; Santana-Sosa 2014; Selvadurai 2002; Turchetta 1991).
In seven of the 11 studies published as full-text articles, FEV1 %
predicted values were used as exclusion criteria (Beaudoin 2017;
Hebestreit 2010; Klijn 2004; Kriemler 2013; Santana-Sosa 2012;
Santana-Sosa 2014, Schneiderman-Walker 2000); this was also
true of the study only available from ClinicalTrials.gov (Douglas
2015). The remaining five studies published as full-text articles
did not specify disease severity based on FEV1 or other outcomes
(Cerny 1989; Hommerding 2015; Moorcroft 2004; Rovedder
2014; Selvadurai 2002), but no information was available in the
remaining two studies (Michel 1989; Turchetta 1991).
In four of the studies, the baseline characteristics of the partici-
pants were different between groups despite randomisation (Cerny
1989; Rovedder 2014; Santana-Sosa 2012; Santana-Sosa 2014).
In the Cerny study, FEV1 and FEF25−75 were significantly lower
in the control compared to the training group at admission (Cerny
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1989). In both Santana-Sosa studies, the training groups had
a lower aerobic exercise capacity (VO2 peak) and lower muscle
strength (most but not all strength measures) (Santana-Sosa 2012,
Santana-Sosa 2014). In the study byRovedder, a significantly lower
body mass index (BMI) was observed in the intervention group
compared to the control group (Rovedder 2014).
In the study byKriemler, the control group experienced anunusual
deterioration of physical health during the study and the results
should be interpreted with caution (Kriemler 2013).
Interventions
As the aim of this review was to assess the efficacy of physical ex-
ercise training, studies which involved respiratory muscle train-
ing exclusively were excluded. All 15 studies included a control
group which did not receive a prescribed exercise programme.
Two studies compared two different types of exercise training pro-
grammes (aerobic training or anaerobic training) with a control
group (Kriemler 2013; Selvadurai 2002). One study compared
anaerobic training alone to a control group (Klijn 2004). Five
studies compared aerobic training alone to a control group (Cerny
1989; Hommerding 2015; Michel 1989; Schneiderman-Walker
2000; Turchetta 1991). Five studies compared the effects of a com-
bined training programme (a mixture of aerobic and anaerobic ex-
ercise training) to a control group (Beaudoin 2017; Douglas 2015;
Moorcroft 2004; Rovedder 2014, Santana-Sosa 2012). One study
used a home-based exercise training with aerobic and strength-
ening exercises without training supervision (Rovedder 2014).
The later Santana-Sosa study compared a combined programme
(aerobic and strength) including additional inspiratory muscle
training with a control group (Santana-Sosa 2014). In a further
study, an individualised exercise programme including endurance
type or strengthening exercises or a combination of both regi-
mens was compared with a control group (Hebestreit 2010). The
Santana-Sosa and the Hebestreit studies were added to the sec-
tion combined aerobic and anaerobic training (Hebestreit 2010;
Santana-Sosa 2014).
In two studies, all participants additionally received intravenous
antibiotic treatment (Cerny 1989; Selvadurai 2002).
Outcomes
The most commonly reported outcome measure was the change
in FEV1 which was reported in all studies except one (Michel
1989). The change in VO2 peak was documented in nine stud-
ies (Beaudoin 2017; Hebestreit 2010; Hommerding 2015; Klijn
2004; Kriemler 2013; Santana-Sosa 2012; Santana-Sosa 2014;
Schneiderman-Walker 2000; Selvadurai 2002). The change in
HRQoL was also reported in nine studies (Beaudoin 2017;
Hebestreit 2010; Hommerding 2015; Klijn 2004; Kriemler
2013; Rovedder 2014; Santana-Sosa 2012; Santana-Sosa 2014;
Selvadurai 2002), the change in muscle strength was reported
in eight studies (Beaudoin 2017; Hebestreit 2010; Klijn 2004;
Kriemler 2013; Rovedder 2014; Santana-Sosa 2012; Santana-
Sosa 2014; Selvadurai 2002). The change in body composi-
tion was reported in 11 studies (Beaudoin 2017; Hebestreit
2010; Hommerding 2015; Klijn 2004; Kriemler 2013; Michel
1989; Moorcroft 2004; Santana-Sosa 2012; Santana-Sosa 2014;
Schneiderman-Walker 2000; Selvadurai 2002). The change
in physical activity was reported in six studies (Beaudoin
2017; Hebestreit 2010; Hommerding 2015; Kriemler 2013;
Schneiderman-Walker 2000; Selvadurai 2002) and the change in
other indices of exercise capacity (other than cardiopulmonary ex-
ercise testing) in four studies (Cerny 1989; Hommerding 2015;
Moorcroft 2004; Rovedder 2014). Only one study reported on
changes in diabetic control after an exercise training intervention
(Beaudoin 2017).
Excluded studies
We excluded 51 studies for the reasons which follow: 16 stud-
ies were not RCTs (Andreasson 1987; Asher 1982; Balfour
1998; Barry 2001; Bongers 2015; de Jong 1994; Edlund
1986; Heijerman 1992; NCT02277860; NCT02715921;
NCT03117764; Orenstein 1981; Petrovic 2013; Salh 1989;
Stanghelle 1998; Tuzin 1998); 24 studies did not include a physi-
cal training programme as per our protocol (Alarie 2012; Albinni
2004; Amelina 2006; Aquino 2006; Balestri 2004; Bieli 2017;
Bilton 1992; Chang 2015; Chatham 1997; Dwyer 2008; Falk
1988;Giacomodonato 2015;Haynes 2016; Irons 2012; Lannefors
1992;NCT02821130;NCT02875366;Ozaydin 2010; Patterson
2004; Rand 2012; Reix 2012; Salonini 2015; Vallier 2016;
Vivodtzev 2013); eight studies did not use a control arm with ’no
physical training’ (Calik-Kutukcu 2016; del Corral Nunez-Flores
2011; Gruet 2012; Kuys 2011; Lima 2014; Lowman 2012;
Orenstein 2004; Shaw 2016); and three studies were acute exer-
cise studies and of insufficient duration (less than 14 days) to be
included in this review (Dwyer 2017; Kriemler 2016; Wheatley
2015).
Studies awaiting classification
There
are 13 studies awaiting classification (ACTRN12617001009303;
Almajan 2011; Housinger 2015; Johnston 2004; Lorenc
2015; Mandrusiak 2011; NCT00609050; NCT00792194;
NCT02552043; NCT03100214; NCT03109912; Oliveira
2010; Phillips 2008). One author of the study informed us that
the trial has been terminated prematurely due to recruitment
problems and that no paper will be published from this study
(NCT00792194).
Trial characteristics
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Nine of the 13 studies awaiting classification were of a randomised
parallel group design (ACTRN12617001009303; Almajan 2011;
Johnston 2004; Lorenc 2015;Mandrusiak 2011; NCT00792194;
NCT02552043; NCT03100214; NCT03109912; Phillips
2008). One study was described as a modified RCT (
Housinger 2015) and one study used a cross-over design (
NCT00609050). The study by Phillips (published as abstract
only) was described as controlled, prospective clinical trial (
Phillips 2008), but is it not clear from the abstract whether
the two study groups were randomly allocated. We contacted
one author of this study, but we did not receive an an-
swer. All studies were single-centre studies and the study size
ranged from 12 to 150 participants (ACTRN12617001009303;
Almajan 2011; Housinger 2015; Johnston 2004; Lorenc
2015; Mandrusiak 2011; NCT00609050; NCT00792194;
NCT02552043; NCT03100214; NCT03109912; Oliveira
2010; Phillips 2008).
Inclusion and exclusion criteria were reported in five studies
(ACTRN12617001009303; NCT00792194; NCT02552043;
NCT03100214; NCT03109912). Six studies included children
(Almajan 2011; Johnston
2004; Mandrusiak 2011; NCT00609050; NCT02552043;
Oliveira 2010); seven studies included children, adolescents
and adults (ACTRN12617001009303; Housinger 2015; Lorenc
2015; NCT00792194; NCT03100214; NCT03109912; Phillips
2008).
Interventions
There was a great variety between studies with respect to exer-
cise training modalities and approaches. Three studies were of
a combined aerobic and anaerobic home-based exercise training
(NCT00792194; NCT03109912; NCT00609050). One study
focused on aerobic type exercises during a six-week supervised pro-
gramme followedby a 16-weekhome-based programme (Johnston
2004). Four exercise training studies were conducted with par-
ticipants hospitalised for treatment of a pulmonary exacerbation
(ACTRN12617001009303; Housinger 2015; NCT03100214;
Phillips 2008); one of these was a web-based intervention to pro-
mote physical activity participation (ACTRN12617001009303).
One study was conducted in hospital followed by a 8- to 12-week
home-based exercise training programme (Mandrusiak 2011).
One study investigated the effects of active video games dur-
ing a six-week domiciliary pulmonary rehabilitation programme
(NCT02552043) and another study investigated the feasibility
and effectiveness of TaiChi as exercise intervention (Lorenc 2015).
Two studies did not report on the type of exercises included in
their training study (Almajan 2011; Oliveira 2010).
Outcomes
Five studies reported on changes in FEV1 after exercise train-
ing (ACTRN12617001009303; Almajan 2011; NCT00609050;
NCT03100214; NCT03109912); in one of these it was a
secondary outcome (ACTRN12617001009303). Eight stud-
ies report on changes in exercise capacity measured with car-
diopulmonary exercise testing (VO2 peak) (NCT00609050;
NCT00792194) or exercise capacity measured by field exer-
cise tests such as the six-minute walk test (Housinger 2015;
NCT03100214; NCT02552043); shuttle test (NCT03109912;
Phillips 2008) or three-minute step test (Oliveira 2010). One
study did not specify the exercise test to measure aerobic
capacity (Johnston 2004). Eight studies report on changes
in HRQoL (ACTRN12617001009303; Housinger 2015;
Lorenc 2015; NCT00609050; NCT02552043; NCT03100214;
NCT03109912; Oliveira 2010) and three studies on changes
in muscle strength after exercise training (Housinger 2015;
NCT02552043; Phillips 2008). Four studies also report on
changes in physical activity (ACTRN12617001009303; Almajan
2011; Johnston 2004; NCT03109912).
Ongoing studies
Four studies are listed as ongoing (Donadio 2017; Gupta 2017;
Hebestreit 2016; NCT02700243).
Trial characteristics
All four studies are of a randomised parallel group design (Donadio
2017; Gupta 2017; Hebestreit 2016; NCT02700243) and regis-
tered with clinicaltrials.gov (https://clinicaltrials.gov/) or WHO
ICTRP (http://apps.who.int/trialsearch/). Three studies are sin-
gle-centre studies (Donadio 2017; Gupta 2017; NCT02700243)
and one study in an international, multi-centre study (Hebestreit
2016). The studies range in duration, from three months (
Donadio 2017), over one year (Gupta 2017; Hebestreit 2016) to
two years (NCT02700243). Inclusion and exclusion criteria are
specified for all studies (Donadio 2017; Gupta 2017; Hebestreit
2016; NCT02700243). All four studies include both genders and
focus on either children and adults (Donadio 2017; Hebestreit
2016), only children and adolescents (Gupta 2017) or only adults
(over 18 years) (NCT02700243). In two studies, participation
in the exercise trial is restricted to participants with an FEV1 ≥
20% predicted (Gupta 2017) and ≥ 35% predicted (Hebestreit
2016) and in one of these participants must additionally have ac-
cess to the Internet (Hebestreit 2016). The target sample size in
the studies ranges from a minimum of 30 to a maximum of 292
study participants (Donadio 2017; Gupta 2017; Hebestreit 2016;
NCT02700243).
Interventions
There is a great variety in interventions with respect to the study
designs. One study provides participants with a written manual
with instructions regarding physical activity and investigates the
effects of the programme on posture and balance (Donadio 2017).
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In the study by Gupta, study participants take part in a one-year
resistance exercise and plyometric jumping exercise training pro-
gramme to improve bone mineral density (Gupta 2017). In the
third study, participants take part in a partially supervised exercise
training intervention using step counters and online diaries as mo-
tivational elements over a period of six months; in the second part
of the study (also six months), supervision by exercise experts is
withdrawn (Hebestreit 2016). The remaining study aims to eval-
uate whether the use of a fitness tracker (Fitbit®) and an exercise
prescription is associated with increased daily physical activity and
exercise tolerance in young adults with CF over a period of two
years (NCT02700243).
Outcomes
The primary outcome measures of the studies are: changes in pos-
ture (Donadio 2017); bone mineral density (Gupta 2017); FEV1,
% predicted (Hebestreit 2016) and submaximal exercise capacity
(NCT02700243). All studies included HRQoL (Donadio 2017;
Gupta 2017; Hebestreit 2016; NCT02700243) as secondary out-
come and three studies included changes in FEV1 as secondary
outcomes (Donadio 2017; Gupta 2017; NCT02700243). Several
other secondary endpoints will be considered, listed under char-
acteristics of ongoing studies.
Risk of bias in included studies
A risk of bias of each study was assessed according to the Cochrane
risk of bias tool, which categorises studies into low, high or unclear
risk of bias (Higgins 2011). The results are displayed graphically
in the figures (Figure 2; Figure 3).
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgments about each methodological quality item
presented as percentages across all included studies.
Allocation
Sequence generation
Three studies described the methods used for generation of the
randomisation sequence and were judged to have a low risk of
bias (Hommerding 2015; Rovedder 2014; Schneiderman-Walker
2000). A total of 10 studies were described as randomised, but did
not give details of themethods used; these were deemed to have an
unclear risk of bias (Beaudoin 2017; Cerny 1989; Douglas 2015;
Klijn 2004; Michel 1989; Moorcroft 2004; Santana-Sosa 2012;
Santana-Sosa 2014; Selvadurai 2002; Turchetta 1991). In two
studies, informationon the generationof the random sequencewas
provided, but the method used in the studies can potentially in-
troduce selection bias and lacks reproducibility; these were judged
as having a high risk of bias (Hebestreit 2010; Kriemler 2013).
Allocation concealment
Only four studies described how allocation was adequately con-
cealed. Two of these studies were judged to have a low risk of
bias (Klijn 2004; Selvadurai 2002). The other two studies were
judged as high risk of bias because allocation concealment is no
longer given when the investigator is aware of the number of lots
in the bag and if for one group all available lots have already been
drawn out (Hebestreit 2010; Kriemler 2013). A total of 11 studies
did not give any details of the method of allocation concealment
(Beaudoin 2017; Cerny 1989;Douglas 2015;Hommerding 2015;
Michel 1989; Moorcroft 2004; Rovedder 2014; Santana-Sosa
2012; Santana-Sosa 2014; Schneiderman-Walker 2000; Turchetta
1991).
Blinding
None of the studies was obviously blinded for group assignment,
as it is impossible to blind exercise training compared to no exercise
training.
Blinding of participants and personnel (performance bias)
In two of the 13 included studies, one researcher of the study team
was blinded to the participants group allocation (Rovedder 2014;
Klijn 2004).Klijn reported that the primary researcherwas blinded
to group allocation, but their role in the study is not clear (Klijn
2004). In the Rovedder study , one researcher was blinded for
randomisation, the intervention and was responsible for database
entries (Rovedder 2014). We judged all included studies to have
an unclear risk of bias.
Blinding of outcome assessment (detection bias)
In five of 15 studies, outcome assessors were blinded to group
allocation (Kriemler 2013; Rovedder 2014; Santana-Sosa 2012;
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Santana-Sosa 2014; Schneiderman-Walker 2000). These studies
were deemed to have a low risk of bias. It is unclear whether
outcome measures were assessed by blinded investigators in nine
of the studies (Beaudoin 2017; Cerny 1989; Douglas 2015;
Hebestreit 2010; Hommerding 2015; Michel 1989; Moorcroft
2004; Selvadurai 2002; Turchetta 1991) and one study reported
that the primary researcher was blinded but is is not clear whether
this person was responsible for outcome assessment (Klijn 2004).
Incomplete outcome data
We evaluated risk of bias for incomplete outcome data with respect
to:
1. the use of an intention-to-treat analysis including
appropriate methods for imputing data;
2. the dropout rate (balanced or unbalanced between groups)
including a description of reasons for dropouts; and
3. the differentiation of the dropout rate between short-term
(less than one month) and long-term studies (over one month).
Information about dropouts was provided in 12 studies (Beaudoin
2017; Cerny 1989; Hebestreit 2010; Hommerding 2015; Klijn
2004; Kriemler 2013; Moorcroft 2004; Rovedder 2014; Santana-
Sosa 2012; Santana-Sosa 2014; Schneiderman-Walker 2000;
Selvadurai 2002). Three studies were published only in abstract
form and did not give any details about dropouts (Douglas 2015;
Michel 1989; Turchetta 1991).
Six studies were rated as having a low risk of bias for incom-
plete outcome data (Cerny 1989;Hommerding 2015; Klijn 2004;
Kriemler 2013; Rovedder 2014, Selvadurai 2002). Two short-term
studies (Cerny 1989; Selvadurai 2002) and one long-term study
(Hommerding 2015) reported no dropouts. In three long-term
studies the dropout rate was balanced among groups and reasons
for dropout were clearly reported (Klijn 2004; Kriemler 2013,
Rovedder 2014). Additionally, Rovedder used multiple imputa-
tion to account formissingdata in the statistical analysis (Rovedder
2014).
Three long-term studies were rated as having a high risk of bias
(Beaudoin 2017; Santana-Sosa 2012; Santana-Sosa 2014). In two
studies, dropout rates were high and not balanced between groups.
The use of intention-to-treat was reported in both studies, while
in one study the last value carried forward method was applied
(Santana-Sosa 2012); in the second study, the method used for
data imputation was not reported (Santana-Sosa 2014). In the
study by Beaudoin, the dropout rate (post-randomisation) was
18% (n = 3) and the group allocation of two study participants
was not reported (Beaudoin 2017). This study was registered as
randomised cross-over study (ClinicalTrials.gov), but the results
were only reported for the first phase and the original publication
described it as a parallel design study (Beaudoin 2017).
The remaining studies were rated as having an unclear risk of bias
for incomplete outcome data (Douglas 2015; Hebestreit 2010;
Michel 1989; Moorcroft 2004; Schneiderman-Walker 2000;
Turchetta 1991). Three of these studies were published only in ab-
stract form and did not give any details about dropouts (Douglas
2015; Michel 1989; Turchetta 1991). In one long-term study,
dropouts were reported and balanced between groups, but rea-
sons for dropouts were not described and intention-to-treat was
not used (Hebestreit 2010). One study reported the reasons for
participants dropping out and that an intention-to-treat analysis
produced similar results for pulmonary function outcomes; how-
ever, data were only reported for 65 participants excluding drop-
outs (Schneiderman-Walker 2000). Another study reported the
use of an intention-to-treat analysis, but missing data were treated
by omission rather than imputation and reasons for dropout were
not clearly described (Moorcroft 2004).
Selective reporting
We judged seven studies to have a low risk of bias since they
reported all outcomes detailed in the ’Methods’ sections for
all time points in the ’Results’ section (Cerny 1989; Kriemler
2013; Moorcroft 2004, Rovedder 2014; Santana-Sosa 2012;
Santana-Sosa 2014; Schneiderman-Walker 2000). One of these
studiesmentioned in the original publication that data forHRQoL
would be addressed separately (Kriemler 2013). Data from this
study were published together with data from another study which
used similar methods (Hebestreit 2010); the combined data are
presented in a separate paper (Hebestreit 2014).
Six studies did not report all outcomes and were deemed to have
an unclear risk of bias (Hebestreit 2010;Hommerding 2015; Klijn
2004; Michel 1989; Selvadurai 2002; Turchetta 1991). Three of
these studies were in abstract format and selective reporting could
not be assessed (Douglas 2015; Michel 1989; Turchetta 1991);
even so, we would expect themost commonmeasure of lung func-
tion (FEV1) to be mentioned which it is not in one of these stud-
ies (Michel 1989). Three studies did not report all outcomes for
HRQoL (Klijn 2004; Hebestreit 2010; Hommerding 2015) and
anaerobic exercise capacity (Hebestreit 2010). Two studies did not
report all variables for cardiopulmonary exercise testing as men-
tioned in the methods section (Hommerding 2015; Selvadurai
2002).
The study by Beaudoin was judged as high risk of bias for selective
reporting, because the study was registered as randomised cross-
over study, but reported as a parallel-design study. The second
part of the study was not reported in the original publication.
Moreover, oxygen saturation and heart rate were measured during
cardiopulmonary exercise testing, but results were not reported in
the full-text publication (Beaudoin 2017).
Other potential sources of bias
Description of inclusion or exclusion criteria
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Three studies are only available in abstract format and do not state
inclusion or exclusion criteria, nor do they describe the meth-
ods of statistical analysis used which could be a source of bias
(Douglas 2015; Michel 1989; Turchetta 1991). Six studies clearly
stated inclusion and exclusion criteria which limits the potential
for bias (Beaudoin 2017; Hebestreit 2010; Hommerding 2015;
Kriemler 2013; Moorcroft 2004; Rovedder 2014; Santana-Sosa
2012; Santana-Sosa 2014; Selvadurai 2002). Three studies de-
scribed the inclusion criteria but not the exclusion criteria, which
could be a potential source of bias (Cerny 1989; Klijn 2004;
Schneiderman-Walker 2000).
Statistical analysis
A total of 11 studies clearly described the methods of statistical
analysis, thus eliminating a potential source of bias (Cerny 1989;
Hebestreit 2010; Hommerding 2015; Klijn 2004; Kriemler 2013;
Moorcroft 2004; Rovedder 2014; Santana-Sosa 2012; Santana-
Sosa 2014; Schneiderman-Walker 2000; Selvadurai 2002).
In one study, the MD between the treatment and control groups
could not be calculated, as the number of participants in each
group was not reported (Michel 1989).
In one study, information on sample size and recruitment goals
differ between the information provided on the trial registry and
the final publication (Beaudoin 2017). The study aimed to recruit
24 participants (12 in each group) but the recruitment goal was
not achieved (18 were recruited and only 17 randomised), but ac-
cording to the power calculation provided in the original publica-
tion, 18 participants (nine per group) were required for the analy-
sis. Only 14 participants actually completed the study (Beaudoin
2017).
Group characteristics
In five studies, significant between-group differences existed at
baseline despite randomisation (Cerny 1989; Kriemler 2013;
Rovedder 2014; Santana-Sosa 2012; Santana-Sosa 2014). In one
study, FEV1 and FEF25−75 were significantly lower in the con-
trol compared to the training group at admission (Cerny 1989).
In a second study, differences in exercise capacity (peak power
was higher in the strength training group compared to the con-
trol group) and in vigorous physical activity (lower in the aero-
bic training group compared to controls) were evident at baseline
(Kriemler 2013). In both Santana-Sosa studies, the training groups
had a lower aerobic exercise capacity (VO2 peak) and lower mus-
cle strength (most but not all strength measures) (Santana-Sosa
2012; Santana-Sosa 2014). In the fifth study, BMI was signifi-
cantly lower in the intervention group compared to the control
group (Rovedder 2014). It is uncertain whether these factors could
be a potential source of bias so we judged the risk to be unclear
for significant between-group differences at baseline.
In six of the 12 studies published as full-text articles, FEV1 %
predicted values were used as exclusion criteria (Beaudoin 2017;
Hebestreit 2010; Klijn 2004; Kriemler 2013; Santana-Sosa 2012;
Santana-Sosa 2014, Schneiderman-Walker 2000). We accept that
studies which exclude participants on the basis of one of our out-
comes may cause a risk of bias to the review. However, the risk of
exercise-induced adverse effects is likely to be higher in people with
severe CF lung disease and many researchers tend to exclude those
people because of this. In one study, financial support was pro-
vided to the training group participants to foster the activity plan;
this study was judged as having an unclear risk of bias (Hebestreit
2010).
Intervention
In the original publication, no information was provided on the
control intervention. We noticed discrepancies between the regis-
tered (clinicaltrials.gov) and published trial design (cross-over ver-
sus parallel-group design) (Beaudoin 2017).
Data discrepancies
Three studies were rated as having a high risk of bias (Beaudoin
2017; Santana-Sosa 2012; Santana-Sosa 2014). Two studies for
which we received some raw data from the authors were rated
as high risk of bias, due to inconsistencies between the raw
data files and the data reported in the original publications
(Santana-Sosa 2012; Santana-Sosa 2014). Furthermore, Beaudoin
reported within-group changes from baseline and not between-
group differences, as would be appropriate for a RCT (Beaudoin
2017). We calculated between-group differences using raw data
provided by the authors and our results suggest no between-group
differences for the primary endpoint. When considered alongside
the fact that the stated power calculation requiring 18 participants
to demonstrate a difference was not achieved (see above), there is
a high risk of bias that the reported effects are not sound.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings - Aerobic training versus no physical training; Summary
of findings 2 Summary of findings - Anaerobic training versus no
physical training; Summary of findings 3 Summary of findings -
Combined aerobic and anaerobic training versus no training
Where primary studies reported differences between groups but
did not provide adequate data (means and SD) that could be pre-
sented in the Review Manager software (Review Manager 2014),
the information from the primary (original) study has been in-
cluded in the results. It was not possible to pool data for any out-
comes due to variations in the type and duration of studies, the
times at which outcomes were measured, the different methods of
reporting outcomes, the omission of data relating to either mean
change from baseline for each group and the SD or SE.
We present the effects of the interventions according to train-
ing modalities, i.e. aerobic training, anaerobic training and com-
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bined aerobic and anaerobic training, these are further differen-
tiated by length of training. There are four short-term (less than
onemonth) aerobic studies (Cerny 1989;Michel 1989; Selvadurai
2002; Turchetta 1991); three longer-term aerobic studies rang-
ing from six months to three years (Kriemler 2013; Hommerding
2015; Schneiderman-Walker 2000); one short-term anaerobic
study (Selvadurai 2002); two longer-term anaerobic studies rang-
ing from three (Klijn 2004) to 24 months (Kriemler 2013); and
five longer-term combined aerobic and anaerobic training studies
ranging from three to 24 months (Beaudoin 2017; Douglas 2015;
Hebestreit 2010; Moorcroft 2004, Rovedder 2014).
In the two studies by Santana-Sosa, means and SE were reported
for baseline, post-training and detraining and we were not able
to calculate the MD (Santana-Sosa 2012; Santana-Sosa 2014).
We received incomplete raw data files from the authors and due
to inconsistencies in the provided data sets, we were unable to
reproduce all data. Due to the review authors’ concerns about data
quality, both studies were excluded from the formal analysis in the
review and data are provided in two additional tables at the end
of the review (Table 1; Table 2). Two studies comparing aerobic
exercise training with no training were published as abstracts (
Michel 1989; Turchetta 1991) and no information on relevant
outcomes for this review was available.
Aerobic training versus no physical training
Five studies with 197 participants are included in this comparison
(Cerny 1989;Hommerding 2015; Kriemler 2013; Schneiderman-
Walker 2000; Selvadurai 2002). In the study by Kriemler, the
control group experienced an unusual deterioration of physical
health during the study and the results should be interpreted with
caution (Kriemler 2013).
Primary outcomes
1. Exercise capacity by VO2 peak
This outcomewas reported in four studies (n =180) (Hommerding
2015; Kriemler 2013; Schneiderman-Walker 2000; Selvadurai
2002). Results are presented in the analysis (very low-quality evi-
dence) (Analysis 1.1).
In the short-term study by Selvadurai, exercise capacity was mea-
sured by VO2 peak during a treadmill exercise test (Selvadurai
2002). Improvements in exercise tolerance during aerobic train-
ing were significantly greater than with no specific training after
hospital discharge, MD 8.53 mL/min per kg body weight (95%
CI 4.85 to 12.21). One month after hospital discharge VO2 peak
remained significantly higher in the aerobic training group com-
pared to the control group, MD 4.91 mL/min per kg body weight
(95% CI 1.13 to 8.69) (Selvadurai 2002).
Two studies reported on this outcome after three months (
Hommerding 2015; Kriemler 2013). In the study by Hommerd-
ing, exercise capacity was measured during cycle ergometry. No
between-group differences in VO2 peak (mL/min per kg body
weight) were observed after three months, MD -1.20 mL/min per
kg body weight (95% CI -7.26 to 4.86) (Hommerding 2015). In
the study by Kriemler, VO2 peak (mL/min per kg body weight)
was measured during cycle ergometry (Kriemler 2013). After three
months, a significant difference in VO2 peak between the aerobic
training group and the control group was observed, MD 9.71 mL/
min per kg body weight (95% CI 0.86 to 18.56). When com-
bined, the data from both studies showed no difference in VO2
peak between the exercise and control groups, pooled MD 2.29
(95% CI -2.71 to 7.29). Heterogeneity between these studies was
high (I² = 75%); most likely due to the unusual deterioration of
the control group.
In the Kriemler study, VO2 peak was significantly higher in the
training compared to the control group after six months, MD
18.33 mL/min per kg body weight (95% CI 8.95 to 27.71). No
differences between groups were observed at six and 18 months
off training, MD 9.51 mL/min per kg body weight (95% CI -
1.32 to 20.34) and 2.86 mL/min per kg body weight (95% CI -
9.70 to 15.42), respectively.
In the study by Schneiderman-Walker, VO2 peak was measured
during cycle ergometry (Schneiderman-Walker 2000). No signif-
icant difference between groups was found in the annual rate of
decline in VO2 peak, MD 0.05 mL/min per kg body weight (95%
CI -1.15 to 1.25) (Schneiderman-Walker 2000).
2. Pulmonary function (FEV1)
This outcome was reported in five studies (n = 197) (Cerny 1989;
Hommerding 2015; Kriemler 2013; Schneiderman-Walker 2000;
Selvadurai 2002). Results are presented in the analysis (low-quality
evidence) (Analysis 1.2).
Two short-term aerobic training studies reported on change in
FEV1 (Cerny 1989; Selvadurai 2002). In the study by Cerny,
there was no difference in the change in FEV1 % predicted (
Cerny 1989). In the study by Selvadurai there was no significant
difference between the groups in FEV1 % predicted at hospital
discharge, MD 2.03% (95% CI -2.31 to 6.37) and one month
after discharge, MD 1.53% (95% CI -2.93 to 5.99) (Selvadurai
2002).
Three long-term studies reported on changes in FEV1 after aer-
obic training compared to no exercise training (Hommerding
2015; Kriemler 2013; Schneiderman-Walker 2000). In the study
by Hommerding, no between-group differences were observed in
FEV1 % predicted after three months, MD -2.80% (95% CI -
10.69 to 5.09). In the Kriemler study, the aerobic training group
had significantly higher values for FEV1 % predicted compared to
control group after three months, MD 12.81% (95% CI 6.91 to
18.71). When combined, the data from both studies showed a sig-
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nificant increase in favour of the exercise group, pooledMD7.21%
(95% CI 2.49 to 11.94). Heterogeneity between these studies was
high (I² = 90%); most likely due to the unusual deterioration of
the control group.
Also after six months, FEV1 %predicted was higher in the exercise
compared to the control group, MD 17.17% (95% CI 8.59 to
25.75) (Kriemler 2013). At the six and 18 months off-training
period, a difference was found between the training and control
group for FEV1, MD 16.92% (95% CI 6.07 to 27.77) and MD
12.45% (95% CI 1.27 to 23.63).
Schneiderman-Walker reported on the effects of aerobic physical
training on lung function at three years (Schneiderman-Walker
2000). The control group was not significantly different from the
intervention group in annual decline in FEV1 % predicted, MD
2.01% (95% CI -0.06 to 4.08) (Schneiderman-Walker 2000).
3. Health-related quality of life
This outcome was reported in three studies (n = 143) (low-qual-
ity evidence) (Hommerding 2015; Schneiderman-Walker 2000;
Selvadurai 2002). No detailed results were presented for HRQoL
scales in the study by Hommerding (Hommerding 2015).
Hommerding assessed HRQoL with the Cystic Fibrosis Ques-
tionnaire (Hommerding 2015). No effects of physical exercise
training were found for HRQoL scales after the intervention. Sel-
vadurai assessed HRQoL using the generic ’Quality of Well-being
Scale’. Since this scale was validated in an outpatient setting, as-
sessment was undertaken on the participants’ admission to hospi-
tal and during the follow-up one month after their discharge, at
which time there was a significant difference between the groups
in favour of the intervention group for the change in HRQoL,
MD 0.10 (95%CI 0.03 to 0.17) (Selvadurai 2002) (Analysis 1.3).
Schneiderman-Walker reported on attitudes toward physical ac-
tivity and perceived feasibility of a regular aerobic exercise pro-
gramme (Schneiderman-Walker 2000). Positive effects, reported
by 43 out of 49 participants, included generally feeling better
about themselves, having more energy and less chest congestion. A
small number of participants reported no differences. Both groups
stated it would be feasible to meet aerobic exercise targets, if re-
quested to do so by doctors (Schneiderman-Walker 2000).
Secondary outcomes
1. CF-related mortality
No data were reported from any of the studies.
2. Muscle strength and anaerobic exercise capacity
This outcomewas reported in two studies (n = 71) (Kriemler 2013;
Selvadurai 2002).
In the Kriemler study, no significant differences in muscle strength
measured by a leg Wingate anaerobic test (WAnT) (change in
mean power in watt (W) per kg body weight) were observed be-
tween the study groups after three months, MD 0.28 W/kg body
weight (95%CI -0.53 to 1.09) and sixmonths,MD -0.09 (95%CI
-0.92 to 0.74) (Analysis 1.4).No significant differences in legmus-
cle strength between the training and control group were found
at the six months off-training time point, MD 0.23 W/kg body
weight (95%CI -0.65 to 1.11) and 18 months off training period,
MD 0.28 W/kg body weight (95% CI -0.72 to 1.28) (Kriemler
2013).
In the study by Selvadurai, the aerobic training group had a sig-
nificantly greater increase in lower limb muscle strength than the
control group at hospital discharge, MD 8.13 Newton metres
(Nm) (95% CI 4.49 to 11.77). This increase remained significant
one month after discharge, MD 6.13 Nm (95% CI 2.47 to 9.79)
(Selvadurai 2002) (Analysis 1.5).
3. Additional indices of exercise capacity
These outcomes were reported in five studies (n = 187) (Cerny
1989; Hommerding 2015; Kriemler 2013; Schneiderman-Walker
2000; Selvadurai 2002).
Three studies reported on peak exercise capacity (Cerny 1989;
Kriemler 2013; Schneiderman-Walker 2000). In the study by
Cerny, results were presented in figures but rawdatawere not avail-
able for this study. Cerny reported no differences between groups
in peak work capacity (Watt (W) per kg body weight) (Cerny
1989). In the Kriemler study, a significant difference between the
training and control group was observed for peak work capacity
after three months, MD 0.52 W/kg body weight (95% CI 0.17
to 0.87) and after six months, MD 0.81 W/kg body weight (95%
CI 0.52 to 1.10) (Analysis 1.6). No between-group differences
existed after the six months off-training period, MD 0.25 W/kg
body weight (95% CI -0.11 to 0.61) and 18 months off-training
period, MD 0.13 W/kg body weight (95% CI -0.46 to 0.72).
Schneiderman-Walker reported on the annual rate of decline in
peak work capacity (Schneiderman-Walker 2000); no significant
difference was found between groups, MD 0.82% (95% CI -1.91
to 3.55) (Analysis 1.7).
One study reported on treadmill speed (km/h) and treadmill ex-
ercise time (min) after three months (Hommerding 2015). In
this study, no differences between groups were found in treadmill
speed, MD -0.60 km/h (95% CI -2.03 to 0.83) or treadmill ex-
ercise time, MD -0.50 min (95% CI -2.06 to 1.06) (Analysis 1.8;
Analysis 1.9).
Three studies reported on heart rate (Cerny 1989; Hommerding
2015; Schneiderman-Walker 2000). In the study by Hommerd-
ing, no differences between groups were found for resting heart
rate, MD 7.00 beats per min (bpm) (95% CI -5.35 to 19.35) or
peak exercise heart rate, MD 4.00 bpm (95% CI -17.03 to 25.03)
after three months (Hommerding 2015). The study by Schnei-
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derman-Walker reported that there was no significant difference
in the annual rate of decline in peak heart rate between groups,
MD 1.10 bpm (95% CI -0.85 to 3.05) (Analysis 1.10). Cerny did
not present any data that we could analyse, but reported that there
was no significant difference between control and treatment arms
in change in peak heart rate or the ratio of peak heart rate to peak
load (Cerny 1989).
One study measured oxygen saturation at rest (Hommerding
2015) and two studies reported on oxygenation during exercise
(Hommerding 2015; Selvadurai 2002). In the study by Hom-
merding, no differences between the training and control groups
were found in either resting oxygen saturation, MD -0.70% (95%
CI -2.53 to 1.13) or peak oxygen saturation during maximal ex-
ercise, MD 9.60% (95% CI -5.20 to 24.40). The reasons for
the large changes in peak oxygen saturation in the control group
(about 10% change in peak oxygen saturation) are unclear to the
authors of this review. In the study by Selvadurai, the aerobic train-
ing group demonstrated less desaturation following training com-
pared to control, MD 0.62% (95% CI 0.32 to 0.92) (Analysis
1.11). These differences did not reach statistical significance in the
original study (Selvadurai 2002).
Two studies reported onminute ventilation at peak exercise (Cerny
1989; Schneiderman-Walker 2000). In the study by Schneider-
man-Walker, there was no significant difference in the annual rate
of decline in maximum minute ventilation between groups, MD
2.09 L/min (95% CI -1.60 to 5.78) (Analysis 1.12). The study by
Cerny again did not present any data we were able to analyse, but
stated that there were no differences between groups in the ratio
change of peak minute ventilation to peak load (Cerny 1989).
Finally, in the study by Hommerding breathlessness and fatigue
was measured with a 0 to 10 Borg scale. Data were presented
as medians (interquartile range) in the original publication and
could not be analysed in this review. Hommerding reported no
differences in either variable between groups after the three-month
intervention (Hommerding 2015).
4. Additional indices of pulmonary function and respiratory
muscle strength
Changes in pulmonary function in addition toFEV1 were reported
in five studies (Cerny 1989; Hommerding 2015; Kriemler 2013;
Schneiderman-Walker 2000; Selvadurai 2002). No study reported
on respiratory muscle strength.
All five studies reported on FVC % predicted (n = 187) (Cerny
1989; Hommerding 2015; Kriemler 2013; Schneiderman-Walker
2000; Selvadurai 2002). In the short-term study by Selvadurai,
there was no significant difference between the groups in change
of FVC % predicted at hospital discharge, MD 0.06% (95% CI -
2.55 to 2.67) and one month after discharge, MD -0.11% (95%
CI -2.64 to 2.42) (Selvadurai 2002) (Analysis 1.13). In the second
short-term study (by Cerny), there was no difference reported in
the change in FVC % predicted among groups (Cerny 1989). In
the longer-term study byHommerding, therewas nodifference be-
tween the study groups in FVC% predicted after the three-month
intervention, MD -1.60% (95% CI -8.22 to 5.02) (Hommerding
2015). In the Kriemler study, significant differences were observed
in the training group compared to the control group for FVC %
predicted at three and six months, MD 9.24% (95% CI 3.82 to
14.66) and MD 12.51% (95% CI 5.90 to 19.12), respectively
(Kriemler 2013). When combined, the data from both studies
showed a significant difference in FVC % predicted between the
exercise and control groups at three months, pooled MD 4.89%
(95% CI 0.69 to 9.08) (Analysis 1.13). Heterogeneity between
these studies was high (I² = 84%); most likely due to the unusual
deterioration of the control group. Further, differences between
groups were found in favour for the exercise group after sixmonths
off-training, MD 15.09% (95%CI 6.01 to 24.17). No differences
between groups were observed after 18 months off-training, MD
9.10% (95% CI -0.94 to 19.14) (Kriemler 2013).
Schneiderman-Walker reported on the effects of aerobic physical
training on lung function at three years (Schneiderman-Walker
2000). The control group demonstrated a significantly greater
mean rate of annual decline in FVC % predicted than the exercise
group, MD 2.17% (95% CI 0.47 to 3.87) (Analysis 1.13).
Two longer-term studies reported on changes in FEF25−75 % pre-
dicted (Hommerding 2015; Schneiderman-Walker 2000). No be-
tween-group differences in FEF25−75 % predicted were found in
the study by Hommerding after three months, MD -9.00% (95%
CI -23.29 to 5.29) (Hommerding 2015). Schneiderman-Walker
also reported that the control group demonstrated a significantly
greater mean rate of annual decline in FEF25−75 %predicted, MD
0.80% (95% CI -2.20 to 3.80), although this was not statistically
significant (Schneiderman-Walker 2000) (Analysis 1.14).
The Kriemler study additionally reported on the ratio of residual
volume to total lung capacity (RV/TLC) in % predicted (Kriemler
2013). Compared to the control group, no differences were ob-
served for this outcome at either three,MD-3.93 (95%CI -9.53 to
1.67) or six months, MD -0.73 (95% CI -7.60 to 6.14) (Analysis
1.15). Results remained non-significant after six, MD 3.19 (95%
CI -4.02 to 10.40) and 18 months off-training, MD -1.98 (95%
CI -8.82 to 4.86).
Hommerding also reported on FEV1/FVC as % predicted (
Hommerding 2015). They found no differences in FEV1/FVC
between the training and control group after the intervention,MD
-1.40% (95% CI -8.66 to 5.86) (Hommerding 2015) (Analysis
1.16).
5. Physical activity
Physical activity was reported in three studies (n = 105) (
Hommerding 2015; Kriemler 2013, Selvadurai 2002).
Hommerding assessed physical activity levels by self-report (diary)
and reported an increase in self-reported physical activity in the
intervention compared to the control group after three months.
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However, in the original publication, data were presented asN (%)
and could not be included in our analysis (Hommerding 2015).
Kriemler measured physical activity levels using accelerometry (
Kriemler 2013). At three months, total physical activity (counts
per min) was higher in the aerobic training group compared to
the control group, MD 121.00 counts per min (95% CI 29.90 to
212.10) (Analysis 1.17). There were no differences in this outcome
at six months, MD -86.00 counts per min (95% CI -375.51 to
203.51); after six months off-training, MD -20.00 counts per min
(95% CI -309.67 to 269.67) and after 18 months off-training,
MD -13.00 counts per min (95%CI -362.46 to 336.46) (Analysis
1.17).
Kriemler also reported on moderate to vigorous physical activity
(hours per week) but found no differences between the aerobic
training group and the control group at any time point reported
during the study: at threemonths,MD -0.50 hours per week (95%
CI -2.30 to 1.30); at six months, MD -0.20 hours per week (95%
CI -2.28 to 1.88); after six months off-training, MD 0.55 hours
perweek (95%CI -1.09 to 2.19); and after 18months off-training,
MD 1.20 hours per week (95% CI -1.05 to 3.45) (Analysis 1.18).
Selvadurai measured physical activity levels with a combination of
accelerometry and activity diaries in a sub-sample of study partic-
ipants (Selvadurai 2002). No between-group differences in phys-
ical activity levels were reported at hospital discharge, MD 1.20
mega joules (MJ) per day (95% CI -0.20 to 2.60) (Analysis 1.19).
6. Body composition
Changes in body composition were reported in five studies
(n = 187) (Hommerding 2015; Kriemler 2013; Michel 1989;
Schneiderman-Walker 2000; Selvadurai 2002).
Selvadurai reported on change in weight (Selvadurai 2002). There
was no difference between groups at hospital discharge, MD -
0.23 kg (95% CI -0.59 to 0.13) and one month after discharge,
MD 0.10 kg (95% CI -0.33 to 0.53) (Analysis 1.20). Michel
also reported on weight at one-month follow up, the mean (SD)
increase in weight in the aerobic exercise group, 6.4 (4.8) lb was
greater than in the non-exercise group 3.8 (3.4) lb (Michel 1989).
These data cannot be entered into the data tables, as the number
of participants assigned to each treatment group was not reported.
We have contacted the authors for further information, but there
is none available.
In the study by Kriemler, no changes were observed in BMI after
three and six months,MD0.30 kg/m² (95%CI -0.13 to 0.73) and
MD 0.40 kg/m² (95% CI -0.00 to 0.80), respectively (Analysis
1.21). At six months off-training, BMI was significantly higher in
the training compared to the control group,MD0.50 kg/m² (95%
CI 0.01 to 0.99), but at 18 months off-training no significant
difference was observed between groups, MD 0.40 kg/m² (95%
CI -0.37 to 1.17). Hommerding reported BMI z scores and found
no differences between the training and the control group at three
months, MD 0.10 (95% CI -0.16 to 0.36) (Hommerding 2015)
(Analysis 1.22).
Selvadurai reported no difference in fat-free mass between the the
aerobic training group and the control group at hospital discharge,
MD0.01kg (95%CI -0.19 to 0.21) and onemonth after discharge
MD 0.04 kg (95% CI -0.19 to 0.27) (Selvadurai 2002) (Analysis
1.23). Kriemler also reported on fat-free mass, for which there
were no significant differences between the aerobic training and
the control groups at three months MD -0.30 kg (95% CI -1.05
to 0.45) and six months MD 0.30 kg (95% CI -0.95 to 1.55)
(Analysis 1.23). This was also the case at six and 18 months off-
training, MD 0.90 kg (95% CI -0.39 to 2.19) and MD 0.50 kg
(95% CI -0.75 to 1.75).
The change in% of body fat reported in the study by Kriemler was
higher in the training compared to the control group after three
months, MD 1.60 % (95% CI 0.36 to 2.84) (Kriemler 2013). No
between group differences were observed after six months, MD
1.40 % (95% CI -0.40 to 3.20) and at six and 18 months off-
training, MD 1.00% (95% CI -1.66 to 3.66) and MD 1.20%
(95% CI -1.64 to 4.04), respectively (Analysis 1.24).
The study by Schneiderman-Walker reported on the annual rate
of decline in % of ideal weight for height (Schneiderman-Walker
2000). There was there was no significant difference between
groups at after 36 months, MD 0.52% (95% CI -0.76 to 1.80)
(Analysis 1.25).
Hommerding measured triceps skinfold thickness and arm mus-
cle circumference (Hommerding 2015).No between-group differ-
ences were observed in either triceps skinfold thickness, MD 0.39
mm (95% CI -0.39 to 1.17) or arm muscle circumference, MD
0.16 cm (95% CI -0.05 to 0.37) (Analysis 1.26; Analysis 1.27).
Michel also reported skinfold thickness and stated that there was
a trend towards a greater increase in the sum of four skin folds in
the exercise group and mid-arm muscle circumference than the
non-exercise group (Michel 1989).
7. Acute exacerbations
One study reported on this outcome (Schneiderman-Walker
2000). There were no between-group differences reported for
the mean number of hospitalisations or mean number of days
in hospital at year one, two and three (low-quality evidence)
(Schneiderman-Walker 2000).
8. Antibiotic use
No data were reported in any of the studies.
9. Bone health
No data were reported in any of the studies.
10. Diabetic control
No data were reported in any of the studies.
11. Compliance with physical exercise training
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Two studies reported on this outcome (n = 92) (Kriemler 2013;
Schneiderman-Walker 2000).
TheKriemler study reported on training compliance for the overall
study groups, but not separately for the different training groups.
Altogether, the training groups fulfilled at least 65% of all training
sessions (i.e. two out of three sessions per week) and 80% of all
participants performed the requested three training sessions per
week (Kriemler 2013).
In the Schneiderman-Walker study, mean (SD) scores for compli-
ance with exercise were reported, where the possible scores ranged
from zero to two indicating poor, partial or full compliance, re-
spectively. These scores within the exercise group for year 1 (1.51),
year 2 (1.51) and year 3 (1.49) were not significantly different, but
theywere always higher than the scores for compliance with airway
clearance techniques. Compliance with airway clearance was not
statistically different between the groups (Schneiderman-Walker
2000).
12. Adverse events
Two studies specifically reported on adverse events (n = 71) (mod-
erate-quality evidence) (Kriemler 2013; Selvadurai 2002). The
Kriemler study reported that no adverse effects (e.g. injuries, pneu-
mothorax, asthma attacks, hypoglycaemia) occurred during the
study (Kriemler 2013). In the study by Selvadurai, one participant
in the aerobic training group injured her ankle and missed two
days of aerobic training. One participant from the control group
developed haemoptysis and withdrew from the study (Selvadurai
2002). No other study reported on adverse events.
Anaerobic training versus no physical training
Three studies with 86 participants are included in this comparison
(Klijn 2004; Kriemler 2013; Selvadurai 2002). In the study by
Kriemler, the control group experienced an unusual deterioration
of physical health during the study and the results should be in-
terpreted with caution (Kriemler 2013).
Primary outcomes
1. Exercise capacity by VO2 peak
This outcome was reported in three studies (n = 86) (Klijn 2004;
Kriemler 2013; Selvadurai 2002). Results are presented in the
analysis (low-quality evidence) (Analysis 2.1).
Selvadurai reported that anaerobic trainingwas not associatedwith
improvements in VO2 peak compared with control at hospital
discharge, MD 1.95 mL/min per kg BW (95% CI -1.61 to 5.51)
and one month after hospital discharge, MD -0.40 mL/min per kg
BW (95%CI -4.03 to 3.23). Two studies reported on this outcome
at three months (Klijn 2004; Kriemler 2013). In the study by
Klijn, the change in VO2 peak was not significantly greater in the
anaerobic training versus control group, MD 3.95 mL/min per kg
bodyweight (95%CI -2.95 to 10.85). Kriemler also reported there
was no difference in VO2 peak in the training group compared to
the control group after three months, MD 9.34 mL/min per kg
body weight (95% CI -1.31 to 19.99). When combined, the data
from both studies showed no between group differences, pooled
MD 5.54 (95% CI -0.25 to 11.34). Klijn reported no significant
changes in VO2 peak in the training group after three months off
training, while VO2 peak significantly decreased in the control
group by -1.5 (1.7) mL/min per kg body weight. No data were
available in the original paper to calculate the mean difference
(Klijn 2004). Kriemler reported significant differences in VO2
peak in the training group compared to the control group after six
months, MD 17.70 mL/min per kg body weight (95% CI 5.98 to
29.42). No significant differences between the groups was found
at six and 18 months off training, MD 11.59 mL/min per kg body
weight (95% CI -1.02 to 24.20) and MD 9.26 mL/min per kg
body weight (95% CI -4.26 to 22.78), respectively.
2. Pulmonary function by FEV1
This outcome was reported in three studies (n = 86) (Klijn 2004;
Kriemler 2013; Selvadurai 2002). Results are presented in the
analysis (Analysis 2.2).
In the study by Selvadurai, the anaerobic training group showed a
significantly greatermean increase in FEV1 %predicted at hospital
discharge, MD of 5.58% (95% CI 1.34 to 9.82) (Selvadurai
2002). This increase was maintained one month after hospital
discharge, MD 5.08% (95% CI 0.66 to 9.50). In the study by
Kriemler, significant differences in FEV1 %predicted in favour for
the anaerobic training group were seen for all study time points: at
threemonths,MD11.11%(95%CI5.16 to 17.06); at sixmonths,
MD 19.51% (95%CI 10.57 to 28.45); at six months off-training,
MD 16.09% (95% CI 4.95 to 27.23) and at 18 months off-
training, MD 17.01% (95% CI 6.27 to 27.75) (Kriemler 2013).
The Klijn study reported that there were no significant between
group differences in lung function parameters, but no data were
reported which could be entered into the analysis (Klijn 2004).
3. Health-related quality of life
This outcome was reported in two studies (n = 64) (low-quality
evidence) (Klijn 2004; Selvadurai 2002).
Selvadurai assessed HRQoL with the ’Quality ofWell-being Scale’
(Selvadurai 2002). Since this scale was previously only validated
in an outpatient setting, assessment was undertaken on the partic-
ipants’ admission to hospital and one month after their discharge.
There was no significant difference between the groups in the
change in HRQoL, MD 0.03 (95% CI -0.04 to 0.10) (Analysis
2.3).
In the Klijn study no significant difference in the HRQoL scale
physical function between the groups was found at the end of the
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anaerobic training period, MD 1.30 (95% CI -11.55 to 14.15)
(Analysis 2.4).Noother differencewas found in any otherHRQoL
domain (Klijn 2004). Klijn reported that there were significantly
higher values for the domain of physical functioning in the train-
ing group after the follow-up period (Klijn 2004). No data were
available in the paper to calculate the MD.
Secondary outcomes
1. CF-related mortality
No data were reported from any of the studies.
2. Muscle strength and anaerobic exercise capacity
These outcomes were reported in three studies (n = 86) (Klijn
2004; Kriemler 2013; Selvadurai 2002).
In two studies (n = 42), a WAnT was performed, but due to
differences in outcome measures, we are not able to combine any
data (Klijn 2004; Kriemler 2013). The Klijn study reported a
significantly greater change in peak power and mean power during
WAnT in the anaerobic training versus control group: peak power,
MD70.30W (95%CI 32.50 to 108.10) (Analysis 2.5); and mean
power, MD 43.30 W (95% CI 22.56 to 64.04) (Analysis 2.6).
Klijn reported a higher peak power andmean power in the training
groups after three months off training; however, no data were
available for analysis from the original publication. The Kriemler
study reported no significant differences in mean power among
the groups after three and six months of anaerobic training, MD
-0.63 W/kg body weight (95% CI -1.30 to 0.04) and MD 0.30
W/kg body weight (95% CI -0.34 to 0.94), respectively (Analysis
2.7). This remained the case at six and 18 months off training,
MD -0.15W/kg body weight (95% CI -0.97 to 0.67) and 0.10 kg
body weight (95% CI -0.94 to 1.14), respectively (Analysis 2.7).
In the study by Selvadurai, the anaerobic training group had a sig-
nificantly greater increase in lower limb strength than the control
group at discharge, MD 24.62 Nm (95% CI 20.73 to 28.51).
The increase remained significant between groups one month af-
ter hospital discharge, MD 19.23 Nm (95% CI 15.24 to 23.22)
(Analysis 2.8) (Selvadurai 2002).
3. Additional indices of exercise capacity
This outcome was reported in three studies (n = 86) (Klijn 2004;
Kriemler 2013; Selvadurai 2002).
In the study by Klijn, peak work capacity was significantly higher
in the anaerobic training versus control group,MD13.00W (95%
CI 4.11 to 21.89) (Analysis 2.9). In the study by Kriemler, peak
work capacity was significantly lower in the training compared
to the control group after three months, MD -0.50 W/kg body
weight (95% CI -0.84 to -0.16) (Analysis 2.10). However, in the
original study by Kriemler, no between-group difference in peak
work capacity was reported after three months training (Kriemler
2013). Our analysis showed significant between-group differences
in favour for the training group in peak work capacity after six
months of training, MD 0.31W/kg body weight (95%CI 0.01 to
0.61). However, the differences were not significant at six months
and 18 months off-training, MD 0.10 W/kg body weight (95%
CI -0.26 to 0.46) and MD, 0.00 W/kg body weight (95% CI -
0.79 to 0.79), respectively (Analysis 2.10).
Klijn also reported on lactate levels (Klijn 2004). At three months
the anaerobic training group showed significant improvements in
serum lactate levels compared to the control group, MD 3.40
mmol/L (95% CI 1.33 to 5.47) (Analysis 2.11).
One study reported on desaturation during exercise (Selvadurai
2002). The anaerobic training group demonstrated significantly
less desaturation following training compared to the control group
at hospital discharge, MD 0.33% (95%CI 0.04 to 0.62) (Analysis
2.12). These differences did not reach statistical significance in the
original study for an unknown reason (Selvadurai 2002).
4. Additional indices of pulmonary function and respiratory
muscle strength
Changes in pulmonary function measures were reported in three
studies (n = 86) (Klijn 2004; Kriemler 2013; Selvadurai 2002).
No study reported on respiratory muscle strength.
Two studies reported on FVC % predicted (Kriemler 2013;
Selvadurai 2002). In the study by Selvadurai, there was no signifi-
cant difference inFVC%predicted in the anaerobic training group
compared to control at hospital discharge, MD 0.17% (95% CI
-2.31 to 2.65) and one month after discharge, MD 0.06% (95%
CI -2.42 to 2.54) (Analysis 2.13). Kriemler reported significant
differences between the training and control group at all study
time points: at threemonths,MD 7.37% (95%CI 1.89 to 12.85);
at after six months, MD 14.05% (95% CI 7.16 to 20.94); at six
months off-training, MD 13.66% (95% CI 4.38 to 22.94) and
18 months off-training, MD 13.63% (95% CI 4.13 to 23.13)
(Kriemler 2013) (Analysis 2.13).
Kriemler also reported RV/TLC % predicted (Kriemler 2013).
The results show significant differences between the anaerobic
training and the control group at threemonths,MD -6.42% (95%
CI -10.87 to -1.97); six months, MD -14.86% (95% CI -21.36
to -8.36); six month off-training, MD -6.86% (95% CI -13.47 to
-0.25), but not at 18 months off-training, MD -4.77% (95% CI
-10.61 to 1.07) (Analysis 2.14).
In the Klijn study there were no significant differences reported
between groups in lung function parameters, but no data were
available for analysis (Klijn 2004).
5. Physical activity
This outcome was reported in three studies (n = 86) (Klijn 2004;
Kriemler 2013; Selvadurai 2002).
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One study assessed physical activity levels using accelerometry
(Kriemler 2013); a second study used a combination of accelerom-
etry and activity diary (Selvadurai 2002); and the third study used
the habitual activity estimation scale to assess physical activity lev-
els (Klijn 2004).
Kriemler observed no between-group differences in total physical
activity after three or six months of training, MD 17.00 counts
per min (95% CI -81.59 to 115.59) and MD 17.00 counts per
min (95% CI -58.95 to 92.95), respectively (Analysis 2.15). This
was also true at six months off-training, MD 10.00 counts per
min (95% CI -98.04 to 118.04) and at 18 months off-training,
MD 105.00 (95%CI -34.90 to 244.90) (Analysis 2.15) (Kriemler
2013).
Kriemler also reported on moderate to vigorous physical activity
(Kriemler 2013). No differences existed in the hours of moderate
to vigorous physical activity undertaken per week for the anaerobic
training and the control groups after three and six months, MD -
1.40 hours per week (95% CI -2.93 to 0.13) and MD 0.20 hours
per week (95% CI -1.58 to 1.98), respectively (Analysis 2.16).
No differences were observed at six months off-training, MD -
1.10 hours per week (95% CI -2.56 to 0.36) and at 18 months
off-training, MD 1.10 hours per week (95% CI -0.85 to 3.05)
(Analysis 2.16).
Selvadurai measured physical activity levels in a subgroup of 18
participants in the anaerobic training group and 16 participants
in the control group (Selvadurai 2002). No differences in physical
activity levels (MJ per day)were observed between the intervention
and control group at hospital discharge, MD 0.65 MJ per day
(95% CI -0.86 to 2.16) (Analysis 2.17).
Klijn reported no differences between the anaerobic training and
control group in habitual physical activity levels after 12 weeks
(Klijn 2004). A subgroup of participants (anaerobic n = 18; control
n = 16) who completed an activity diary and wore an activity
accelerometer showed no significant differences for between group
comparisons in habitual activity at follow-up (Klijn 2004).
6. Body composition
Outcomes related to changes in body composition were reported
in three studies (n = 86) (Klijn 2004; Kriemler 2013; Selvadurai
2002).
Selvadurai reported a significantly greater change in weight at
hospital discharge in the training group compared to the control
group, MD 1.73 kg (95% CI 1.35 to 2.11) and one month after
discharge, MD 1.65 kg (95% CI 1.24 to 2.06) (Analysis 2.18).
Kriemler reported had lower values for BMI in the control group
at all time points during the study: at three months, MD 0.50
kg/m² (95% CI 0.07 to 0.93); after six months, MD 0.70 kg/m²
(95% CI 0.27 to 1.13); after six months off-training, MD 1.10
kg/m² (95% CI 0.45 to 1.75); and after 18 months off-training,
MD 1.30 kg/m² (95% CI 0.34 to 2.26) (Analysis 2.19).
Kriemler and Selvadurai both reported fat-free mass (Kriemler
2013; Selvadurai 2002). Selvadurai reported a significant differ-
ence favouring the training group at hospital discharge, MD 1.80
kg (95% CI 1.57 to 2.03) and again one month after discharge
MD 1.71 kg (95% CI 1.46 to 1.96). Kriemler observed no sig-
nificant differences in fat-free mass between groups after three
months, MD 0.70 kg (95% CI -0.34 to 1.74). However, signifi-
cantly higher values for fat-free mass favouring the exercise group
were found after six months, MD 1.50 kg (95% CI 0.08 to 2.92);
after six months off-training, MD 2.00 kg (95% CI 0.14 to 3.86)
and after 18 months off-training, MD 3.20 kg (95% CI 1.02 to
5.38) (Analysis 2.20).
Only one study reported on body fat as a% of the whole (Kriemler
2013). Nodifferences between groups in%body fat were reported
after three and six months, MD 1.20% (95% CI -0.26 to 2.66)
and MD 0.80% (95% CI -0.85 to 2.45), respectively. This was
also true after six months off-training, MD 1.70% (95% CI -0.14
to 3.54) and 18 months off-training, MD 1.10% (95% CI -1.65
to 3.85), respectively (Analysis 2.21).
Klijn reported that there was no significant difference in change
in body composition between the groups at end of the training
period, but no data were available for analysis (Klijn 2004).
7. Acute exacerbations
No data were reported for this outcome in any of the studies.
8. Antibiotic use
No data were reported for this outcome in any of the studies.
9. Bone health
No data were reported for this outcome in any of the studies.
10. Diabetic control
No data were reported for this outcome in any of the studies.
11. Compliance with physical exercise training
Twostudies reportedoncompliance (n=42) (Klijn 2004;Kriemler
2013). In the study by Klijn, the mean (SD) attendance rate at
exercise sessions was 98.1% (4.3) with reasons for absence being
holidays or sickness (Klijn 2004).
TheKriemler study reported onoverall training compliance for the
study groups, but not separately for the different groups. Overall,
the training groups fulfilled at least 65% of all training sessions
(i.e. two out of three sessions per week) and 80% of all participants
performed the requested three training sessions per week (Kriemler
2013).
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12. Adverse events
The Kriemler study (n = 22) reported that no adverse effects (e.g.
injuries, pneumothorax, asthma attacks, hypoglycaemia) occurred
during the study (moderate-quality evidence) (Kriemler 2013).
Combined aerobic and anaerobic training versus no
training
Seven studies with 257 participants are included in this compari-
son (Beaudoin 2017; Douglas 2015; Hebestreit 2010; Moorcroft
2004; Rovedder 2014; Santana-Sosa 2012; Santana-Sosa 2014).
Additional data were provided by the authors of the two San-
tana-Sosa studies, which included 42 participants (Santana-Sosa
2012; Santana-Sosa 2014). However, due to inconsistencies be-
tween the data provided and the published results, the results for
these studies are not formally included in this review. Published
results of the two studies are summarised in the additional tables
(Table 1; Table 2). These results showed significant group x time
interactions for VO2 peak and muscle strength in the training
compared to the control group after eight weeks of training. In
one study, during a four-week detraining period, when no exer-
cise training was performed, VO2 peak decreased to pre-training
values but muscle strength was maintained (Santana-Sosa 2012).
In the second study, which combined aerobic and anaerobic train-
ing with respiratory muscle training, the improvements in VO2
peak and muscle strength were largely preserved during the four-
week detraining period (Santana-Sosa 2014). In this later study,
respiratory muscle strength (PImax ) improved in the intervention
group after eight weeks (Santana-Sosa 2014), while the earlier
study without respiratory muscle training did not show any ef-
fects on PImax (Santana-Sosa 2012). One of the studies showed a
group x time interaction effect for fat mass and fat-free mass (% of
total) (Santana-Sosa 2014). In both studies, exercise training did
not have any effect on pulmonary function or HRQoL.
The study by Beaudoin published within-group changes for the
exercise and control group from baseline to 12 weeks (Beaudoin
2017). The investigators provided uswith participant-level data al-
lowing us to calculate values for the change from baselinemeasure-
ments for all relevant outcomes by intervention group. We note
that, for this reason, the results presented in the review are differ-
ent from the results presented in the published report (Beaudoin
2017). There were several methodological inadequacies in this
study (see Characteristics of included studies for further details),
including that the study was originally designed as a cross-over
study but the authors present only the first period as if it was a
parallel study. The study also did not reach the target sample size
so is likely to be underpowered. For these reasons, we have not
combined results from the Beaudoin study with any other results
and we encourage that the results from this study should be inter-
preted with caution (Beaudoin 2017).
Primary outcomes
1. Exercise capacity by VO2 peak
These outcomes were reported in two studies (n = 52) using a
maximal cardiopulmonary exercise test on a cycle ergometer (low-
quality evidence) (Hebestreit 2010; Beaudoin 2017).
Hebestreit reported the change from baseline to the three-month
to six-month assessment period and observed significantly higher
values for VO2 peak, in the training compared to the control
group, MD 2.04 mL/min per kg body weight (95% CI 0.08 to
4.00).During the follow-up period, no differences between groups
were observed six months off-training, MD 0.70 mL/min per kg
body weight (95% CI -1.61 to 3.01), but a significantly higher
VO2 peakwas found in the training compared to the control group
after 12 to 18 months off-training, MD 3.73 mL/min per kg body
weight (95% CI 1.32 to 6.14) (Analysis 3.1) (Hebestreit 2010).
In the Beaudoin study, no between group differences were found
for VO2 peak after 12-weeks, MD -2.13 mL/min per kg body
weight (95% CI -4.93 to 0.67) (Analysis 3.1) (Beaudoin 2017).
2. Pulmonary function (FEV1)
This outcome was reported in four studies (n = 144) (low-quality
evidence) (Beaudoin 2017; Hebestreit 2010; Moorcroft 2004;
Rovedder 2014). Results on FEV1 were not reported in detail in
the original paper by Hebestreit (Hebestreit 2010).
Three studies (n = 100) reported FEV1 % predicted (Beaudoin
2017;Hebestreit 2010; Rovedder 2014). At three months, Roved-
der observed no between-group differences after three months,
MD -4.00% (95% CI -11.86 to 3.86) (Analysis 3.2). Our calcula-
tions using the data from the Beaudoin study, also showed no dif-
ferences between groups for FEV1 % predicted at this time point,
MD -0.75% (95% CI -5.62 to 4.12) (Analysis 3.2). After three
to six months, Hebestreit also reported no between-group differ-
ences in FEV1 % predicted, MD 2.00% (95% CI -5.31 to 9.31).
Hebestreit also found no differences in FEV1 % predicted at six
months and 12 to 18 months off-training, MD -1.10% (95%CI -
8.69 to 6.49) and MD 3.60 (95% CI -4.37 to 11.57), respectively
(Analysis 3.2) (Hebestreit 2010).
Moorcroft reported the annual change in FEV1 (mL) (Moorcroft
2004). This study showed no significant change in FEV1 after one
year of training compared to the control group, MD 107.00 mL
(95% CI -73.98 to 287.98) (Analysis 3.3).
3. Health-related quality of life
This outcomewas reported in three studies (n =93) (very low-qual-
ity evidence). All studies used the disease-specific questionnaire the
Cystic Fibrosis Questionnaire (CFQ) to assess HRQoL (Beaudoin
2017; Hebestreit 2010; Rovedder 2014); the Rovedder study ap-
plied an additional questionnaire (Medical Outcomes Study-36
Item Short-Form Health Survey, SF-36) (Rovedder 2014).
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In the Beaudoin study, no differences were observed in any single
HRQoL scale between the training and control group after 12
weeks (Beaudoin 2017): physical functioning, MD -0.04 (95%
CI -4.35 to 4.27); vitality, MD 0.38 (95%CI -0.78 to 1.53); emo-
tional state, MD -1.17 (95%CI -2.78 to 0.45); treatment burden,
MD -0.50 (95% CI -2.17 to 1.17); health perception, MD -0.50
(95% CI -1.93 to 0.93); social limitations, MD -1.38 (95% CI -
3.28 to 0.53); body image, MD -0.54 (-1.88 to 0.80); role limi-
tations, MD 0.54 (95% CI -1.13 to 2.21); respiratory symptoms,
MD -0.58 (95%CI -3.51 to 2.35); digestion symptoms,MD1.33
(95% CI -0.49 to 3.16) (Analysis 3.5). Effect estimates (MD and
95% CIs) are not estimable for the scales eating disturbances and
weight problems as mean (SD) change values for all participants
in the control group were zero.
In the study by Hebestreit, the HRQoL subscale of “subjective
health perception” was higher in the training compared to the
control group after three to six months, MD 9.91 (95% CI 0.89
to 18.93) (Hebestreit 2010). No differences between groups were
found six months off-training, MD -2.31 (95% CI -15.46 to
10.84), while there were significant between group differences
at 12 to 18 months off-training, MD 9.89 (95 % CI 0.64 to
19.14). No other HRQoL scales were significantly different be-
tween groups (Analysis 3.4). Results for the other HRQoL scales
were reported as non-significant for all time points in the original
paper (Hebestreit 2010).
In the study by Rovedder, no differences were found in any single
HRQoL scale between the training and control group in either the
CFQ-R or the SF-36 questionnaire after three months (Rovedder
2014). Data for each single HRQoL scale were reported for both
questionnaires in the original publication.The datawere presented
as medians (interquartile range) in the publication and could not
be analysed in the review. Data are presented in additional tables
(Table 3).
Secondary outcomes
1. CF-related mortality
No data were reported for this outcome in any of the studies.
2. Muscle strength and anaerobic exercise capacity
These outcomes were reported in the publications of two studies
(n = 55) (Beaudoin 2017; Rovedder 2014); Data on anaerobic
capacity were not reported in detail in the original paper by Hebe-
streit (n = 32), but additional data have been made available by
the study investigators (Hebestreit 2010).
Beaudoin measured muscle strength (leg press, chest press, latpull
down and biceps curl) using the 1RM test; muscle endurance was
assessed using different exercises (push-up, sit-up, flexibility and
handgrip-strength) (Beaudoin 2017). After 12 weeks, there were
no between-group differences in leg press,MD19.26 kg (95%CI -
7.33 to 45.85) (Analysis 3.9); chest press,MD3.14 (95%CI -5.64
to 11.91) (Analysis 3.10); latpull down, MD 1.95 kg (95% CI -
2.80 to 6.70) (Analysis 3.11) and biceps curl, MD -1.09 kg (95%
CI -3.20 to 1.03) (Analysis 3.12). Moreover, no between-group
differences were found for the number of push ups, MD 7.18
(95% CI -13.7 to 15.73) (Analysis 3.13); the number of sit-ups,
MD6.07 (95%CI -2.26 to 14.41) (Analysis 3.14); flexibility,MD
-1.96 cm (95% CI -15.64 to 11.71) (Analysis 3.15) and handgrip
strength, MD -5.92 kg (95% CI -18.48 to 6.63) (Analysis 3.16).
In the original study, Beaudoin reported significantly higher values
for leg press, chest press and the number of push-ups in the exercise
group after 12 weeks of training (Beaudoin 2017).
Hebestreit measured anaerobic capacity measured by a WAnT
(Hebestreit 2010). After three to six months, no differences were
observed for peak power, MD -0.44 W per kg body weight (95%
CI -0.98 to 0.10); there were also no differences between groups
found during the follow-up period at six months and 12 to 18
months off-training, MD -0.43 W per kg body weight (95% CI -
2.23 to 1.37) and MD 0.37W per kg body weight (95% CI -0.66
to 1.40), respectively (Analysis 3.6). The results reported for mean
power were also not significant between the training and control
group at three to six months, MD -0.22 W per kg body weight
(95% CI -0.58 to 0.14); six months off-training, MD -0.08 W
per kg body weight (95% CI -0.94 to 0.78) and 12 to 18 months
off-training, MD 0.17 W per kg body weight (95% CI -0.34 to
0.68) (Analysis 3.7).
Rovedder measured muscle strength of elbow flexors and knee ex-
tensors using the one repetition maximum (1RM) strength test
(Rovedder 2014). After three months, the training group had sig-
nificantly higher values compared to the control group for right
upper limb muscle strength, MD 1.00 kg (95% CI 0.15 to 1.85)
and left upper limb muscle strength, MD 1.40 kg (95% CI 0.33
to 2.47) (Analysis 3.8). A significant difference between groups
was also observed for left lower limb muscle strength, MD 1.60
kg (95% CI 0.15 to 3.05), but not for right lower limb muscle
strength, MD 1.10 kg (95% CI -0.51 to 2.71) (Analysis 3.8). In
the original paper by Rovedder, differences of left lower limbmus-
cle strength among groups did not reach statistical significance (P
value > 0.05) (Rovedder 2014).
3. Additional indices of exercise capacity
Peak work capacity
One study reported changes in peak work capacity (n = 38)
(Hebestreit 2010). This study found significantly higher values for
peak work capacity in the training compared to the control group
after three to six months, MD 0.25 W/kg body weight (95% CI
0.03 to 0.47) (Analysis 3.17). During the follow-up period, no dif-
ferences were found six months off-training, MD0.19W/kg body
weight (95% CI -0.03 to 0.41), but significantly higher values in
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favour for the exercise training group were observed between 12
and 18 months off-training, MD 0.37 W/kg body weight (95%
CI 0.15 to 0.59) (Analysis 3.17).
Functional exercise capacity
Rovedder (n = 41) assessed changes in functional exercise capac-
ity after physical training using a six-minute walk test (6MWT)
(Rovedder 2014). After three months of combined aerobic and
strength training no differences were observed in walk distance,
MD -0.80 m (95% CI -24.59 to 22.99) or the change in %
predicted walking distance, MD 1.90% (95% CI -3.01 to 6.81)
(Analysis 3.18).
Heart rate
Two studies (n = 92) reported on heart rate (Moorcroft 2004;
Rovedder 2014). Rovedder did not observe any between group
differences in peak heart rate at the end of the 6MWT, MD 4.70
bpm (95% CI -9.17 to 18.57) (Rovedder 2014) (Analysis 3.19).
Moorcroft reported on the heart rate response whichwasmeasured
at the end of an identical constant work rate of 55% of partici-
pants’ maximal workload at baseline on an incremental arm and
bicycle ergometry (Moorcroft 2004). The study showed a signifi-
cant reduction in heart rate in favour of the training group at the
pre-defined cycling intensity, MD -8.20 bpm (95% CI -15.61 to
-0.79), but not during arm ergometry, MD -1.40 bpm (95% CI
-10.20 to 7.40) (Analysis 3.20).
Ventilation
Moorcroft (n = 51) also reported the annual change in peak venti-
lation (VE) (Moorcroft 2004). There was no significant reduction
in VE in the training group compared to the control group during
during whole body cycle ergometry, MD -2.50 L/min (95% CI -
6.11 to 1.11), but a significant reduction during arm ergometry,
MD -3.30 L/min (95% CI -6.40 to -0.20) (Analysis 3.21).
Beaudoin reported VE during maximal cardiopulmonary exercise
testing (Beaudoin 2017). After 12 weeks, there were no between-
group differences in VE, MD -6.74 L/min (95% CI -17.35 to
3.87) (Analysis 3.22).
Lactate levels
Only Moorcroft (n = 51) reported on lactate levels (Moorcroft
2004). Lactate levels decreased significantly during whole body
ergometry, MD -0.83 mmol/L (95% CI -1.54 to -0.12), but not
during arm ergometry,MD -0.32mmol/L (95%CI -1.14 to 0.50)
(Analysis 3.23).
Respiratory rate and respiratory exchange ratio
Two studies (n = 92) reported on respiratory rate (Moorcroft
2004; Rovedder 2014). At three months Rovedder reported no
significant difference in respiratory rate during the 6MWT, MD
-1.00 (95% CI -5.56 to 3.56) (Analysis 3.24). Moorcroft also
reportedno significant changes in respiratory rate at one year either
for whole body bicycle ergometry, MD -0.80 (95% CI -4.90 to
3.30), or arm ergometry, MD 1.50 (95% CI -3.11 to 6.11) (
Analysis 3.25).
Only Moorcroft presented data for the annual change in respira-
tory exchange ratio (RER) (Moorcroft 2004). No significant dif-
ferences were identified for either testing modalities; whole body,
MD 0.02 (95% CI -0.02 to 0.06) and arm ergometry, MD 0.00
(95% CI -0.04 to 0.04) (Analysis 3.26).
Oxygen saturation
One study measuring oxygenation at rest and at the end of a
6MWT report on oxygen saturation by ear or finger oximetry
(n = 41) (Rovedder 2014). After the three-month intervention
no differences in resting oxygen saturations (SaO2) were found
between the exercise and control group, MD 0.90 % (95% CI -
0.15 to 1.95); or at the end of the 6MWT, MD 2.60 % (95% CI
-0.11 to 5.31) (Analysis 3.27).
Breathlessness and fatigue
Two studies reported on breathlessness and fatigue using the Borg
scales (n = 92) (Moorcroft 2004; Rovedder 2014).
Rovedder reported on breathlessness and fatigue after a three-
month intervention (Rovedder 2014). No differences between the
exercise and control groups were observed either at rest, MD 0.00
(95% CI -0.38 to 0.38) and during the 6MWT, MD -0.10 (95%
CI -1.31 to 1.11) (Analysis 3.28). Moorcroft reported on the an-
nual change in breathlessness score (Moorcroft 2004). No signif-
icant reduction was shown by the Moorcroft study data for Borg
scale scores between the training compared to the control groups
either during bicycle ergometry, MD 0.00 (95%CI -1.00 to 1.00)
or during arm ergometry, MD -0.90 (95% CI -1.90 to 0.10)
(Analysis 3.29).
Furthermore, Rovedder found no differences between groups in
Borg fatigue scale either at rest, MD 0.02 (95% CI -0.50 to 0.54)
or during the 6MWT,MD -0.60 (95%CI -1.87 to 0.67) (Analysis
3.30). Moorcroft also found no difference between the training
group compared to the control group in the change scores for
muscle fatigue during bicycle ergometry, MD -0.30 (95% CI -
1.50 to 0.90) or during arm ergometry, MD 0.30 (95% CI -0.99
to 1.59) (Analysis 3.31).
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4. Additional indices of pulmonary function and respiratory
muscle strength
This outcome was reported in four studies (n = 144) (Beaudoin
2017; Hebestreit 2010; Moorcroft 2004; Rovedder 2014);. Data
for RV/TLC were not reported in detail in the original paper by
Hebestreit, but the data were made available by the investigators
(Hebestreit 2010).
Three studies reported FVC%predicted (n = 93) (Beaudoin 2017;
Hebestreit 2010; Rovedder 2014). In the study by Beaudoin, there
were no differences in FVC % predicted between the exercise and
control group after 12weeks,MD3.29%(95%CI -4.36 to 10.94)
(Analysis 3.32); for the reasons already stated above, we have not
combined the data from this study with other studies. In the study
by Rovedder, no between-group differences were observed after
three months, MD -3.30 (95% CI -11.73 to 5.13) (Analysis 3.32)
Hebestreit, too, found no difference between training and control
group after three to six months, MD 0.50% (95% CI -4.30 to
5.30); and six months off-training, MD 2.71 (95% CI -4.37 to
9.79). However, the difference between groups was significant at
12 to 18 months off-training, MD 6.06 (95% CI 0.43 to 11.69)
(Analysis 3.32).
The study by Moorcroft showed a significant improvement in the
annual change in FVC (mL) in the training group compared to
the control group, MD 213.00 mL (95% CI 3.01 to 422.99)
(Moorcroft 2004) (Analysis 3.33).
Additionally, Hebestreit measured RV/TLC; there was no ob-
served difference between groups after three to six months, MD
-0.90% (95% CI -6.73 to 4.93), six months off-training, MD -
2.20% (95%CI -11.33 to 6.93) and 12 to 18months off-training,
MD -4.90% (95% CI -13.68 to 3.88) (Hebestreit 2010) (Analysis
3.34).
5. Physical activity
This outcome was reported in one study using accelerometry (n =
38) (Hebestreit 2010) and in another study using a combination
of a physical activity monitor (SenseWear armband) and a physical
activity questionnaire (n = 14) (Beaudoin 2017). The instrument
used by Beaudoin is available at www.ircm.qc.ca/CLINIQUE/
educoeur/Documents/questionnaire.pdf; however, the authors of
this review are not aware of any study that has validated this phys-
ical activity questionnaire in the CF population.
No differences between groups were found in total energy expen-
diture in the Beaudoin study, MD -108.92 k/cal (95%CI -360.20
to 142.37) (Analysis 3.35); the same was true for the number of
daily steps, MD -110.58 (95% CI -2260.72 to 2039.56) (Analysis
3.36). However, after 12 weeks questionnaire-assessed physical ac-
tivity was significantly higher in the training group compared to
the control group, MD 19.85 % (1.92 to 37.80) (Analysis 3.37)
(Beaudoin 2017).
In the study by Hebestreit, after three to six months, no differ-
ences were observed in vigorous physical activity (hours per week)
between the training and control group, MD 1.05 hours per week
(95% CI -0.66 to 2.76) or after six months off training, MD 2.08
(95% CI -1.84 to 6.00); however, a significant difference favour-
ing the training group was seen after 12 to 18 months off training,
MD 1.63 (95% CI 0.02 to 3.24) (Analysis 3.38).
6. Body composition
Changes in body composition were reported in three studies (n =
103) (Beaudoin 2017; Hebestreit 2010; Moorcroft 2004). Data
on body weight, BMI, body fat and fat-freemass were not reported
in detail in the original paper by Hebestreit, but were additionally
provided and analysed for this review (Hebestreit 2010).
Beaudoin reported on body weight and found no differences be-
tween groups after 12 weeks, MD -0.27 kg (95% CI -1.76 to
1.22) (Analysis 3.39) (Beaudoin 2017). Hebestreit also reported
on total body weight and found no differences between the groups
at three to six months, MD 1.10 kg (95% CI -0.42 to 2.62); after
six months off training, MD 0.20 (95% CI -2.52 to 2.92); and
after 12 to 18 months off training, MD 0.00 (95% CI -3.78 to
3.78) (Analysis 3.39) (Hebestreit 2010).
Three studies reported on the change in BMI, but none of the re-
sultswere significant (Beaudoin 2017;Hebestreit 2010;Moorcroft
2004). In the study by Beaudoin no between group differences
were found after 12 weeks, MD 0.10 kg/m² (95% CI -0.61 to
0.80) (Analysis 3.40). Hebestreit reported at three to six months,
MD 0.40 kg/m² (95% CI -0.17 to 0.97); after six months off-
training, MD 0.00 kg/m² (95% CI -0.78 to 0.78); and after 12
to 18 months off-training, MD -0.10 kg/m² (95% CI -1.12 to
0.92); Moorcroft reported the change at one year, MD 0.54 kg/
m² (95% CI -0.09 to 1.17) (Analysis 3.40).
Hebestreit additionally reported on the sum of four skin folds,
which was not significantly different between groups at three to six
months, MD -1.19 mm (95% CI -4.95 to 2.57); however, there
were significant differences favouring the control group both after
six months off-training, MD -5.68 mm (95% CI -10.83 to -0.53)
and after 12 to 18 months off-training, MD -7.10 mm (95% CI
-13.37 to -0.83) (Analysis 3.41).
Hebestreit and Beaudoin further analysed the changes in body fat
and fat-free mass (Beaudoin 2017; Hebestreit 2010). In the study
by Beaudoin, after 12 weeks significantly lower values for body fat
(%) and fatmass (kg)were found in the exercise group compared to
the control group, MD -1.21% (95% CI -2.38 to -0.05) (Analysis
3.42) and 1.09 kg (95% CI -1.80 to -0.39), respectively (Analysis
3.43); however, no difference was found between the two groups
for fat-free mass, MD -0.15 kg (95% CI -1.55 to 1.26) (Analysis
3.44) (Beaudoin 2017).
In the study by Hebestreit, there were no significant differences at
any time point in % body fat: at three to six months, MD 1.30%
(95%CI -2.35 to 4.95); after sixmonths off-training,MD-0.50%
(95% CI -4.77 to 3.77); and after 12 to 18 months off-training,
MD 2.20% (95% CI -3.90 to 8.30) (Analysis 3.42). Likewise,
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there were no differences between groups in fat-free mass: at three
to six months, MD 0.90 kg (95% CI -4.76 to 6.56); after six
months off-training, MD 0.70 kg (95%CI -2.08 to 3.48); or after
12 to 18 months off-training, MD -1.40 kg (95% CI -6.86 to
4.06) (Analysis 3.44).
7. Acute exacerbations
No data were reported for this outcome in any of the studies.
8. Antibiotic use
No data were reported for this outcome in any of the studies.
9. Bone health
No data were reported for this outcome in any of the studies.
10. Diabetic control
Only Beaudoin reported on this outcome and the investigators
have provided additional raw data from the study (Beaudoin
2017). The outcomes measured were HbA1c and the plasma glu-
cose and insulin response to a two-hour oral glucose tolerance test
before and after 12 weeks (very low-quality evidence) (Beaudoin
2017).
No differences in the change inHbA1c were observed between the
exercise and control groups, MD -0.00 % (95% CI -0.01 to 0.00)
(Analysis 3.45). In our analysis, this was also true for area under
the curve for plasma glucose, MD -5.59 (95% CI -13.51 to 2.33)
(Analysis 3.46) (in the original publication the authors reported a
significant improvement in this outcome for the training group)
and area under the curve for plasma insulin, MD -20.02 (95%
CI -52.90 to 12.85) (Analysis 3.47). However, after 12 weeks the
insulin sensitivity index was significantly higher in the exercise
compared to the control group, MD 0.02 (95% CI 0.00 to 0.04)
(Analysis 3.48).
The authors of this review further analysed data for plasma glucose
and plasma insulin at different time points during the oral glucose
tolerance test (time point 0 and 30, 60, 90 and 120 minutes after
the oral glucose load). The authors presented these data in figures
in the original publication (Beaudoin 2017).
Plasma glucose values were not different between groups at time
points 0 minutes, MD 0.44 mmol/L (95% CI -0.41 to 1.28);
60 minutes, MD -1.86 mmol/L (95% CI -4.11 to 0.40); and 90
minutes, MD -1.69 mmol/L (95% CI -5.09 to 1.71). Significant
differences in favour of the intervention group were noted for the
time points 30 minutes after ingestion of the glucose solution,
MD -1.96 mmol/L (95% CI -3.58 to -0.33) and at 120 minutes
after ingestion of the glucose solution, MD -3.24 mmol/L (95%
CI -6.41 to -0.06) (Analysis 3.49). Plasma insulin values were not
different between groups at 0minutes,MD-2.10µU/mL (95%CI
-5.46 to 1.26); at 90 minutes, MD 6.20 µU/mL (95% CI -17.05
to 29.45); and at 120 minutes, MD 2.23 µU/mL (95% CI -13.98
to 18.45). Significant differences in favour for the intervention
group were noted for the time points 30 and 60 minutes after the
ingestion of the glucose solution, MD -13.90 µU/mL (95% CI
-19.47 to -8.33) and MD -12.39 µU/mL (95% CI -22.14 to -
2.65), respectively (Analysis 3.50).
The results presented herein are different to the results reported in
the original publication by Beaudoin (Beaudoin 2017). Beaudoin
reported within-group changes for plasma glucose and plasma in-
sulin at different time points (Figure 1 A-D in the original publi-
cation) during the oral glucose tolerance test for the exercise and
control group separately (Beaudoin 2017). The results presented
herein should be interpreted with caution due to the low sample
size and high chance for type II error.
11. Compliance with physical exercise training
This outcome was reported in two studies (Beaudoin 2017;
Douglas 2015).
Beaudoin reported that over 80% (n = 8) were compliant to the
exercise programme; this information was available from the study
diary (Beaudoin 2017). Beaudoin excluded one participant from
the exercise group due to non-compliance based on self-report
and information derived from the study diary; but a definition
of “compliance” and “non-compliance” was not provided in the
original publication.
In an interim analysis of the INSPIRE-CF study, Douglas re-
ported on participation and attendance and non-attendance (%)
in the physical exercise programme (Douglas 2015). Results were
only reported for intervention group participants (n = 34) and
between-group differences can not be computed for this outcome.
Narrative results from the abstract state that overall the mean
(SD) attendance was 53.5 (23)% of 52 potential weeks in the
first 12 months. Individual attendance ranged between 0% and
92% of sessions. Boys attended more often than girls (58% ver-
sus 49%). Major reasons for non-attendance were: no member-
ship with a fitness centre in place (6.4%), family (5.8%) or trainer
holidays (6.3%) and unexplained non-attendance (4.5%). Minor
reasons were recorded as child illness (3%), hospital admissions or
clinic appointments (2.8%), public holidays (2.5%), school events
(1.9%), family events (1.7%), staff training (2.3%), with other
reasons less than 1% accounting for the remaining missed sessions
(3.5%).
12. Adverse events
No data were reported for this outcome in any of the studies.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Anaerobic training compared with no physical training for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: anaerobic training
Comparison: no physical training
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No physical training Anaerobic training
Exer-
cise capacity: change
in VO2 peak during max-
imal exercise (mL/ min
per kg BW)
Follow-up: f rom hospi-
tal discharge up to 3
years
One study showed a signif icant improvement
in exercise capacity following anaerobic train-
ing at 6 months compared to no physical
training
No signif icant dif f erences between groups
were observed at any other t ime points
NA 86
(3 studies)
⊕⊕©©
low1,2
Pulmonary function:
change in FEV1 (% pre-
dicted)
Follow-up: f rom hospi-
tal discharge up to 3
years
Two studies showed a signif icant improve-
ment in pulmonary funct ion during and follow-
ing anaerobic training at hospital discharge,
1 month af ter discharge, 3 months, 6 months
and 18 months post-training compared to no
physical training
The second study showed no signif icant dif -
ferences in lung funct ion at any t ime point
NA 86
(3 studies)
⊕⊕©©
low1,2
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HRQoL: Quality of Well-
being Scale or HRQoL
scale physical funct ion
Follow-up: up to 2 years
No signif icant dif f erences between groups
were observed according to the Quality of
Well-being Scale or HRQoL scale physical
funct ion
NA 64
(2 studies)
⊕⊕©©
low1,3
CF- related mortality
Follow-up: NA
Outcome not reported. NA
Pulmonary exacerba-
tions
Follow-up: NA
Outcome not reported. NA
Diabetic control
Follow-up: NA
Outcome not reported. NA
Adverse events
Follow-up: 2 years
One study reported that no adverse ef fects
occurred.
NA 22
(1 study)
⊕⊕⊕©
moderate1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; HRQoL: health-related quality of lif e; NA: not applicable; VO2 peak: peak oxygen consumption.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to risk of bias: methodological details of the studies relat ing to randomisat ion and allocat ion
concealment were unclear; one study used an inadequate method of randomisat ion and allocat ion concealment which may
have introduced bias.
2. Downgraded once due to applicability: the no physical training group of one study deteriorated more than expected, this
should be taken into account when interpret ing results.
3. Downgraded once due to applicability: unclear if the measures and quest ionnaires used were validated in this populat ion.
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Combined aerobic and anaerobic training compared with no physical training for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: combined aerobic and anaerobic training
Comparison: no physical training
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No physical training Combined aerobic and
anaerobic training
Exer-
cise capacity: change
in VO2 peak during max-
imal exercise (mL/ min
per kg body weight)
Follow-up: 12 weeks to
two years
A signif icant ly higher VO2 peak was found in the
combined training compared to the no physical
training group af ter 12 to 18 months in 1 study
No signif icant dif f erence between groups was
found at any other t ime point
NA 52
(2 studies)
⊕⊕©©
low1,2
Two addit ional stud-
ies recruit ing 42 part ic-
ipants showed signif i-
cant group x t ime inter-
act ions for VO2 peak;
however, these results
are not included in this
review due to concerns
over inconsistencies in
the data provided to us
by the original trial au-
thors
Pulmonary function:
change in FEV1 (% pre-
dicted) or mL
Follow-up: 12 weeks to
two years
No signif icant dif f erences in pulmonary funct ion
were observed between treatment groups at any
t ime point
NA 103
(3 studies)
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HRQoL: CFQ,
Medi-
cal Outcomes Study-36
Item Short-Form Health
Survey, SF-36
Follow-up: 12 weeks to
2 years
Two studies showed no signif icant dif f erences
in any HRQoL scale
One study showed a signif icant improvement
in subject ive health percept ion in the combined
training group af ter 3 to 6 months and af ter 12 to
18 months (but not between 6 and 12 months)
NA 93
(3 studies)
⊕©©©
very low1,2,3
CF- related mortality
Follow-up: NA
Outcome not reported. NA
Pulmonary exacerba-
tions
Follow-up: NA
Outcome not reported. NA
Diabetic control
Follow-up: 12 weeks
Signif icant dif f erences in some of the parameters
were observed in the no physical training group
compared to the combined training group and
vice versa
Also no signif icant dif f erences were observed
for some parameters
NA 14
(1 study)
⊕©©©
very low1,2,3
The study reported a
range of metabolic
parameters (HbA1c(%),
Glucose AUC, Total In-
sulin AUC, Insulin Sen-
sit ivity Index) Plasma
Glucose and Plasma In-
sulin
Adverse events
Follow-up: NA
Outcome not reported. NA
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AUC: area under the curve; CFQ: Cyst ic Fibrosis Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; HRQoL: health-related quality of lif e; NA:
not applicable; VO2 peak: peak oxygen consumption.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.3
6
P
h
y
sic
a
l
e
x
e
rc
ise
tra
in
in
g
fo
r
c
y
stic
fi
b
ro
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
1. Downgraded once due to risk of bias: methodological details of the studies relat ing to randomisat ion and allocat ion
concealment were unclear; one study used an inadequate method of randomisat ion and allocat ion concealment which may
have introduced bias.
2. Downgraded once due to risk of bias: one study had many methodological inadequacies including early term inat ion and
low stat ist ical power. These inadequacies are likely to have impacted on results.
3. Downgraded once due to imprecision: wide CIs around ef fect est imates due to small numbers of part icipants analysed.
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D I S C U S S I O N
Summary of main results
This systematic review shows limited evidence from both short-
and long-term studies that in people with CF aerobic or anaerobic
physical exercise training or a combination of both has a posi-
tive effect on exercise capacity, pulmonary function and HRQoL.
Although improvements are not consistent between studies and
ranged from no effects to clearly positive effects the most consis-
tent effects of the heterogeneous exercise training modalities and
durations were found for maximal aerobic exercise capacity mea-
sured by VO2 peak (in four out of seven studies) with unclear
effects on FEV1 (in two out of 11 studies) and HRQoL (in two
out of seven studies).
Also, the length of training required to obtain any physiological
benefits in CF cannot be defined based on this review, but it is
unlikely that training for short periods of less than one month
would achieve physiological benefit (Casaburi 1992). Lung func-
tion as measured by FEV1 was not responsive of change, except
in two studies (Kriemler 2013; Selvadurai 2002). Whether this
finding is an indication of true non-responsiveness or rather ex-
plained by poor exercise adherence, insufficient exercise training
(sub-optimal modality, insufficient frequency, intensity, duration)
or by the inappropriate methodology of the current literature (i.e.
insufficient power) has to be determined.
Overall completeness and applicability of
evidence
The improvement of VO2 peak is of clinical relevance as exercise
training addresses low exercise capacity as an important risk factor
and strong predictor of mortality in CF (Nixon 1992). In order to
have any measurable beneficial effect on exercise capacity, exercise
training should be performed for at least six weeks, with exercises
for an initially tolerable time, but progressing to at least 20 to 30
minutes of exercise at an intensity of 55% to 64% of maximum
heart rate, for three to five days a week (ACSM 2010). Although
many of the included studies were sufficient to achieve a training
effect, this condition was not always fulfilled. Yet, no data are
available on the minimal important difference of VO2 peak in CF
that would provide us with some information about the clinical
relevance of improvement in aerobic capacity.
Nevertheless, as the studies in this review recruited mixed popula-
tions with regard to age, gender, disease severity and stability, the
results have some applicability to the general CF population. Due
to the small number and heterogeneity of included studies, we
were unable to tease out effects of different length, types (aerobic
versus anaerobic versus a combination of both), level of supervi-
sion of training, and whether effects were different for subgroups
by age, gender, genetical constellation, or severity of disease.
It is possible that more sophisticated functional measures such as
pulmonary diffusing capacity andmultiple-breathwashoutmay be
more sensitive to document subtle, but clinically relevant effects of
exercise training on pulmonary function than FEV1 . Furthermore,
in the included studies, HRQoL was rarely assessed and if so,
mostly by non-validated or generic questionnaires.
Quality of the evidence
Overall, there is very low- to low-quality of evidence that aerobic
or anaerobic physical exercise training or a combination of both
has positive effects on VO2 peak, FEV1 and HRQoL. We are
uncertain about the estimates and further research will very likely
have an important impact on our confidence in the estimate of
effect and is likely to change the estimate.
It should be highlighted that considerable caution is indicated
when interpreting the results of this review. The training modal-
ities and durations were heterogenous, sometimes of very short
duration and combined with additional treatments such as in-
tensive physiotherapy, nutritional rehabilitation and intravenous
antibiotic treatment in the short-term in-hospital studies (Cerny
1989; Selvadurai 2002). Further, most studies showed consider-
able methodological shortcomings based on the Cochrane risk of
bias tool that was used (Higgins 2011); this may also reflect the
inappropriate methodology of the current literature (i.e. insuffi-
cient power) in general. All studies had small sample sizes, which
puts them at risk of imprecision and lack of power which can work
in two ways, i.e. under- or overestimation of intervention effects
(Ellis 2010).This phenomenon can at least in part be explained
by a publication bias, as small studies are unlikely be published if
they present negative results (Hopewell 2009).
A lack of effectiveness does not necessarily mean that the treat-
ment was ineffective; especially in longer-term studies, poor ad-
herence to training, which requires precise monitoring, could be
a reason for lack of treatment effects. Although standard outcome
measures were used in the included studies to assess efficacy of
physical exercise training, estimates for the minimal clinically im-
portant differences of these outcome measures were not available.
Although the effect sizes for some of the outcome measures in
this review were statistically significant, the clinical significance of
these results remains open to interpretation.
Potential biases in the review process
There are some potential biases in the review process that need
to be addressed. One important issue is participant selection bias
which limits external validity. In 64% of the included full-text arti-
cles (where inclusion and exclusion criteria were reported) partic-
ipants were excluded based on disease severity expressed by FEV1,
which is one of our primary outcome measures. We acknowledge
that study investigators are ethically bound to keep potential exer-
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cise-induced adverse reactions at a minimum; however, this limits
the generalisability of findings to people with mild to moderate
CF lung disease and may not be representative to the overall pop-
ulation of people with CF. We have chosen FEV1 and VO2 peak
as primary outcomes measures because both are clinically relevant
and predictive for mortality in people with CF.Moreover, HRQoL
was chosen as important patient-reported outcome.Overall, FEV1
was measured in all and VO2 peak and HRQoL in about half of
the included studies, but results were mostly inconclusive. De-
spite extensive searches it is theoretically possible that we failed to
identify studies. However, since the field of researchers publishing
on physical exercise training in CF is relatively small and close-
knit, we are quite confident that we did not miss any potentially
relevant study. In summary, this review includes a limited number
of mostly small studies with low to moderate quality and predom-
inantly unclear risk of bias.
Agreements and disagreements with other
studies or reviews
To the best of the authors’ knowledge, there are no other published
systematic reviews on physical exercise training in people with CF.
Due to the lownumber of included studies and the inability to pool
study results in this review update, the overall conclusions have
not substantially changed compared to the previously published
versions of this Cochrane physical training review despite a larger
number of included studies (Bradley 2002; Bradley 2008; Radtke
2015a).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Conclusions about the efficacy of physical exercise training in cys-
tic fibrosis (CF) are limited by the small size, duration and in-
complete reporting of most of the studies included in this review.
However, there is limited evidence that physical exercise training
is beneficial.
The benefits obtained from including physical exercise training
in a package of care may be influenced by the type of training
programme and the inclusion of aerobic and anaerobic training.
Physical exercise training is already part of the regular care offered
to most people with CF and there is no evidence to actively dis-
courage this.
In conclusion, the limited number of available studies with low
to moderate quality does not allow us to make firm conclusions
about the efficacy of physical exercise training on peak oxygen
consumption (VO2 peak), forced expiratory volume in one sec-
ond (FEV1) and health-related quality of life (HRQoL) (primary
outcomes) and other (secondary) outcomes.
Implications for research
Further research is needed to comprehensively assess the benefits
of exercise programmes in people with CF and the relative benefits
of the addition of aerobic versus anaerobic versus a combination
of both types of physical training to the care of people with CF.
There is a need for high-quality randomised controlled studies
with sufficient numbers of study participants and well-chosen, ob-
jectively measurable, reproducible and sensitive primary outcome
measures. Physical exercise training components (type, intensity,
duration, and frequency) should be sufficient to elicit beneficial
adaptations and should be clearly reported and monitored. There
is a lack of studies investigating the effects of physical exercise
training on important and clinically relevant outcomes such as
bone health, diabetic control and exacerbations, which could be
a focus of future work. Investigators should also consider adher-
ence to the training regimens. Moreover, the use of more sophisti-
cated diagnostic techniques such as multiple-breath washout and
the measurement of pulmonary diffusing capacity during exercise
may improve our understanding about the effects of physical ex-
ercise training on pulmonary function in CF. For all outcomes,
meaningful and patient-relevant changes of the outcomes need to
be determined.
To draw firm conclusions, larger high-quality studies are clearly
needed to assess whether exercise training is safe, effective andwell-
tolerated by people with CF. While exercise training appears to be
safe in CF (Ruf 2010), safety measures should be implemented
in exercise training studies and include the documentation of any
(exercise-related) adverse events, pulmonary function, exacerba-
tions and oxygen saturation. Other important outcomes which
should be used to measure effectiveness are improved (functional)
exercise capacity and HRQoL.
The optimal training components (e.g. type, frequency, intensity,
duration) need to be determined in the future by large high-qual-
ity studies. Study investigators should carefully select the number
and type of study endpoints as a high number of outcomes requir-
ing time-consuming assessments may decrease participants’ com-
pliance and on the other hand increase the risk of false-positive
results by chance. Besides selecting the clinically relevant and par-
ticipant-oriented outcomes, testing of the interrelationship of the
outcome measures would ascertain whether, for instance, changes
in HRQoL correlate with changes in exercise capacity (Hebestreit
2014).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beaudoin 2017
Methods Design: single-centre, open-label, parallel RCT (the record on clinicaltrials.gov states
cross-over design, but this is not evident from published paper)
Inclusion criteria: participantswithCF; age > 18 years; sedentary (less than100min/week
of structured exercise assessed by physical activity questionnaire and phone interview;
FEV1 > 40 % predicted; clinically stable for the last 6 weeks; IGT; CFRD without
pharmacological treatment or elevated 1-h plasma glucose concentration during an oral
glucose tolerance test (indeterminate 1-h glucose concentration of > 11.0 but 2-h plasma
glucose concentration < 7.8 mmol/L−1).
Exclusion criteria: current pulmonary exacerbation; use of oral or intravenous corticos-
teroids; low SaO2 during exercise; history of haemoptysis in the last 6 weeks
Participants 14 participants with CF.
Group demographics
Exercise group (n = 8): mean (range) age 31.9 (24; 41) years
Control groups (n = 6): mean (range) age 35.5 (22; 57) years
Interventions 12-week combined aerobic and resistance training study.
Exercise group: aerobic and resistance training exercises 3x per week for about 20 -
40 minutes with a day off between the training sessions (in total 36 training sessions).
Exercise intensity and volume were progressively increased. Participants recorded their
training sessions in a diary.Once every 4weeks, participants received a supervised training
session and a phone call on a weekly basis
• Aerobic training consisted of walking, jogging, cycling and elliptic trainer.
Training intensity progressively increased throughout the study, starting at 60% of
VO2 peak during the first 4 weeks. Thereafter, intensity was increased to 70% (week 5
- 8) and 80% (week 9 - 12) of VO2 peak.
• Resistance training consisted of 5 - 7 exercises for large muscle groups using the
own body weight, free weights and elastic bands (goal 8 - 12 repetitions with a weight
of 30% - 50% of one repetition maximum). Exercise intensity and volume were
progressively increased.
Control group: no information was reported in the original publication. Detailed infor-
mation on control intervention is available on clinicaltrials.gov
Outcomes Included in this study were: pulmonary function (FVC, FEV1); metabolic parameters
(HbA1c, plasma glucose area under the curve, insulin sensitivity index, plasma insulin
area under the curve (0 - 120 min); exercise capacity measured by a cycle cardiopul-
monary exercise test (VO2 peak and VE at VO2 peak); muscle strength (leg press, chest
press, latpull down, biceps curl) and endurance (push-up, sit-up, flexibility, handgrip
strength); body composition (bodyweight, BMI, body fat and fat-free mass); HRQoL
and objectively measured physical activity (steps per days; energy expenditure) and as-
sessed by questionnaire
Further, inflammatory markers were measured in this study (e.g., IL-1; IL-6; IL-8; YKL-
40 and CRP-hs) but inflammatory biomarkers are not outcomes relevant for this review
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Beaudoin 2017 (Continued)
Notes Study registration:
The studywas registered as cross-over trial (Clinicaltrials.govNCT02127957) but results
were reported as parallel-design study. The authors confirmed that they had to stop the
study due to recruitment problems. The authors presented only results from the first
study phase (12 weeks)
Information provided on clinicaltrials.gov
“Intervention Model: Crossover Assignment”
“Following the visit #6, patients in the control group will be invited to participate in a
second study phase to participate in supervised exercise program. This participation will
involve an additional 12 weeks of follow-up, which included the same visit as Group
1 with exercises. In this case, to simplify participation and reduce the volume of blood
collected, the final visit (#5) of the project will also be the first visit of exercises phase.
This part of study, involves 2 supervised training sessions and 8 follow up phone call.
The exercises program will be performed three times per week for about one hour.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned open-label study with
two parallel arms. Randomisation was con-
ducted in blocks by gender with a ratio of
2:2. No details given for generation of se-
quence
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to inter-
vention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk At screening,1 participant could not be ran-
domized due to an adverse event during
cardiopulmonary exercise testing
There were 3 dropouts post-randomisa-
tion (18%).
• 2 participants dropped out due to a
pulmonary exacerbation; group allocation
for these 2 participants was not reported.
• 1 patient was excluded due to non-
compliance with the exercise program, but
the criteria for the decision of “non-
compliance” were not reported in the
publication.
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Beaudoin 2017 (Continued)
The study was registered as crossover study
but results for the second study part were
not presented
Selective reporting (reporting bias) High risk Heart rate and SaO2 were measured dur-
ing cardiopulmonary exercise testing, but
results were not reported. The second study
phase was not reported in the original pub-
lication
Other bias High risk Sample size
Information on sample size and recruit-
ment goals differ between the information
provided under Clinicaltrials.gov and the
final publication. This study aimed to re-
cruit 24 participants (12 exercise group,
12 control group), see Clinicaltrials.gov,
NCT02127957. The recruitment goal was
not achieved (N = 18 were recruited but
only 17 randomised ), but no information
was provided in the final paper. According
to the power calculation provided in the
original publication, 18 participants (9 per
group) were required for the analysis. Fi-
nally, 14 participants completed the study
so the study is likely to be underpowered
Statistical analyses
The authors reported pre-post within-
group changes and no between-group dif-
ferences as would be appropriate for a RCT.
We received raw data from the authors
and calculated between-group differences
for plasma glucose and plasma insulin val-
ues during the oral glucose tolerance test.
Our results differ compared to the results
reported in the original publication. The
initial power analysis, aiming to demon-
strate a difference of 1.5 mmol/L in plasma
glucose levels 120 minutes after ingestion
of the glucose solution after exercise train-
ing required a study sample of 18 partici-
pants (9 per group). Finally, only 14 par-
ticipants completed the study that reduces
the statistical power to observe a difference
between the interventions in the study
Control intervention
In the original publication, no informa-
tion was provided on the control inter-
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vention. We noticed discrepancies between
the registered (clinicaltrials.gov) and pub-
lished trial design (cross-over versus paral-
lel-group design)
Cerny 1989
Methods Design: single-centre, parallel RCT during hospital admission for acute exacerbation
Inclusion criteria: participants with CF who were admitted to the hospital for treatment
of an acute exacerbation. Those who were able to perform a pulmonary function test
and provided written informed consent (assumed patient or parental depending on age)
were included
Exclusion criteria: not described.
Participants 17 participants with CF.
Group demographics
Exercise group (n = 9): mean (SD) age 15.4 (4.9) years.
Bronchial hygiene group (n = 8): mean (SD) age 15.9 (4.9) years
Interventions Short-term aerobic study.
Group 1: 2 cycle ergometer sessions and 1 bronchial hygiene session per day during
admission: mean (SD) 13 (3) days
Group 2: 3 bronchial hygiene sessions per day during admission: mean (SD) 13 days (2.
6 days)
Outcomes Included in this study were: pulmonary function (FVC, ERV, IC, FEV1, FEF25−75 ,RV,
FRC, TLC, Raw, SGAW, SaO2, and PFS); exercise performance during cycle ergometry
with load increased by 0.3 W/kg every 2 minutes until participant could continue no
longer (SaO2, peak load, EMG activity, peak HR, peak VE to peak load ratio, peak HR
to peak load ratio); cough (15 min post treatment session); sputum (wet and dry weight,
volume)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no details of
the method.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no dropouts.
Selective reporting (reporting bias) Low risk All outcomes detailed in methods were re-
ported in results. Data reported for all time
points
Other bias Unclear risk Stated the inclusion criteria but not the ex-
clusion criteria
Pulmonary function values FEV1 and
FEF25−75 were significantly lower in the
control compared to the training group at
admission
Clearly described statistical analysis meth-
ods.
Douglas 2015
Methods Design: single-centre RCT (INSPIRE-CF) in the UK; duration 24 months. Powered
to show changes in primary outcome measure of FEV1 z score after 24 months (66
participants needed).
Inclusion criteria: not described in abstract.
Exclusion criteria: not described in abstract.
Participants Recruited 71 participants with CF; age 6 to 15.5 years; mean (SD) FEV1 89 (16) %
predicted.
Group demographics
Intervention group (n = 37).
Control group (n = 34).
67 children completed the study.
Interventions Intervention group: standard specialist care including weekly exercise training
Control group: standard specialist care without weekly exercise training
Outcomes Included in this study were: average and individual exercise training attendance rates
(%); reason for non-attendance to the exercise training programme
At baseline,12 and 24 months the following outcomes were measured: multiple-breath
washout (lung clearance index); spirometry (FEV1, FVC, FEV1/FVC (measured in litres
and converted to z scores)); growth parameters (height; weight; BMI (measured in cm²;
kg; and converted to z scores); cardiopulmonary exercise test (Bruce protocol): at peak
and anaerobic threshold (VO2 peak;work rate (power); VE/VCO2; RER;HRmax; SaO2;
10m modified shuttle walk test (25-level version) (distance in meters; level achieved);
HRmax; SaO2; Cystic Fibrosis Questionnaire (CFQ UK version).
At 6 months only spirometry and the 10 m modified shuttle walk test were repeated
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Notes INSPIRE-CF is an 24-month exercise training study that investigates the effects of
an individually tailored and supervised exercise training programme on lung function,
exercise capacity and HRQoL for children with CF
This abstract evaluates the participation in the intervention group in the first year of the
study (study has been completed, but not yet published in full)
Study was powered to show changes after 24 months in primary outcome measure of
FEV1 z score; Required 66 participants.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised but no details of
the method.
Randomised by minimisation to one of the
two groups (after baseline testing) by an
independent blinded medical statistician
using the SiMin software package (Wade
2006)
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants to inter-
vention. Investigators confirmed that lung
function (spirometry and multiple inert
gas washout tests), and cycle ergometer
cardiopulmonary exercise tests were per-
formed by clinicians who were not made
aware of the randomised grouping of the
children
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators confirmed blinded outcome
assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 participants dropped out: 1 from the con-
trol group at 6 months (social concerns); 3
from the intervention group at 12 months
(1 due to moving to a new area and chang-
ing hospitals; 2 because they no longer
wished to exercise)
Selective reporting (reporting bias) Unclear risk This is an abstract so unable to assess if
all outcome used in methods were reported
in results. Unable to assess if data were re-
ported for all time points
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Other bias Unclear risk None identified based on limited informa-
tion available.
Hebestreit 2010
Methods Design: multicentre parallel RCT; duration 24 months (6-month intervention and long-
term, open follow-up period)
Inclusion criteria: participants with CF; age > 12 years; FEV1 > 35 % predicted; ability
to perform physical activities.
Exclusion criteria: non CF-related chronic diseases and CF-related conditions posing an
increased risk to the participant when exercising. These were specifically oesophageal
varicosis, pulmonary bullae, a < 80% drop in arterial oxygen saturation with exercise
and signs of pulmonary hypertension on electrocardiogram and/or echocardiogram
Participants 38 participants with CF.
Group demographics
Exercise group (n = 23): mean (SD) age 19.5 (6.4) years.
Control group (n = 15): mean (SD) age 19.4 (5.3) years.
Interventions Long-term partially supervised conditioning programme.
Group 1 (intervention): exercise intervention with endurance-type and strengthening
exercises. Participants agreed to increase their vigorous physical activities by a minimum
of 3x 60 min per week in the first 6 months of the study. An individual exercise plan was
devised for participants; activity counselling was stopped after the first 6 months and
participants were encouraged to maintain or further increase their physical activity level
Group 2 (control): participants told to keep their activity level constant during the first
12 months of the study. During the second year (period from 12 - 24 months) they were
free to change their activity behaviour
Outcomes Included in this study were: VO2 peak; peak workload; Wingate Anaerobic Test (PP,
MP); FVC; FEV1; RV/TLC; vigorous physical activity; skinfold thickness; body fat; fat-
free mass and HRQoL
Outcomes were measured at baseline and after 3, 6, 12, 18 and 24 months
Notes This study is a full text article of the Hebestreit 2003 abstract. The author provided
additional raw data for this review were not reported in detail in the original paper (e.g.
data for RV/TLC, bodyweight, BMI, body fat and fat-free mass)
The control group in this study is also used in the Kriemler study (Kriemler 2013).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk 40 folded paper tickets were put into a bag
with a 3:2 ratio, i.e. 24 tickets for the inter-
vention group and16 for the control group.
Participants drew a ticket at random and
the drawn ticket was then destroyed. Prin-
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cipal investigator was aware of the number
of lots in the bag
Allocation concealment (selection bias) High risk Participants drew a foldedpaper ticket from
an opaque bag with closed eyes. In case that
all lots have been drawn out by 1 study
group, allocation concealment would no
longer exist
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors were not blinded with
respect to the participants’ group allocation
for VO2 peak and skinfold measurements.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 participants dropped out during the first
12 months of the study: 3 gave no reason,
1 joined another study and 1 moved away
At 18 and 24 months, dropout rate was
13% and 26% respectively. Dropouts were
balanced between groups. Reasons for drop
out were not recorded
Intention-to-treat was not performed.
Selective reporting (reporting bias) Unclear risk Anaerobic capacity (PP, MP) was only re-
ported for 18 - 24 months follow up (non-
significant) and results forHRQoL are only
presented for the scale ’physical function-
ing’. No effects were observed for all other
HRQoL scales
Other bias Unclear risk Financial support (max 200 Euro) was of-
fered for intervention group participants to
foster the realisation of the exercise training
plan
Hommerding 2015
Methods Design: Single-centre parallel RCT; 3-month duration
Inclusion criteria: participants with CF aged 7 - 20 years; stable disease, no signs of
exacerbation of respiratory symptoms in last 15 days
Exclusion criteria: cognitive impairment, nonCF-related bone andmuscle abnormalities,
heart disease with haemodynamic instability
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Participants 34 participants with CF (20 boys, 14 girls).
Group demographics
Exercise group (n = 17): mean (SD) age 13.4 (2.8) years.
Control group (n = 17): mean (SD) age 12.7 (3.3) years.
Interventions Aerobic exercise program based on verbal and written guidelines
Exercise group: participants took part in a 3-month aerobic exercise training program
based on verbal and written guidelines. The program included exercises such as jogging,
swimming, walking, ball games and stretching exercises. Participants were told to prac-
tice the exercises at least twice a week for at least 20 min. No recommendations were
provided regarding exercise intensity. Participants received telephone calls every 2 weeks
and instructions were provided by one of the authors
Control group: Participants were instructed about aerobic exercises once at baseline
according to the CF center routine
Outcomes Included in this study were: VO2 peak; FVC; FEV1; FEV1/FVC; FEF25−75; HRQoL;
self-reported physical activity; body weight; BMI z score; triceps skinfold thickness; arm
muscle circumference; SaO2 at rest and peak exercise, treadmill time; treadmill speed;
peak HR; Borg breathlessness and fatigue
Notes The sample size was estimated based on a mean (SD) change of 18.1 (13.8) points
in the physical score of the HRQoL questionnaire. The estimated sample size was 15
participants in each group (95% power at a 5% level of significance). 2 more participants
were included in each group to account for potential dropouts. Another study from the
same group using the same aerobic exercise program was published recently (Schindel
2015). The responsible author of this publication confirmed that the vast majority of
included participants were the same as in the Hommerding study (Hommerding 2015)
. There were only marginal differences in lung function (FEV1, FVC and FEF25−75)
compared to the Hommerding study for which reasons we decided not to include lung
function data in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated to the interven-
tion or control group in blocks of 6. A
computer-based program was used for ran-
domisation
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs were reported during the
study.
Selective reporting (reporting bias) Unclear risk Blood pressure was measured prior to and
after cardiopulmonary exercise testing but
not reported. HR at rest and SaO2 at peak
exercise were measured but results were not
reported at baseline
Other bias Unclear risk No validity criteria for maximal perfor-
mance during cardiopulmonary exercise
testing were reported in the methods. The
mean (SD) peak heart rate reached during
the exercise test was 157.1 (38.5) beats per
min in the training group and 167.7 (20.
8) beats per min in the control group, in-
dicative of a submaximal effort. This likely
underestimates the true VO2 peak of the
study participants.
Klijn 2004
Methods Design: Single-centre, parallel RCT, 3-month duration.
Inclusion criteria: Participants with CF aged 9 - 18 years; a stable clinical condition (i.e.,
no need for oral or IV antibiotic treatment in the 3 months prior to testing); the absence
of musculoskeletal disorders; and an FEV1 > 30 % predicted.
Exclusion criteria: not specified.
Participants 20 participants with CF (stable disease) completed the study.
Group demographics
Group 1 (training) (n = 11): mean (SD) age 13.6 (1.3) years.
Group 2 (control) (n = 9): mean (SD) age 14.2 (2.1) years.
3 participants dropped out; 1 withdrew from the training group for practical reasons
(training group) and 2 from the control group as they did not complete assessments due
to pulmonary exacerbations
Interventions Long-term anaerobic study (12 weeks).
Group 1: anaerobic exercise (2 days per week for 30 - 45 min)
Group 2: normal daily activities.
Outcomes Included in this study were: BMI; FEV1; FVC; FEF25−75; RV/TLC; Wingate Anerobic
Test (PP, MP); VO2 peak; peak working capacity; VCO2; VE; RER; lactate; habitual
activity estimation scale; HRQoL; fat-free mass
Outcomes measured again at 12 weeks follow up.
Notes To achieve a difference in PP per kg body weight of 10% with an SD of 0.8 W/kg and a
statistical power of 80%, it was calculated that 8 participants had to be included in each
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study group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details of
the method.
Allocation concealment (selection bias) Low risk Allocation concealed in opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. The primary researcher was
blinded but their role in the study is un-
clear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The primary researcher was blinded, but it
is unclear whether this researcher was re-
sponsible for outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear description and details about drop-
outs.
3 participants dropped out: 1 participant
from the training group withdrew for prac-
tical reasons; 2 from the control group
did not complete assessments due to pul-
monary exacerbations
Intention-to-treat analysis was not per-
formed.
Selective reporting (reporting bias) Unclear risk Results for HRQoL are only presented for
the scale ’physical functioning’ which was
significantly higher in the training group af-
ter the 12-week training period. No change
in this HRQoL scale was observed in the
control group after 12-weeks. No signif-
icant effects were observed for any other
HRQoL scales. Data were not reported in
detail
Other bias Unclear risk Clearly stated inclusion criteria but exclu-
sion criteria were not reported. Described
statistical methods used in analysis
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Methods Design: multi-centre, parallel RCT with 3 arms; 24 months (6-month intervention and
long-term, open follow-up period)
Inclusion criteria: diagnosis of CF; aged 12 years and over; a FEV1 % predicted≥ 35%;
ability to perform physical activity without harm
Exclusion criteria: non-CF related chronic diseases and conditions posing an increased
risk to the participant when exercising
Participants 39 participants with CF split into 3 groups.
Group demographics
Group 1 (aerobic training) (n = 17): mean (95% CI) age 23.8 (21.5 to 26.5) years
Group 2 (strength training) (n = 12): mean (95% CI) age 19.0 (16.0 to 22.0) years
Group 3 (control) (n = 10): mean (95% CI) age 20.3 (17.0 to 23.6) years
A separate control group from a parallel study (Hebestreit 2010) was added due to an
unusual deterioration of physical health in the control group in this study (n = 15), mean
(95% CI) age 19.5 (16.8 to 22.2) years
Interventions Long-term exercise study.
Group 1: participants consented to perform 3 aerobic training sessions per week of 30 -
45min duration for the first 6months and received support which was stopped thereafter
Group 2: participants consented to perform 3 strength training sessions per week of
30 - 45 min duration for the first 6 months and received support which was stopped
thereafter
Group 3: participants in the control group were told to keep their activity level constant.
Free access to a fitness centre for 1 year was offered after the first study year
Outcomes Included in this study were: FEV1; FVC; RV/TLC; VO2 peak; peak workload; Wingate
anaerobic test (PP, MP); physical activity; body fat; fat-free mass
Notes This study is a full text article of the Kriemler 2001 and Hebestreit 2003 abstracts
The control group experienced a deterioration of physical health during the study. In
the original paper, a second control group from a German study with similar design and
methods (Hebestreit 2010) was used for comparisons.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomly assigned by a
lot thatwas drawn fromanopaque bagwith
closed eyes. Investigator was aware of the
number of lots in the bag
Allocation concealment (selection bias) High risk Participants drew a lot from an opaque bag
with closed eyes. In case that all lots have
been drawn out by one study group, allo-
cation concealment would no longer exist
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded for pul-
monary function testing (primary outcome
FEV1). Outcome assessors were not in-
volved in supervision and delivery of the
intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear description and details about ex-
cluded participants and drop-outs
3 participants were excluded at baseline due
to FEV1 below 35% predicted. 8 partici-
pants dropped out at different time points
(exacerbation n = 1; non-compliance n = 2;
death n = 2; unclear reasons n = 3). 2 of the
participants that dropped out for unclear
reasons were in the control group and one
was in the aerobic training group
Dropout rate was 21%.
Intention-to-treat analysis was not per-
formed.
Selective reporting (reporting bias) Low risk All outcome detailed in methods were re-
ported in results exceptHRQoL (secondary
outcome) which was mentioned to be re-
ported separately. In the meantime pub-
lished as Hebestreit et al. BMC PulmMed.
2014, 27;14:26. HRQoL data were pooled
from two intervention studies (Hebestreit
2010; Kriemler 2013) and results were pre-
sented for baseline and 6-month follow up
Other bias Unclear risk Clearly stated inclusion and exclusion crite-
ria anddescribed statisticalmethods used in
analysis. Due to the deterioration of physi-
cal health in the control group, the results of
this study should be interpreted with cau-
tion
Michel 1989
Methods Design: single-centre, parallel RCT during hospital admission
Inclusion criteria: not specified.
Exclusion criteria: not specified.
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Participants 9 participants with CF, not stated how many allocated to each group.
Group demographics
Exercise group: mean (SD) age 25.5 (10.5) years.
Non-exercise group: mean (SD) age 21.5 (3.2) years.
Interventions Short-term aerobic study.
Group 1: exercise and standardised CF protocol.
Group 2: standardised CF protocol.
Outcomes Included in this study were: skin folds; mid-arm circumference; grip strength; respiratory
muscle strength; ideal body weight
Measured at 1 month post-discharge.
Notes Limited information as published as abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details of
method.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details of dropouts or whether inten-
tion-to-treat analysis had been used
Selective reporting (reporting bias) Unclear risk This is an abstract so unable to assess if
all outcome used in methods were reported
in results. Unable to assess if data were re-
ported for all time points
Other bias Unclear risk Do not state inclusion or exclusion criteria,
nor do they describe the methods of statis-
tical analysis used
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Moorcroft 2004
Methods Design: single-centre, parallel RCT; 1-year duration.
Inclusion criteria: participants with CF who were willing to participate were recruited
from a population of 150 attending the adult CF centre in Manchester at the time of the
study. All participants had documented CF on the basis of clinical history plus either an
increased sweat chloride or abnormal genetic testing
Exclusion criteria: participation in another clinical trial; pregnancy; transplant listing, or
clinical cor pulmonale
Participants 51 participants with CF were randomised; 42 completed the study.
Group demographics
Exercise group (n = 30): mean (SD) age 23.5 (6.4) years.
Control group (n = 18): 23.6 (5.5) years.
3 participants dropped out at the start of programme: 1 from training group due to
failure to attend on initial assessment; and 2 in the control group were withdrawn due
to ill health. A further 6 participants dropped out during the 1-year period
Interventions Long-term aerobic and anaerobic study over 1 year.
Group 1: unsupervised exercise (based on individual preferences general aerobic exercises
for lower body and weight training for upper body) 3 times per week
Group 2: control (continue with usual activities).
Outcomes Included in this study were: FEV1; FVC; whole blood lactate; RER; heart rate; Borg
breathlessness and muscle effort; VE, RR peak for arm and bicycle ergometry at 55%
maximal workload; BMI and weight
Notes This study is a full text article of Dodd 1998 and Moorcroft 2000 abstracts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised to either active or control
groups in a ratio of 3:2. A stratified ran-
domisation in blocks (block size not stated)
was used to balance the groups for FEV1,
sputum colonisation by Burkholderia cepa-
cia and gender. No details of method re-
ported.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. Unclear whether personnel was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants dropped out at the start of
programme: 1 from training group due to
failure to attendon initial assessment; and 2
in the control groupwere withdrawndue to
ill health. A further 6 participants dropped
out during the 1-year period. Reasons for
dropout were not clearly reported
After 1 year, overall dropout rate was 18%
and balanced among the groups (19% in
the intervention and 15% in the control
group)
Intentition-to-treat analysis was not per-
formed.
Missing data were treated by omission and
only data for those who completed study
presented
Selective reporting (reporting bias) Low risk All outcome detailed in methods were re-
ported in results. Data reported for all time
points
Other bias Low risk Clearly stated inclusion and exclusion crite-
ria and describedmethod of statistical anal-
ysis used
Rovedder 2014
Methods Design: single-centre, parallel RCT; 3-months home-based exercise programme
Inclusion criteria: participants diagnosed with CF in accordance with the criteria of the
consensus;aged ≥16 years; ≥ 30 days of clinical respiratory disease stability
Exclusion criteria: participants who refused to take part in the study; pregnant ladies;
individuals with heart disease, orthopaedic or traumatological problems
Participants 41 participants with CF.
Group demographics
Exercise group (n = 22): mean (SD) age 23.8 (8.3) years.
Control group (n = 19): mean (SD) age 25.4 (6.9) years.
2 study participants in the exercise group could not be assessed at the 3-months follow
up due to lung transplant assessment
Interventions 3-month home-based exercise programme.
Group 1: participants received printed guidance for aerobic and muscle strengthening
exercises and were advised to perform the programme on a daily basis. Weekly telephone
contacts were performed during the 3-month period
Group 2: control group participants received standard programme without any specific
exercise instructions
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Outcomes Included in this study were: HRQoL; FEV1; FVC; walking distance (6MWT); SaO2 at
peak exercise; RR at peak exercise; peak exercise HR; dyspnoea and fatigue scores; upper
and lower body muscle strength
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated in
blocks of 6 to the exercise or control group.
A computer programme was used to gen-
erate randomisation sequence
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to in-
tervention. 1 researcher was blinded to the
randomisation and intervention and was
responsible for database entries
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants in the exercise group could
not be assessed at the 3-month visit due
to submission to the lung transplant pro-
gramme
Intention-to-treat analysis was used and
imputations for missing data were per-
formed for these 2 participants
Selective reporting (reporting bias) Low risk All outcome detailed in methods were re-
ported in results. Data reported for all time
points
Other bias Unclear risk Clearly stated inclusion and exclusion crite-
ria and describedmethod of statistical anal-
ysis used. Baseline between-group differ-
ences existed in BMI which could possibly
impact on HRQoL (primary outcome)
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Santana-Sosa 2012
Methods Design: single-centre, parallel RCT; 3-month duration (8 weeks training, 4 weeks de-
training)
Inclusion criteria: potential participants included 111 children previously diagnosed
using a genetic test for CF and treated at the Children’s Hospital Nino Jesus in Madrid.
Males or females aged 5 to 15 years and living in the Madrid area (able to attend training
sessions)
Exclusion criteria: severe lung deterioration, as defined by an FEV1 < 50% predicted; un-
stable clinical condition (i.e. hospitalisation within the previous 3 months); Burkholderia
cepacia infection; musculoskeletal disease or any other disorder impairing exercise
Participants 22 participants with CF.
Group demographics.
Training group (n = 11): mean (SEM, range) age 11 years (3 years, 5 - 15 years)
Control group (n = 11): mean (SEM, range) age 10.0 years (2 years, 6 - 14 years)
Interventions 8-week intrahospital programme followed by a 4-week detraining period. All participants
received the same chest physiotherapy during the entire study period
Group 1: endurance and strengthening exercises, 3 times per week
Group 2: control.
Outcomes Included in this study were: VO2 peak; upper and lower body strength (bench press, leg
press, seated row); FEV1; FVC; PImax ; SaO2 at peak exercise; body weight; BMI; fat-free
mass; body fat; HRQoL; Timed Up and Go test (TUG); Timed Up and Down Stairs
test (TUDS)
Notes Additional raw data for all included outcomes provided by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned to ex-
ercise or control group with a block on gen-
der based on the randomisation sequence.
No details about how randomisation se-
quence was generated
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to inter-
vention. Personnel involved in training not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to partic-
ipants group assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk Clear description of missing outcome data.
5 participants could not be assessed at dif-
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Santana-Sosa 2012 (Continued)
ferent time points (1 post-intervention and
4 after detraining) due to hospitalisations
(n = 3), relocation (n = 1) and parents who
declined further evaluation (n = 1)
Dropout rate was unbalanced with 28% in
the control group and 9% in the interven-
tion group after the detraining period
Intention-to-treat analysis was used and
missing outcome data (at post-training or
detraining visit) were replaced by baseline
data
Selective reporting (reporting bias) Low risk All outcomes detailed in methods were re-
ported in results. Data reported for all time
points
Other bias High risk Some raw data were made available, but
therewere inconsistencies between rawdata
and data reported in the original publica-
tion. There were significant between-group
differences in primary (VO2 peak) and sec-
ondary (strength measures) outcome mea-
sures at baseline
Santana-Sosa 2014
Methods Design: single-centre, parallel RCT; 3-month study (8weeks training, 4weeks detraining)
Inclusion criteria: potential participants included 95 outpatient children previously di-
agnosed with CF by genetic testing and treated at the Children’s Hospital Nino Jesus in
Madrid. Males or females aged 6 - 17 years and living in the Madrid area (able to attend
training sessions)
Exclusion criteria: severe lung deterioration (FEV1 < 50% predicted); unstable clinical
condition (i.e., hospitalisation within the previous 3 months); Burkholderia cepacia in-
fection or any disorder (e.g., musculoskeletal) impairing exercise
Participants 20 participants with CF.
Group demographics
Training group (n = 10): mean (SEM) age 11.1 (1.1) years.
Control group (n = 10): mean (SEM) age 10.1 (1.1) years.
Interventions 8-week programme followed by a 4-week detraining period. All participants received the
same standard chest physiotherapy
Group 1: whole body aerobic and weight training 3 times per week, plus two daily
inspiratory muscle training sessions
Group 2: control group performed inspiratory muscle training only at a low intensity
Outcomes Included in this study were: VO2 peak; FVC; FEV1; PImax; SaO2 at peak exercise,muscle
strength; body weight; body fat; fat-free mass; and HRQoL
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Notes Additional raw data for all included outcomes provided by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation to intervention or control
group with block on gender. No details
given for sequence generation
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to inter-
vention. Personnel involved in training not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to partic-
ipants group assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk Clear description of missing outcome data.
3 participants of the control group could
not be assessed at different time points (1
for post-intervention and detraining phase
and 2 after detraining phase) due to hos-
pitalisation for lung transplantation prepa-
ration (n = 1), infection with Burkholderia
cepacia (n = 1) and refusal (n = 1).
Unbalanced distribution of dropouts.
Dropout rate in the control group was 30%
versus none in the intervention group
Intention-to-treat analysis was reported,
but it is not clear how missing data were
handled
Selective reporting (reporting bias) Low risk All outcome detailed in methods were re-
ported in results. Data reported for all time
points
Other bias High risk Some raw data were made available, but
therewere inconsistencies between rawdata
and data reported in the original publi-
cation. Significant between-group differ-
ences in primary outcomes (VO2 peak and
strength measures) existed at baseline.
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Schneiderman-Walker 2000
Methods Design: single-centre, parallel RCT, 3-year duration.
Inclusion criteria: participants with CF aged 7 - 19 years with an FEV1 > 40% predicted.
Exclusion criteria: not specified.
Participants 65 participants with CF; 2 groups similar at baseline. 7 dropouts.
Group demographics
Exercise group (n = 30): mean (SD) age 13.4 (3.9 years).
Control group (n = 35): mean (SD) age 13.3 (3.6) years.
Interventions Long-term aerobic study.
Group 1: minimum of 20 min aerobic activity plus 5 min warm up and cool down 3
times per week
Group 2: maintained regular activity (control).
Outcomes Included in this study were: FVC; FEV1; FEF25−75; PEFR; TV; VO2 peak; VCO ; peak
exercise heart rate; peak exercise VE; VE peak/MVV; RER; blood pressure; % of ideal
weight for height; compliance and sense of well-being; feasibility of exercise; hospital
stays and number of days in hospital; chest X-ray; and Schwachman scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to
intervention. Unclear whether personnel
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pulmonary function assessors were blinded
to group assignment (primary outcome
measure)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Clear description and details about 7 drop-
outs were recorded
Intention-to-treat analysis was reported to
yield similar results for pulmonary function
Results were only reported for 65 partici-
pants who completed the 2-year follow up
Selective reporting (reporting bias) Low risk All outcome detailed in methods were re-
ported in results. Data reported for all time
points
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Other bias Unclear risk Groups similar at baseline.
Stated the inclusion criteria but not the ex-
clusion criteria.
Described statistical methods used in anal-
ysis.
Selvadurai 2002
Methods Design: single-centre, parallel RCT; hospital admission for recurrent chest infections
Inclusion criteria: children with CF, aged 8 - 16 years who were admitted the the Royal
Alexandria Hospital for Children for the treatment of an infectious pulmonary exacer-
bation
Exclusion criteria: children with known pulmonary hypertension, or who required day-
time oxygen prior to the pulmonary exacerbation which led to the hospital admission
Participants 66 children with CF (28 males, 38 females). No dropouts.
Group demographics
Aerobic training group (n = 22): mean (SD) age 13.2 (2.0) years), 9 males and 13 females
Resistance training group (n = 22): mean (SD) age 13.1 (2.1) years, 10 males and 12
females
Control group (n = 22): mean (SD) age 13.2 (2.0) years, 9 male and 1 females
Interventions Short-term aerobic and anaerobic/strength training study during hospital admission
(mean duration 18.7 days, range 14 - 36 days).
Group 1: 30 min supervised aerobic exercise training 5 times per week
Group 2: 30 min supervised resistance training 5 times per week
Group 3: no specific training.
Outcomes Included in this study were: VO2 peak; peak VE; VCO ; peak HR; HRQoL; FEV1;
FVC; weight; lower limb strength; and fat-free mass.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random allocation in sets of 6. No details
given for generation of sequence
Allocation concealment (selection bias) Low risk Concealed information inside opaque en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to
intervention. Unclear whether personnel
blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Stated no dropouts.
Selective reporting (reporting bias) Unclear risk Did not report on all secondary outcomes
detailed in methods (e.g. VE, VCO2, RQ)
in results. Data reported for all time points.
Other bias Low risk Clearly stated inclusion and exclusion cri-
teria.
Described statistical methods used to anal-
yse data.
Turchetta 1991
Methods Design: single-centre, parallel RCT; hospital admission for routine assessment of clinical
condition
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Participants 12 children with CF, 8 males, mean age 12.3 years.
No group demographics available.
Interventions Short-term aerobic study.
Group 1: 20 min running or treadmill per day for 2 weeks.
Group 2: normal hospital treatment.
Outcomes Included in this study were: FEV1 and FVC.
Notes This study has only been reported in a single abstract and therefore the information is
limited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details
given for sequence generation
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants to
intervention. Unclear whether personnel
blinded
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Turchetta 1991 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details of dropouts or whether inten-
tion-to-treat analysis had been used
Selective reporting (reporting bias) Unclear risk This is an abstract so unable to assess if
all outcome used in methods were reported
in results. Data were reported for all time
points
Other bias Unclear risk Do not state inclusion or exclusion criteria,
nor do they describe the methods of statis-
tical analysis used
BMI: body mass index
CF: cystic fibrosis
CFRD: cystic fibrosis-related diabetes
FEF25−75: forced expiratory flow 25-75%
FEV1: forced expiratory volume at one second
FRC: functional residual capacity
FVC: forced vital capacity
HRQoL: health-related quality of life
IGT: impaired glucose tolerance
MP: mean power
MVV: maximal voluntary ventilation
PFS: progression-free survival
PImax : maximum inspiratory mouth pressure
PP: peak power
Raw: airways resistance
RCT: randomised controlled trial
RER: respiratory exchange ratio
RR: respiratory rate
RV: residual volume
SaO2: oxygen saturation
SD: standard deviation
SEM: standard error of the mean
SGAW: specific airways conductance
TLC: total lung capacity
VE: minute ventilation
VO2 peak: peak oxygen consumption
VCO2: carbon dioxide production
VO2: oxygen uptake
W: watt
WAnT: Wingate Anaerobic Test
6MWT: six-minute walk test
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alarie 2012 This study compared the acute cardiovascular response in participants playing different active video
games. No control group included
Albinni 2004 This study was designed with the exercise group as the control group, therefore we could not compare
data with baseline, no physical exercise training as per our protocol
Amelina 2006 IMT training and not physical exercise training as per our protocol
Andreasson 1987 Not a randomised controlled study.
Aquino 2006 This study was designed with the aim of comparing the effectiveness of a single treatment sessions
of exercise and PEP on sputum clearance. Participants in this study did not undertake a programme
of physical training
Asher 1982 IMT training and not physical exercise training as per our protocol
Balestri 2004 This study was designed with the aim of comparing the effectiveness of a single treatment session
of exercise and PEP on sputum clearance. Participants in this study did not undertake a programme
of physical training
Balfour 1998 Not a physical exercise training study, comparison of different tests for assessing exercise capacity
Barry 2001 Not a randomised controlled study.
Bieli 2017 Study of respiratory muscle endurance training, not a physical exercise training study
Bilton 1992 This study was designed with the aim of comparing the effectiveness of a single treatment session
of exercise or physiotherapy or exercise and physiotherapy on sputum clearance and lung function.
Participants in this study did not undertake a programme of physical training
Bongers 2015 Study evaluating the clinical usefulness of the steep ramp test and not a physical training study
Calik-Kutukcu 2016 No control group with no physical training.
Chang 2015 Study of methods for evaluating muscle function and not a physical training study
Chatham 1997 This study involved respiratory muscle training exclusively. This intervention does not constitute
physical training as defined within our protocol
de Jong 1994 Not a randomised controlled study.
del Corral Nunez-Flores 2011 No control group with no physical training.
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Dwyer 2008 Study duration insufficient,
Dwyer 2017 Study duration insufficient,
Edlund 1986 Not a randomised controlled study.
Falk 1988 This study was designed with the aim of comparing the effectiveness of a single treatment session of
exercise or positive expiratory pressure on lung function. Participants in this study did not undertake
a programme of physical training
Giacomodonato 2015 Study of respiratory muscle endurance training and not a physical training study
Gruet 2012 No control group with no physical training.
Haynes 2016 Evaluation of the incremental step test not a study of physical training
Heijerman 1992 Not a randomised controlled study.
Irons 2012 Not a physical exercise training study, examines effect of a singing program compared to no singing
Kriemler 2016 Study duration insufficient, only 3 single day interventions on non-consecutive days of a week
Kuys 2011 Compares Nintendo Wii exercise training to an existing exercise programme, no control group with
no physical training
Lannefors 1992 This study was designed with the aim of comparing the effectiveness of a single treatment session of
exercise and FET or positive expiratory pressure and FET or postural drainage, thoracic expansion
exercises and FET on mucous clearance. Participants in this study did not undertake programme of
physical training
Lima 2014 No physical exercise training study, study looks at effect of non-invasive ventilation on exercise
capacity and lung function
Lowman 2012 No control group with no physical training.
NCT02277860 Not a randomised controlled study, single arm trial of physical exercise,
NCT02715921 Not a randomised controlled study, single arm trial of physical exercise,
NCT02821130 A study of CFTR potentiator therapy and effects on exercise capacity
NCT02875366 A study of CFTR potentiator therapy and effects on exercise capacity
NCT03117764 Not a randomised controlled study, study of the effect of antibiotics on muscular strength and not
physical training
Orenstein 1981 Not a randomised controlled study.
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Orenstein 2004 Compares aerobic training to upper-body strength training, no control group with no physical
training
Ozaydin 2010 IMT training and not physical exercise training as per our protocol
Patterson 2004 Study to evaluate the efficacy of the test of incremental respiratory endurance, not a physical training
study
Petrovic 2013 Not a randomised controlled study.
Rand 2012 Not a physical exercise training study. This study was designed to develop an incremental field
exercise test for children with CF
Reix 2012 Acute study comparing exercise with expiratory breathing manoeuvres to breathing techniques for
airway clearance
Salh 1989 Not a randomised controlled study.
Salonini 2015 A comparison of two exercise interventions (Xbox Kinect versus stationary cycle). No control group
with no physical training
Shaw 2016 No control group with no physical training.
Stanghelle 1998 Not a randomised controlled study.
Tuzin 1998 Not a randomised controlled study.
Vallier 2016 Study to evaluate modified shuttle test and not a study of physical training
Vivodtzev 2013 This study evaluated neuromuscular electrical stimulation prior to endurance training in people
with CF. No control group with no physical training
Wheatley 2015 Intervention only given on 3 single days, comparison of physical training and albuterol for airway
clearance
CF: cystic fibrosis
FET: forced expiration technique
IMT: inspiratory muscle training
PEP: positive expiratory pressure
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Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12617001009303
Methods RCT.
Parallel design.
Duration: 12 weeks.
Participants Target sample size: 150.
Inclusion criteria: confirmed diagnosis of CF, hospital inpatient admission (including hospital in the home) for IV
antibiotic therapy for a respiratory cause, informed consent, access to the Internet via computer or mobile device
Exclusion criteria: presence of severe co-morbidity limiting mobilisation or physical activity participation, previous
lung transplantation, pregnancy
Age minimum: 12 Years
Age maximum: 24 Years
Gender: Both males and females
Interventions Intervention group: use of the ActivOnline program, via the Internet, as well as usual care. ActivOnline was
developed in accordance of the principles of motivational interviewing and has been used to promote physical activity
participation in older adults with chronic respiratory disease. Those allocated to the ActivOnline group will be
provided with a unique logon and password to access the ActivOnline program and will be asked to record their daily
physical activity and exercise using the secure portal. When logging onto ActivOnline they will be prompted to set
goals, will record their PA or exercise using a pedometer or other device of their choice and will regularly enter data
about that will be displayed graphically so they can see their progress
Control group: usual care.
Usual care provides details for an online resource regarding physical activity participation and physical activity tar-
gets for children and young adults (www.nhs.uk/Livewell/fitness/Pages/physical-activity-guidelines-for-young-peo-
ple.aspx) as well as activity and exercise guidance, as indicated, as part of their routine clinical care on hospital
discharge
Outcomes Primary outcome
Change in physical activity participation objectively measured via accelerometry
Secondary outcomes
Change in exercise capacity as measured by the MST
Change in health related quality of life as assessed by the CFQ-R
Change in HADS
Change in lung function as measured by FEV1
Change in physical activity participation objectively measured via accelerometry
Change in physical activity participation self reported by the HAES
Change in the CES-D scale
Change in the PSQI
Number of hospital inpatient days by medical record review
Time to first hospital admission, by medical record review
Notes Supported by UK CF Trust.
Email confirmation from lead investigator (17 August 2017) that trial has been completed and they are currently
analysing data. We hope to obtain data for the CF participants once the trial has been published
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Almajan 2011
Methods Parallel design RCT.
6-month intervention.
Participants 38 participants with CF aged 7 - 13 years.
No group demographics available.
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Interventions Group 1 (n = 19): classical physiotherapy plus sport activities 3 times per week
Group 2 (n = 19): classical physiotherapy alone.
Outcomes Eligible for inclusion are: FEV1; FVC; FEF25−75 ; number of hospitalisations; participation at school; and activities
of daily living
Notes No information were available in the abstract about types of exercises, intensity, frequency and duration of exercise
training
Housinger 2015
Methods Design: Modified RCT; motivational incentive-based walking program for patients hospitalised with pulmonary
exacerbation
Series of 2-week intervals with 1-week wash-out periods were created and randomized as either treatment or control
Participants 29 participants with CF (11 males; 18 females).
Group demographics:
Intervention group (n = 18)
Control group (n = 11)
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Interventions Intervention group (n = 18): incentive-based walking program plus standard care including daily (Monday to Friday)
physical therapy
Control group (n = 11): standard care including daily (Monday to Friday) physical therapy
Outcomes Included in this study were: 6MWT distance; vital signs; Bruininks-Oseretsky Test of Motor Proficiency; strengths
assessment score and HRQoL (CFQ-R)
Data were collected within 72 hours of hospital admission and within 48 hours of hospital discharge
Notes
Johnston 2004
Methods Design: parallel RCT; 6-week exercise programme followed by a 16-week home-based programme
Participants 89 participants aged 7 - 11 years old and with different lung conditions: asthma (n = 60), CF (n = 12), a history of
chronic neonatal lung disease (n = 17)
Group demographics are not available. No information on dropouts.
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Johnston 2004 (Continued)
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Interventions 6-week exercise programme with weekly exercise sessions followed by a home-based programme using behaviour
change strategies to promote aerobic exercise. Participants were evaluated at baseline, 7 weeks and 24 weeks
Intervention group: n = 45.
Control group: n = 44.
Outcomes Included in this study were: aerobic fitness (exercise test not specified); vigorous physical activity; self perception of
athletic competence and physical appearance
Notes We plan to contact the authors to obtain the CF-specific data
Lorenc 2015
Methods Design: parallel RCT; single centre comparative effectiveness trial at the Royal Brompton Hospital, London, UK.
Phase 2 study
Participants 72 participants with CF aged over 6 years from the Royal Brompton Hospital, London
Group demographics are not available.
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Interventions Phase 2 study.
Group 1: 8x one-on-one Tai Chi sessions then given a DVD and a handout to use at home for 9 months and
encouraged to practice up to 5 times per week
Group 2: no treatment (standard care) for the first 3 months (this is the control), then 8x online Tai Chi sessions (e.
g. via Skype) and given a DVD and a handout to use at home for 6 months and again encouraged to practice up to
5 times per week
The programme was evaluated at baseline and after 3, 6 and 9 months
Outcomes Included in this study were: HRQoL; mindfulness, sleep (not specified); medical data (not specified) and respiratory
function (not specified); participants’ experience; Tai Chi feasibility; perceived health impact and study participation
Notes We plan to contact the authors to obtain more information on study design and results
Mandrusiak 2011
Methods Design: parallel RCT, 10 - 14 day inpatient period at a tertiary hospital followed by a 8 - 12 week home-based
program. Blinded assessor
Participants 31 participants with CF aged 8.5 to 17.6 years and with a mean FEV1 of 66.74 %.
Group demographics
Group 1: exercise program (n = 15).
Group 2: standard physiotherapy exercise (n = 16).
Inclusion criteria: not specified.
Exclusion criteria: not specified.
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Interventions Group 1 (n = 15): a novel exercise program including a portable exercise package (FitKit™ - exercise in a bag
including instruction cards, exercise equipment and daily exercise log)
Group 2 (n = 16): standard physiotherapy exercise practice.
Outcomes Performance on study measures (scoped within the framework of the International Classification of Functioning,
Disability and Health model) - details not reported
Assessment at 3 time points:
• admission to the inpatient period;
• at discharge from the 10 - 14 day inpatient period; and
• at conclusion of the 8 - 12 week home program.
Notes No data available currently, but will be added when study published in full
NCT00609050
Methods Design: cross-over RCT; single blind (outcome assessor); 6months duration; single-centre study at Children’sHospital
of Pittsburgh, USA
Participants Enrolment goal: 38 participants with CF.
Inclusion criteria: CF diagnosis; males and females; age 10 - 18 years; reliable pulmonary function test; living at
home; able to read; able to ride a stationary bike; able to walk and/pr run on a treadmill
Exclusion criteria: enrolled in another intervention study; participation in structured aerobic exercise for 30 con-
tinuous minutes 3 times per week; sibling enrolled in study
Interventions Intervention group: home-based exercise programme at least 3 times per week for 6 months with telephone rein-
forcement. After the first 6 months, participants receive instructions to maintain their self-regulated exercise activity
for another 6 months without receiving telephone calls
Control group: standard recommendations for exercise activity during the first 6 months. Thereafter, the control
group will cross over to the self-regulated exercise without telephone reinforcement
Outcomes Included in this study were: VO2 peak; peak workload; VO2 150 (VO2 at a heart rate of 150 bpm per minute during
an exercise test); FEV1; sustained phonation time; HRQoL (CF questionnaire and well-being scale) and exercise
experiences of children and parents assessed with interviews
Notes A 6-month program of self-regulated, home-based exercise programme with telephone reinforcement on cardiores-
piratory fitness, pulmonary function and HRQoL of children with CF, compared to controls. A secondary aim is to
exploring the exercise experiences of the children and parents
The principal investigator confirmed that the trial is completed and data are currently being analyzed
NCT00792194
Methods Design: parallel RCT; open-label; duration24months; partially-supervised; single-centre study atUniversityHospital,
Strasbourg, France
Participants Enrolment goal: 50 participants with CF.
Inclusion criteria: males and females aged 15 - 65 years with CF diagnosed by clinical history and positive genetic
or sweat testing; signed informed consent (or by parents for paediatric participants); participant covered by social
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security; participant has no indication of cardiac issues; stable disease (FEV1 > 1000 mL); in the case of insulin-
dependent diabetes, it must be stable; participant had been informed of the results of the medical examination;
women of childbearing age confirmed not to be pregnant by urine test
Exclusion criteria: participant with unstable diabetes or known cardiac issues; participant on transplant list
Interventions Intervention group: partially-supervised exercise training programme with the aim of exercising 3x per week over
24 months; exercise intensity controlled with heart rate monitors and supported by exercise coaches
Control group: normal daily activities and physiotherapy regimen.
Outcomes Included in this study were: VO2 peak; HRQoL (CFQ-14+ and SF 36).
Notes The principal investigator of this study responded on our request and confirmed that the study has been closed
prematurely due to local organisational and recruitment problems. No publication is planned for this study
NCT02552043
Methods Design: parallel RCT; duration 6 weeks; open-label; single-centre study at Universidad Autonoma de Madrid, Spain
Participants Enrolment goal: 41 participants with CF.
Inclusion criteria: males and females aged 7-18 years diagnosed with CF; clinically stable with no exacerbations of
the disease in the previous 6 weeks to the inclusion date
Exclusion criteria: clinical evidence of cardiovascular, neuromuscular or osteo-articular co-morbidities that limit
the participation in exercise programmes; lung transplant candidates and participants that followed any kind of
rehabilitation programme 12 months before the study
Interventions Intervention group: 30 - 60 min exercise using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2, 5
days/week for 6 weeks. The exercise activities are loaded into each participant’s console during the clinical interview
and the exercises adjusted according to their age: <12 years and >13 years. The program consists of 6 different
workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th
weeks: cardio exercises) with gradually increasing intensities reaching the maximum load at the end of the training
Control group: routine clinical management.
Outcomes Included in this study were: exercise capacity (6MWT; modified shuttle walk test); muscular strength (horizontal
jump test, medicine ball throw, handgrip strength); HRQoL using 3 versions of the CFQ-R (CFQ-R 6-11, CFQ-R
14+, CFQ-R Parents)
Notes The aim of this study is to evaluate the efficacy of a long-term domiciliary exercise program using theWii video game
platform as a training modality in people with CF
NCT03100214
Methods Design: parallel RCT; outcome assessor (exercise supervisor) blinded; single-centre study at Hospital de Clínicas de
Porto Alegre, Brazil
Participants Estimated enrolment: 68 participants with CF.
Inclusion criteria: males and females age 16 - 50 years, diagnosed with CF according to consensus criteria and
regularly followed up in the Hospital de Clinicas de Porto Alegre Programme for Adolescents and Adults with CF;
80Physical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT03100214 (Continued)
admitted to hospital (for at least 24 hours) due to exacerbation of lung disease
Exclusion criteria: participants with cardiac, orthopedic or trauma complications that make it impossible to perform
the proposed exercises; pregnancy; participants with haemodynamic instability, massive haemoptysis, pneumothorax,
and continuous use of non-invasive ventilation
Interventions Intervention group: aerobic and anaerobic exercise 5 times a week during the hospitalisation period, with sessions
lasting about an hour, programme beginning within 48 hours of admission
Control group: physiotherapeutic follow-up (including respiratory physiotherapy, inhalation therapy and techniques
for removal of secretions) performed by the physiotherapist of the programme for adults with CF during the hospi-
talisation period
Outcomes Included in this study were: primary outcome: 6MWT distance; secondary outcomes: FEV1; HRQoL (CFQ-R); C-
reactive protein; interleukin-6; interleukin-8 and tumor necrosis factor
Notes This study study aims to evaluate the effects of an early rehabilitation programme based on aerobic training and
muscle strength training in adolescent and adult participants with CF hospitalised at Hospital de Clinicas de Porto
Alegre for exacerbation of lung disease
NCT03109912
Methods Design: parallel RCT (“Do More, B’More, Live Fit”), duration 6 months; single-centre study at Johns Hopkins
University, Baltimore, US
Participants Enrollment goal: 60 participants with CF.
Inclusion criteria: males and females aged 12 - 21 years old with CF and cared for at Johns Hopkins; participants
must have a smartphone and/or computer with universal serial bus (USB) to set-up FitBit Flex
Exclusion criteria: FEV1 < 40% predicted; individuals already participating in vigorous physical activity (as assessed
by the study team) in year-round organised sports and/or aerobic exercise for longer than 30 minutes more than 5x
per weeks may or may not be included in this study at the discretion of the principal investigator and study team
Interventions Intervention group: at baseline assessment participants given individualised exercise prescriptions with the aim of
achieving 30-minutes of an endurance-style exercise (team sports, walking, jump roping, stair climbing or more
complexTabata-styleworkouts) 5 times/week for 6months. At 4-6weeks and8-10weeks post-enrolment, participants
attend a follow-up 30-minute session which will vary based on initial assessment and previous exercise prescription
success, but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as
reinforcement of previously learned techniques with additional individualised recommendations. Participants will
also receive motivational messages starting 14 days after enrolment via preferred contact method (SMS, telephone
call and/or email) every 3-4 days over the 6-month study period. Participants also given access to “Do More, B’More,
Live Fit” web page which includes spotlighted exercises, instructional exercise photos and videos; also invited to join
the “Do More, B’More, Live Fit” Activity Group via the FitBit Dashboard and to friend the study team members
and other exercise-intervention participants in order to take part in FitBit step-goal challenges
Control group: at baseline assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps.
At routine clinic visits, baseline and follow-up assessments (3 and 6 month clinic visits) participants given generic,
non-personalised encouragement and recommendations (if requested by the participant) for physical activity. At the
3- and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing
data concerning for equipment failure or user error
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NCT03109912 (Continued)
Outcomes Included in this study were:
Primary outcomes: LCI (LCI 2.5 and LCI 5.0); daily activity via FitBit step count and daily step count (mean,
median and highest daily) recorded through participant FitBit flex
Secondary outcomes: FEV1 %predicted; self-reported physical activity (Habitual Activity estimationScale);HRQoL
(CFQ-R); exercise capacity (modified shuttle walk test); acceptability and feasibility of the programme using semi-
structured interviews
Notes This study evaluates the “Do More, B’More, Live Fit”, a 6-month fitness programme designed to optimise exercise
habits of participants with CF through structured exercises with personalised coaching, exercise equipment including
the FitBit Flex, online support and motivational messages delivered electronically. The intervention incorporates
fitness preferences and encompasses endurance, strength and flexibility exercises while adjusting to physical fitness
needs. The hypothesis is that intervention participants will have increased and sustained engagement and better
health outcomes compared to control group participants
Oliveira 2010
Methods Design: parallel, prospective controlled clinical study; single-centre study; not clear from the abstract whether par-
ticipants were randomly allocated to different interventions
Participants 20 participants with CF, mean age 13.21 years.
Intervention group: n = 10.
Control group: n = 10.
Inclusion criteria: not specified
Exclusion criteria: not specified.
Interventions Group 1: physical training at a private clinic and physiotherapy clinic
Group 2: no physical training.
Outcomes Included in this study were: lung function (not specified), 3-minute step test, maximum exertion test (not specified)
, collection of blood samples and a quality of life questionnaire
Notes Unclear whether this is a RCT. We contacted one author of the abstract, but have not received a reply to date. No
information available in the abstract about types of exercises, intensity, frequency and duration of exercise training
Phillips 2008
Methods Design: parallel RCT.
Participants 35 participants aged 8 - 21 years with an FEV1 < 60%, who were admitted for a ≥ 10 day hospitalisation for a CF
exacerbation
29 participants, mean (SD) age 15 (3.5) years, completed the study; 4 dropouts were recorded
Inclusion criteria: not specified.
Exclusion criteria: not specified.
Interventions Training for PT management of a CF exacerbation during an inpatient hospital stay
Group 1: standardized moderate-to-high intensity resistance and aerobic training consisting of 1 hour of resistance
training and flexibility training 3 days per week and 20 - 30 min of aerobic and balance training 2 days per week
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Phillips 2008 (Continued)
Group 2: current standard of care which included 20 - 30 min of variable intensity aerobic training 5 days per week
Outcomes MST and multiple measures of peripheral muscle performance at admission and discharge. Adverse effects
Notes Study completed in 2008.
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire - revised
FEF25−75: mid forced expiratory flow
FEV1: forced expiratory volume
FVC: forced vital capacity
HRQoL: health-related quality of life
MST: modified shuttle test
PT: physical therapy
RCT: randomised controlled trial
SD: standard deviation
VO2 max: maximum oxygen consumption
6MWT: 6-minute walk test
Characteristics of ongoing studies [ordered by study ID]
Donadio 2017
Trial name or title Effect of exercise orientations in the posture and plantar pressure distribution in children and adolescents
with cystic fibrosis
Methods RCT (open-label).
Design: parallel (2 arms).
Duration: 3 months.
Participants Target sample size: 34
Inclusion criteria: diagnosis of CF, clinically stable disease and regular follow-up at the CF outpatient clinic
Exclusion criteria: children and adolescents with comprehension deficits and/or who present arms/legs
problems that would make it impossible to perform the tests
Age minimum: 6 years.
Age maximum: 20 years.
Interventions Intervention group (n = 17): participants will receive a written manual with orientations regarding physical
activity, including weekly frequency. The manual contains physical activities and stretching orientations and
participants are advised to perform their favourite exercise modality with a minimal frequency of 3 times per
week, during 40 minutes. The manual also contains a calendar where the participant will mark the days when
activities were performed
Control group (n = 17): participants will keep with their regular routine care orientations
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Donadio 2017 (Continued)
Outcomes Primary outcome
General posture improvement: measured by the number of degrees obtained for kyphosis, lordosis, head
position and chest size, using a specific software
Secondary outcomes
Change in balance (measured using a baropodometer).
Lung function using spirometry (FEV1).
Starting date Date of first enrolment; 01 November 2013.
Recruitment completed.
Contact information Márcio Vinícius Fagundes Donadio (mdonadio@pucrs.br) - União Brasileira de Educação e Assistência -
Porto Alegre, RS, Brazil
Notes
Gupta 2017
Trial name or title Effects of exercise intervention program on bone mineral accretion in children and adolescents with cystic
fibrosis
Methods RCT (stratified block randomization, allocation concealed using sequentially numbered, sealed, opaque en-
velopes, open label)
Design: parallel.
Single centre.
Duration: 1 year.
Participants Total sample size: 30.
Inclusion criteria: childrenwith confirmeddiagnosis ofCF (sweat chloride≥ 60mEq/l on2ormore occasions
in a child with clinical features suggestive of CF), stable medical condition (not required IV antibiotics for
last 1 month prior to enrolment), FEV1 ≥ 20%.
Exclusion criteria: children unwilling to participate in the study; presence of any prior diagnosed muscu-
loskeletal disorder such as rheumatoid arthritis, muscular dystrophy, chronic renal failure
Age minimum: 6 years.
Age maximum: 18 years.
Gender: both.
Interventions Intervention group: exercise program - resistance exercise and plyometric jumping exercise, 1x daily, 3x a
week for 1 year.
Control group: no exercise program, continue with regular physical activity for 1 year
Outcomes Primary outcome
Mean bone mineral density at 1 year.
Secondary outcomes
Lung function (FEV1 and FVC) at baseline, 3 months, 6 months, 9 months and at the end of 1 year.
Exercise capacity at baseline and at the end of 1 year.
CFQ-R at baseline and at the end of year.
Starting date Date of first enrolment: 08 September 2012.
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Gupta 2017 (Continued)
Contact information Sumita Gupta (Physiotherapist)
All India Institute of Medical Sciences, Department of Pediatrics, AIIMS, Ansari Nagar,New Delhi, DELHI
110029, India.
Email sumitabisoi@gmail.com
Professor SK Kabra
Department of Pediatrics, AIIMS, Ansari Nagar,New Delhi, DELHI 110029, India.
Email: skkabra@hotmail.com
Notes
Hebestreit 2016
Trial name or title Effects of a Partially Supervised Conditioning Program in CF (ACTIVATE-CF, NCT01744561)
Methods Design: parallel RCT; duration 12 months; international, multicentre study
Participants A total of 292 participants will be recruited.
Inclusion criteria: males and females aged 12 years and older with a confirmed diagnosis of CF; FEV1 ≥
35% predicted and access to Internet.
Exclusion criteria: participation in another clinical trial up to 4 weeks prior to the first baseline visit;
pregnancy or breast feeding; inability to exercise; more than 4 hours of reported strenuous physical activities
per week currently or up to 3 months prior to baseline measurements and not already planned within the
coming 6 months; unstable condition precluding exercise (major haemoptysis or pneumothorax within the
last 3 months, acute exacerbation and IV antibiotics during the last 4 weeks, planned surgery, listed for lung
transplantation, major musculoskeletal injuries such as fractures or sprains during the last 2 months, others
according to the impression of the doctor); cardiac arrhythmias with exercise; requiring additional oxygen
with exercise; recent diagnosis of diabetes 3 months prior to screening or at screening; recent changes in
medication 1 month or less prior to screening (systemic steroids, ibuprofen, inhaled antibiotics, mannitol,
DNAse, hypertonic saline); at least one G551D mutation and not on ivacaftor (VX770) yet but planned start
or planned stop of ivacaftor during the trial and colonization with Burkholderia cenocepacia.
Interventions Intervention group: addition of 3 hours of intense physical activities per week to baseline activities. Weekly
exercise should include at least 30 min of strength building activities and at least 2 hours of aerobic activities.
Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time. Participants
are given exercise counselling to boost motivation towards an active lifestyle, strategies include face-to-face
information, motivational interviewing, clear goal settings, a written “activity contract” with specific informa-
tion on which activities are scheduled for which day and for how long, a pedometer, a web-based activity diary
(www.activate-cf.org) providing feedback on missing time in intense activities to reach the weekly goal, and
repeated counselling via telephone contacts and during clinic visits. A full manual describing the intervention
and all intervention materials including the website are available in four languages: Dutch, English, French,
and German
Control group: the control group is requested to their keep activity level constant
Outcomes Primary outcome: FEV1 % predicted (change from baseline to 6 months)
Secondary outcomes: VO2 peak (% predicted change from baseline to 6 months and baseline to 12 months)
; maximal aerobic power (% predicted change from baseline to 6 months and baseline to 12 months); steps
per day (change from baseline to 6 months and baseline to 12 months); exercise steps per day (change from
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Hebestreit 2016 (Continued)
baseline to 6 months and baseline to 12 months); self-reported physical activity (baseline to 6 months and
baseline to 12 months); FEV1 (% predicted, change from 6months to 12 months and baseline to 12 months)
; FVC (% predicted, change from baseline to 6 months and baseline to 12 months); residual volume in % of
total lung capacity (change from baseline to 6 months and baseline to 12 months); time to first exacerbation
(baseline to 6 months and baseline to 12 months); number of upper respiratory tract infections from diary
(baseline to 6months and baseline to 12 months); days on additional oral or IV antibiotics from questionnaire
(baseline to 6 months and baseline to 12 months); body mass index (baseline to 6 months and baseline to 12
months); muscle mass (baseline to 6 estimated from skinfold thickness (baseline to 6 months and baseline to
12 months); body fat estimated from skinfold thickness (baseline to 6 months and baseline to 12 months)
; HRQoL (CFQ-R, baseline to 6 months and baseline to 12 months); depression, anxiety and stress scores
from Depression Anxiety Stress Scales (baseline to 6 months and baseline to 12 months); plasma glucose
concentrations 1 and 2 hours after a standardised glucose load (standardised oral glucose tolerance test only
for participants without CF-related diabetes mellitus (baseline to 9 months); adverse events possibly or likely
related to exercise (causality as judged by investigator, baseline to 6 months and baseline to 12 months); severe
adverse events and serious adverse events (baseline to 6 months and baseline to 12 months)
Other outcome measures: compliance with the exercise goal based on questionnaire and diary (baseline to
6 months and baseline to 12 months); lung clearance index based on nitrogen multiple breath washout, in
selected centres only (baseline to 6 months and baseline to 12 months); time spent in moderate-and-vigorous
physical activity based on accelerometry, in selected centres only (baseline to 6 months and baseline to 12
months); bone mineral density and body composition based on dual energy x-ray absorptiometry, in selected
centres only (baseline to 6 months and baseline to 12 months); mucociliary clearance with exercise based on
nuclear medicine scans, US centres only (baseline to 6 months)
Starting date July 2014
Contact information Prof. Dr. Helge U Hebestreit
Telephone: +49 931 201 22 728
E-mail: hebstreit@uni-wuerzburg.de
Notes ACTIVATE-CF is an international, multicentre, randomised controlled trial to assess the effects of additional
intense physical activity on a variety of outcomes. A combination of several strategies is used to boost moti-
vation towards an active lifestyle. The primary objective of this study is to evaluate the effects of a 12-months
partially supervised exercise intervention along with regular motivation on FEV1 in a large international group
of people with CF.
NCT02700243
Trial name or title Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial (INTERACT)
Methods Design: parallel RCT, single-centre study at Boston Children’s Hospital, USA
Participants Enrolment goal: 80 participants with CF.
Inclusion criteria: males and females aged 18 years and older with a confirmed diagnosis of CF; able to
complete at least level 1 of the baseline exercise fitness test; participants must not have required IV antibiotics
for a CF exacerbation within 30 days of starting the study
Exclusion criteria: pregnancy at enrolment; a history of CF exacerbation requiring IV antibiotics with the
last month; use of a fitness tracker or similar product with 6 months of enrolment
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NCT02700243 (Continued)
Interventions Intervention group: given a Fitbit and followed for 1 year, completing surveys and exercise tests
Control group: usual care for 1 year, then offered a Fitbit in the 2nd year. Followed to assess use of Fitbit
and health outcomes
Outcomes Included in this study were:
Primary outcome: submaximal exercise capacity (graded exercise test: 2 years at enrolment, 6 months, 12
months, 24 months)
Secondary outcomes: Fitbit activity data (2 years); self-reported physical activity (Habitual Activity Estima-
tion Scale, 2 years); FEV1 relative change (% predicted, 2 years); FEV1 from before study (baseline, to each
data collection time point, and from one data collection time point to the next); FVC relative change (%
predicted, 2 years); FVC from before study (baseline, to each data collection time point, and from one data
collection time point to the next); FEF25−75 relative change (% predicted, 2 years; FEF25−75 from before
study (baseline, to each data collection time point, and from one data collection time point to the next);
incidence of exacerbations requiring IV antibiotics (2 years); body mass index (2 years); HRQoL (CFQ-R, 2
years); overall qualitative assessment of participant’s satisfaction with the Fitbit (2 years; 6-month time point)
; overall qualitative assessment of participant’s potential barriers to Fitbit use (2 years, 6-month time point)
; qualitative data obtained by open-ended interview; depression (PHQ9, 2 years: enrolment, 6 months, 12
months, 18 months, 24 months); anxiety (GAD-7, 2 years: enrolment, 6 months, 12 months, 18 months,
24 months)
Starting date March 14, 2016
Contact information Ahmet Uluer, Director, Adult Cystic Fibrosis Program, Boston Children’s Hospital
Notes The aim of this study is to evaluate whether the use of a Fitbit device and an exercise prescription is associated
with increased daily activity and in turn increased exercise tolerance in young adult patients with cystic fibrosis
(CF). The investigators hypothesize that use of the Fitbit and an exercise prescription will be associated with
increased exercise tolerance compared to standard counselling and an exercise prescription alone
CES-D scale: Centre for Epidemiological Studies - Depression scale
CF: cystic fibrosis
CFQ-R: Cystic Fibrosis Questionnaire-Revised
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
HADS: Hospital Anxiety and Depression Scale
HAES: Habitual Activity Estimation Scale
IV: intravenous
MST: modified shuttle test
PSQI: Pittsburgh Sleep Quality Index
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Aerobic training versus no physical training
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in VO2 peak during
maximal exercise (ml/min per
kg BW)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At hospital discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 8.53 [4.85, 12.21]
1.2 At 1 month after discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 4.91 [1.13, 8.69]
1.3 At 3 months 2 59 Mean Difference (IV, Fixed, 95% CI) 2.29 [-2.71, 7.29]
1.4 At 6 months 1 25 Mean Difference (IV, Fixed, 95% CI) 18.33 [8.95, 27.71]
1.5 At 6 months off training 1 22 Mean Difference (IV, Fixed, 95% CI) 9.51 [-1.32, 20.34]
1.6 At 18 months off training 1 18 Mean Difference (IV, Fixed, 95% CI) 2.86 [-9.70, 15.42]
2 Change in FEV1(% predicted) 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At hospital discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 2.03 [-2.31, 6.37]
2.2 At 1 month after discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 1.53 [-2.93, 5.99]
2.3 At 3 months 2 58 Mean Difference (IV, Fixed, 95% CI) 7.21 [2.49, 11.94]
2.4 At 6 months 1 25 Mean Difference (IV, Fixed, 95% CI) 17.17 [8.59, 25.75]
2.5 At 6 months off training 1 23 Mean Difference (IV, Fixed, 95% CI) 16.92 [6.07, 27.77]
2.6 At 18 months off training 1 20 Mean Difference (IV, Fixed, 95% CI) 12.45 [1.27, 23.63]
2.7 Annual rate of change over
36 months
1 65 Mean Difference (IV, Fixed, 95% CI) 2.01 [-0.06, 4.08]
3 Change in health-related quality
of life
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 At 1 month after discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in mean power during
WAnT (W per kg BW)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 At 18 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in strength (Newton
metres)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 At 1 month after discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in peak work capacity
during maximal exercise (W
per kg BW)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 At 18 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Annual rate of change in peak
work capacity during maximal
exercise over 36 month (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Change in treadmill speed
(km/h)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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8.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in treadmill exercise
time (min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in heart rate (beats per
min)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At rest at 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At maximal exercise at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 At maximal exercise -
annual rate of change over 36
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Change in oxygen saturation
(%)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 During maximal exercise
at hospital discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 During maximal exercise
at 3 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 At rest at 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Annual rate of change in peak
VE over 36 months (L/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Change in FVC (% predicted) 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 At hospital discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 0.06 [-2.55, 2.67]
13.2 At 3 months 2 58 Mean Difference (IV, Fixed, 95% CI) 4.89 [0.69, 9.08]
13.3 At 6 months 1 25 Mean Difference (IV, Fixed, 95% CI) 12.51 [5.90, 19.12]
13.4 At 1 month after
discharge
1 44 Mean Difference (IV, Fixed, 95% CI) -0.11 [-2.64, 2.42]
13.5 At 6 months off training 1 23 Mean Difference (IV, Fixed, 95% CI) 15.09 [6.01, 24.17]
13.6 At 18 months off
training
1 20 Mean Difference (IV, Fixed, 95% CI) 9.10 [-0.94, 19.14]
13.7 Annual rate of change
over 36 months
1 65 Mean Difference (IV, Fixed, 95% CI) 2.17 [0.47, 3.87]
14 Change in FEF25-75 (%
predicted)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Annual rate of change 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in RV/TLC (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Change in FEV1/FVC (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Change in total physical
activity (counts per min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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17.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Change in
moderate-to-vigorous physical
activity (hours per week)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Change in total physical
activity (MJ/day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Change in body weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 At 1 month after
discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Change in BMI (kg/m2) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Change in BMI z score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Change in fat-free mass (kg) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
23.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.2 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.3 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.4 At 1 month after
discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.5 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.6 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Change in body fat (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Annual rate of change of ideal
weight for height (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26 Change in triceps skinfold
thickness (mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Change in arm muscle
circumference (cm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Anaerobic training versus no physical training
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in VO2 peak during
maximal exercise (ml/min per
kg BW)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At hospital discharge 1 44 Mean Difference (IV, Fixed, 95% CI) 1.95 [-1.61, 5.51]
1.2 At 1 month after discharge 1 44 Mean Difference (IV, Fixed, 95% CI) -0.40 [-4.03, 3.23]
1.3 At 3 months 2 41 Mean Difference (IV, Fixed, 95% CI) 5.54 [-0.25, 11.34]
1.4 At 6 months 1 18 Mean Difference (IV, Fixed, 95% CI) 17.7 [5.98, 29.42]
1.5 At 6 months off training 1 16 Mean Difference (IV, Fixed, 95% CI) 11.59 [-1.02, 24.20]
1.6 At 18 months off training 1 15 Mean Difference (IV, Fixed, 95% CI) 9.26 [-4.26, 22.78]
2 Change in FEV1 (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 1 month after discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 At 18 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in HRQoL 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 1 month after discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in HRQoL physical
function (CF questionnaire)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in peak power during
WAnT (W)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in mean power during
WAnT (W)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in mean power during
WAnT (W per kg BW)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 At 18 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in lower limb strength
(Newton metres)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 At 1 month after discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in peak work capacity
during maximal exercise (W)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in peak work capacity
during maximal exercise (W
per kg body weight)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Change in lactate during
maximal exercise (mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Change in peak oxygen
saturation during maximal
exercise (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Change in FVC (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 At 1 month after
discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.5 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.6 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in RV/TLC (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in total physical
activity (counts per min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Change in moderate to
vigorous physical activity
(hours per week)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Change in physical activity
(MJ/day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Change in weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 At 1 month after
discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Change in BMI (kg/m2) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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20 Change in fat-free mass (kg) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 At hospital discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.3 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.4 At 1 month after
discharge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.5 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.6 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Change in body fat (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.4 At 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Combined aerobic and anaerobic training versus no physical training
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in VO2 peak during
maximal exercise (ml/min per
kg BW)
2 Mean Difference (Fixed, 95% CI) Totals not selected
1.1 At 12 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in FEV1 (% predicted) 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Annual change in FEV1 (mL) 1 Mean Difference (Fixed, 95% CI) Totals not selected
3.1 At 12 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in subjective health
perception (CFQ-R)
1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in Quality of Life:
CFQ-R
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Physical Functioning at
12 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Vitality at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.3 Emotional state at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Eating disturbances at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Treatment burden at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Health perception at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Social limitations at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Body image at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.9 Role limitations at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.10 Weight problems at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.11 Respiratory symptoms at
12 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.12 Digestion symptoms at
12 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in peak power during
WAnT (W per kg body weight)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in mean power during
WAnT (W per kg body weight)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in muscle strength (all
limbs) (1RM test)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Right upper limb at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Left upper limb at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Right lower limb at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Left lower limb at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in muscular strength -
leg press (kg; 1 RM test)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in Muscular Strength -
Chest press (kg; 1 RM test)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Change in Muscular Strength -
Latpull down (kg; 1 RM test)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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12 Change in Muscular Strength -
Biceps curl (kg; RM test)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Change in Muscular Endurance
- Number of push ups
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in Muscular Endurance
- Number of sit ups
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in Muscular Endurance
- Flexibility (cm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Change in Muscular Endurance
- hand grip strength (kg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Change in peak work capacity
during maximal exercise (W
per kg BW)
1 Mean Difference (Fixed, 95% CI) Totals not selected
17.1 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
17.3 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Change in functional exercise
capacity
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 6MWT distance (m) at 3
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 6MWT distance (%
predicted) at 3 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Change in peak heart rate
during 6MWT (beats/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Annual change in peak heart
rate (beat/min)
1 Mean Difference (Fixed, 95% CI) Totals not selected
20.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Annual change in VE (L/min) 1 Mean Difference (Fixed, 95% CI) Totals not selected
21.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Change in peak ventilation
(VE) during maximal exercise
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Annual change in lactate
(mmol/l)
1 Mean Difference (Fixed, 95% CI) Totals not selected
23.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
23.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
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24 Change in RR during 6MWT
(breaths/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Annual change in RR
(breaths/min)
1 Mean Difference (Fixed, 95% CI) Totals not selected
25.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
25.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
26 Annual change in RER 1 Mean Difference (Fixed, 95% CI) Totals not selected
26.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
26.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Change in oxygen saturation
(%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 At rest (at 3 months) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.2 During 6MWT (at 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Change in Borg breathlessness
score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
28.1 At rest (at 3 months) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.2 During 6MWT (at 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
29 Annual change in Borg
breathlessness score
1 Mean Difference (Fixed, 95% CI) Totals not selected
29.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
29.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
30 Change in Borg fatigue score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
30.1 At rest (at 3 months) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.2 During 6MWT (at 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
31 Annual change in Borg muscle
effort
1 Mean Difference (Fixed, 95% CI) Totals not selected
31.1 Constant load bicycle
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
31.2 Constant load arm
ergometry (at 1 year)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
32 Change in FVC (% predicted) 3 Mean Difference (Fixed, 95% CI) Totals not selected
32.1 At 12 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
32.2 At 3 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
32.3 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
32.4 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
32.5 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
33 Annual change in FVC (mL) 1 Mean Difference (Fixed, 95% CI) Totals not selected
33.1 At 1 year 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
34 Change in RV/TLC (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
34.1 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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34.2 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
34.3 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
35 Change in Total Energy
Expenditure (k/cal)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
35.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
36 Change in the Number of Steps 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
36.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
37 Change in Physical Activity
(%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
37.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
38 Change in vigorous physical
activity (hours per week)
1 Mean Difference (Fixed, 95% CI) Totals not selected
38.1 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
38.2 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
38.3 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
39 Change in body weight (kg) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
39.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
39.2 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
39.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
39.4 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
40 Change in BMI (kg/m2) 3 Mean Difference (Fixed, 95% CI) Totals not selected
40.1 At 12 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
40.2 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
40.3 Annual change 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
40.4 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
40.5 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
41 Change in sum of four
skinfolds (mm)
1 Mean Difference (Fixed, 95% CI) Totals not selected
41.1 At 3-6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
41.2 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
41.3 At 12-18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
42 Change in body fat (%) 2 Mean Difference (Fixed, 95% CI) Totals not selected
42.1 At 12 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
42.2 At 3 - 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
42.3 At 6 months off training 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
42.4 At 12 - 18 months off
training
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
43 Change in fat-mass (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
43.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
44 Change in fat-free mass (kg) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
44.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
44.2 At 3 - 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
44.3 At 6 months off training 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
44.4 At 12 - 18 months off
training
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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45 Change in metabolic
parameters (HbA1c (%))
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
45.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
46 Change in metabolic
parameters (Glucose AUC)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
46.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
47 Change in metabolic
parameters (Total Insulin
AUC)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
47.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
48 Change in metabolic
parameters (Insulin Sensitivity
Index)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
48.1 At 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
49 Change in Plasma Glucose
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
49.1 After 0 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
49.2 After 30 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
49.3 After 60 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
49.4 After 90 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
49.5 After 120 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
50 Change in Plasma Insulin
(µU/mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
50.1 After 0 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
50.2 After 30 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
50.3 After 60 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
50.4 After 90 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
50.5 After 120 minutes 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Aerobic training versus no physical training, Outcome 1 Change in VO2 peak
during maximal exercise (ml/min per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 1 Change in VO2 peak during maximal exercise (ml/min per kg BW)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 7.31 (6.29) 22 -1.22 (6.15) 100.0 % 8.53 [ 4.85, 12.21 ]
Subtotal (95% CI) 22 22 100.0 % 8.53 [ 4.85, 12.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
2 At 1 month after discharge
Selvadurai 2002 22 7.56 (6.75) 22 2.65 (6.02) 100.0 % 4.91 [ 1.13, 8.69 ]
Subtotal (95% CI) 22 22 100.0 % 4.91 [ 1.13, 8.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
3 At 3 months
Hommerding 2015 17 1.1 (4.6) 17 2.3 (11.9) 68.0 % -1.20 [ -7.26, 4.86 ]
Kriemler 2013 15 7.26 (12.1) 10 -2.45 (10.3) 32.0 % 9.71 [ 0.86, 18.56 ]
Subtotal (95% CI) 32 27 100.0 % 2.29 [ -2.71, 7.29 ]
Heterogeneity: Chi2 = 3.97, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.90 (P = 0.37)
4 At 6 months
Kriemler 2013 15 6.85 (12.6) 10 -11.48 (11.1) 100.0 % 18.33 [ 8.95, 27.71 ]
Subtotal (95% CI) 15 10 100.0 % 18.33 [ 8.95, 27.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.00013)
5 At 6 months off training
Kriemler 2013 14 0.16 (13.1) 8 -9.35 (12.1) 100.0 % 9.51 [ -1.32, 20.34 ]
Subtotal (95% CI) 14 8 100.0 % 9.51 [ -1.32, 20.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
6 At 18 months off training
Kriemler 2013 11 -4.5 (13.8) 7 -7.36 (12.9) 100.0 % 2.86 [ -9.70, 15.42 ]
Subtotal (95% CI) 11 7 100.0 % 2.86 [ -9.70, 15.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
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Analysis 1.2. Comparison 1 Aerobic training versus no physical training, Outcome 2 Change in FEV1(%
predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 2 Change in FEV1(% predicted)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 6.54 (7.76) 22 4.51 (6.9) 100.0 % 2.03 [ -2.31, 6.37 ]
Subtotal (95% CI) 22 22 100.0 % 2.03 [ -2.31, 6.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 At 1 month after discharge
Selvadurai 2002 22 6.25 (7.94) 22 4.72 (7.15) 100.0 % 1.53 [ -2.93, 5.99 ]
Subtotal (95% CI) 22 22 100.0 % 1.53 [ -2.93, 5.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 At 3 months
Hommerding 2015 17 -1.8 (8.6) 17 1 (14.2) 35.9 % -2.80 [ -10.69, 5.09 ]
Kriemler 2013 14 4.89 (8) 10 -7.92 (6.7) 64.1 % 12.81 [ 6.91, 18.71 ]
Subtotal (95% CI) 31 27 100.0 % 7.21 [ 2.49, 11.94 ]
Heterogeneity: Chi2 = 9.64, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 2.99 (P = 0.0028)
4 At 6 months
Kriemler 2013 15 6.17 (11.6) 10 -11 (10.1) 100.0 % 17.17 [ 8.59, 25.75 ]
Subtotal (95% CI) 15 10 100.0 % 17.17 [ 8.59, 25.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
5 At 6 months off training
Kriemler 2013 15 1.09 (13.1) 8 -15.83 (12.4) 100.0 % 16.92 [ 6.07, 27.77 ]
Subtotal (95% CI) 15 8 100.0 % 16.92 [ 6.07, 27.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.06 (P = 0.0022)
6 At 18 months off training
Kriemler 2013 12 0.31 (13.2) 8 -12.14 (12) 100.0 % 12.45 [ 1.27, 23.63 ]
Subtotal (95% CI) 12 8 100.0 % 12.45 [ 1.27, 23.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
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(. . . Continued)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
7 Annual rate of change over 36 months
Schneiderman-Walker 2000 30 -1.46 (3.55) 35 -3.47 (4.93) 100.0 % 2.01 [ -0.06, 4.08 ]
Subtotal (95% CI) 30 35 100.0 % 2.01 [ -0.06, 4.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
-50 -25 0 25 50
Favours No Physical Training Favours Aerobic Training
Analysis 1.3. Comparison 1 Aerobic training versus no physical training, Outcome 3 Change in health-
related quality of life.
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 3 Change in health-related quality of life
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month after discharge
Selvadurai 2002 22 0.09 (0.12) 22 -0.01 (0.12) 0.10 [ 0.03, 0.17 ]
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Analysis 1.4. Comparison 1 Aerobic training versus no physical training, Outcome 4 Change in mean power
during WAnT (W per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 4 Change in mean power during WAnT (W per kg BW)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 12 0.86 (1.2) 10 0.58 (0.7) 0.28 [ -0.53, 1.09 ]
2 At 6 months
Kriemler 2013 13 -0.42 (1.3) 10 -0.33 (0.7) -0.09 [ -0.92, 0.74 ]
3 At 6 months off training
Kriemler 2013 12 -0.28 (1.1) 8 -0.51 (0.9) 0.23 [ -0.65, 1.11 ]
4 At 18 months off training
Kriemler 2013 9 -1.13 (1.2) 8 -1.41 (0.9) 0.28 [ -0.72, 1.28 ]
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Analysis 1.5. Comparison 1 Aerobic training versus no physical training, Outcome 5 Change in strength
(Newton metres).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 5 Change in strength (Newton metres)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 1.83 (6.23) 22 -6.3 (6.1) 8.13 [ 4.49, 11.77 ]
2 At 1 month after discharge
Selvadurai 2002 22 1.9 (6.12) 22 -4.23 (6.25) 6.13 [ 2.47, 9.79 ]
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Analysis 1.6. Comparison 1 Aerobic training versus no physical training, Outcome 6 Change in peak work
capacity during maximal exercise (W per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 6 Change in peak work capacity during maximal exercise (W per kg BW)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 15 0.33 (0.5) 10 -0.19 (0.4) 0.52 [ 0.17, 0.87 ]
2 At 6 months
Kriemler 2013 13 0.46 (0.4) 10 -0.35 (0.3) 0.81 [ 0.52, 1.10 ]
3 At 6 months off training
Kriemler 2013 12 0.04 (0.4) 8 -0.21 (0.4) 0.25 [ -0.11, 0.61 ]
4 At 18 months off training
Kriemler 2013 9 -0.1 (0.6) 7 -0.23 (0.6) 0.13 [ -0.46, 0.72 ]
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Analysis 1.7. Comparison 1 Aerobic training versus no physical training, Outcome 7 Annual rate of change
in peak work capacity during maximal exercise over 36 month (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 7 Annual rate of change in peak work capacity during maximal exercise over 36 month (%)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schneiderman-Walker 2000 30 -1.68 (5.16) 35 -2.5 (6.08) 0.82 [ -1.91, 3.55 ]
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Analysis 1.8. Comparison 1 Aerobic training versus no physical training, Outcome 8 Change in treadmill
speed (km/h).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 8 Change in treadmill speed (km/h)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 -0.5 (2.6) 17 0.1 (1.5) -0.60 [ -2.03, 0.83 ]
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Analysis 1.9. Comparison 1 Aerobic training versus no physical training, Outcome 9 Change in treadmill
exercise time (min).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 9 Change in treadmill exercise time (min)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 -0.3 (1.7) 17 0.2 (2.8) -0.50 [ -2.06, 1.06 ]
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Analysis 1.10. Comparison 1 Aerobic training versus no physical training, Outcome 10 Change in heart rate
(beats per min).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 10 Change in heart rate (beats per min)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At rest at 3 months
Hommerding 2015 17 3 (20.4) 17 -4 (16.1) 7.00 [ -5.35, 19.35 ]
2 At maximal exercise at 3 months
Hommerding 2015 17 10.5 (37.8) 17 6.5 (23) 4.00 [ -17.03, 25.03 ]
3 At maximal exercise - annual rate of change over 36 months
Schneiderman-Walker 2000 30 0.51 (3.68) 35 -0.59 (4.33) 1.10 [ -0.85, 3.05 ]
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Analysis 1.11. Comparison 1 Aerobic training versus no physical training, Outcome 11 Change in oxygen
saturation (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 11 Change in oxygen saturation (%)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 During maximal exercise at hospital discharge
Selvadurai 2002 22 -1.28 (0.43) 22 -1.9 (0.56) 0.62 [ 0.32, 0.92 ]
2 During maximal exercise at 3 months
Hommerding 2015 17 -1 (2.9) 17 -10.6 (31) 9.60 [ -5.20, 24.40 ]
3 At rest at 3 months
Hommerding 2015 17 0.2 (1.1) 17 0.9 (3.7) -0.70 [ -2.53, 1.13 ]
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Analysis 1.12. Comparison 1 Aerobic training versus no physical training, Outcome 12 Annual rate of
change in peak VE over 36 months (L/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 12 Annual rate of change in peak VE over 36 months (L/min)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schneiderman-Walker 2000 30 3.93 (8.31) 35 1.84 (6.57) 2.09 [ -1.60, 5.78 ]
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Analysis 1.13. Comparison 1 Aerobic training versus no physical training, Outcome 13 Change in FVC (%
predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 13 Change in FVC (% predicted)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 2.34 (4.62) 22 2.28 (4.22) 100.0 % 0.06 [ -2.55, 2.67 ]
Subtotal (95% CI) 22 22 100.0 % 0.06 [ -2.55, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
2 At 3 months
Hommerding 2015 17 0.4 (6.7) 17 2 (12.2) 40.2 % -1.60 [ -8.22, 5.02 ]
Kriemler 2013 14 3.67 (7.3) 10 -5.57 (6.2) 59.8 % 9.24 [ 3.82, 14.66 ]
Subtotal (95% CI) 31 27 100.0 % 4.89 [ 0.69, 9.08 ]
Heterogeneity: Chi2 = 6.17, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 2.28 (P = 0.022)
3 At 6 months
Kriemler 2013 15 4.66 (8.9) 10 -7.85 (7.8) 100.0 % 12.51 [ 5.90, 19.12 ]
Subtotal (95% CI) 15 10 100.0 % 12.51 [ 5.90, 19.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00021)
4 At 1 month after discharge
Selvadurai 2002 22 2.2 (4.27) 22 2.31 (4.29) 100.0 % -0.11 [ -2.64, 2.42 ]
Subtotal (95% CI) 22 22 100.0 % -0.11 [ -2.64, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
5 At 6 months off training
Kriemler 2013 15 -0.67 (10.9) 8 -15.76 (10.4) 100.0 % 15.09 [ 6.01, 24.17 ]
Subtotal (95% CI) 15 8 100.0 % 15.09 [ 6.01, 24.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
6 At 18 months off training
Kriemler 2013 12 -3.29 (12.1) 8 -12.39 (10.6) 100.0 % 9.10 [ -0.94, 19.14 ]
Subtotal (95% CI) 12 8 100.0 % 9.10 [ -0.94, 19.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
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(. . . Continued)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
7 Annual rate of change over 36 months
Schneiderman-Walker 2000 30 -0.25 (2.81) 35 -2.42 (4.15) 100.0 % 2.17 [ 0.47, 3.87 ]
Subtotal (95% CI) 30 35 100.0 % 2.17 [ 0.47, 3.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.013)
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Analysis 1.14. Comparison 1 Aerobic training versus no physical training, Outcome 14 Change in FEF25-75
(% predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 14 Change in FEF25−75 (% predicted)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Annual rate of change
Schneiderman-Walker 2000 30 -3.07 (5.34) 35 -3.87 (7) 0.80 [ -2.20, 3.80 ]
2 At 3 months
Hommerding 2015 17 -3.8 (13.8) 17 5.2 (26.7) -9.00 [ -23.29, 5.29 ]
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Analysis 1.15. Comparison 1 Aerobic training versus no physical training, Outcome 15 Change in RV/TLC
(%).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 15 Change in RV/TLC (%)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 14 -1.26 (6.9) 10 2.67 (6.9) -3.93 [ -9.53, 1.67 ]
2 At 6 months
Kriemler 2013 13 1.02 (8.5) 10 1.75 (8.2) -0.73 [ -7.60, 6.14 ]
3 At 6 months off training
Kriemler 2013 15 3.05 (7.8) 8 -0.14 (8.7) 3.19 [ -4.02, 10.40 ]
4 At 18 months off training
Kriemler 2013 12 1.41 (7.4) 8 3.39 (7.8) -1.98 [ -8.82, 4.86 ]
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Analysis 1.16. Comparison 1 Aerobic training versus no physical training, Outcome 16 Change in FEV1/FVC
(% predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 16 Change in FEV1/FVC (% predicted)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 -0.4 (7.7) 17 1 (13.2) -1.40 [ -8.66, 5.86 ]
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Analysis 1.17. Comparison 1 Aerobic training versus no physical training, Outcome 17 Change in total
physical activity (counts per min).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 17 Change in total physical activity (counts per min)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 13 0 (93) 9 -121 (116) 121.00 [ 29.90, 212.10 ]
2 At 6 months
Kriemler 2013 14 -133 (539) 9 -47 (98) -86.00 [ -375.51, 203.51 ]
3 At 6 months off training
Kriemler 2013 14 -118 (522) 8 -98 (138) -20.00 [ -309.67, 269.67 ]
4 At 18 months off training
Kriemler 2013 12 -96 (589) 7 -83 (142) -13.00 [ -362.46, 336.46 ]
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Analysis 1.18. Comparison 1 Aerobic training versus no physical training, Outcome 18 Change in
moderate-to-vigorous physical activity (hours per week).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 18 Change in moderate-to-vigorous physical activity (hours per week)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 13 -0.2 (2.5) 9 0.3 (1.8) -0.50 [ -2.30, 1.30 ]
2 At 6 months
Kriemler 2013 14 -0.8 (2.6) 9 -0.6 (2.4) -0.20 [ -2.28, 1.88 ]
3 At 6 months off training
Kriemler 2013 14 0.15 (2.3) 8 -0.4 (1.6) 0.55 [ -1.09, 2.19 ]
4 At 18 months off training
Kriemler 2013 12 0.4 (3.6) 7 -0.8 (1.3) 1.20 [ -1.05, 3.45 ]
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Analysis 1.19. Comparison 1 Aerobic training versus no physical training, Outcome 19 Change in total
physical activity (MJ/day).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 19 Change in total physical activity (MJ/day)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 12.82 (2.44) 22 11.62 (2.29) 1.20 [ -0.20, 2.60 ]
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Analysis 1.20. Comparison 1 Aerobic training versus no physical training, Outcome 20 Change in body
weight (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 20 Change in body weight (kg)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 0.8 (0.64) 22 1.03 (0.58) -0.23 [ -0.59, 0.13 ]
2 At 1 month after discharge
Selvadurai 2002 22 1.1 (0.78) 22 1 (0.66) 0.10 [ -0.33, 0.53 ]
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Analysis 1.21. Comparison 1 Aerobic training versus no physical training, Outcome 21 Change in BMI
(kg/m2).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 21 Change in BMI (kg/m
2
)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 15 0 (0.6) 10 -0.3 (0.5) 0.30 [ -0.13, 0.73 ]
2 At 6 months
Kriemler 2013 15 0 (0.5) 10 -0.4 (0.5) 0.40 [ 0.00, 0.80 ]
3 At 6 months off training
Kriemler 2013 15 0.1 (0.5) 8 -0.4 (0.6) 0.50 [ 0.01, 0.99 ]
4 At 18 months off training
Kriemler 2013 12 0 (0.8) 8 -0.4 (0.9) 0.40 [ -0.37, 1.17 ]
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Analysis 1.22. Comparison 1 Aerobic training versus no physical training, Outcome 22 Change in BMI z
score.
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 22 Change in BMI z score
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 0.2 (0.5) 17 0.1 (0.2) 0.10 [ -0.16, 0.36 ]
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Analysis 1.23. Comparison 1 Aerobic training versus no physical training, Outcome 23 Change in fat-free
mass (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 23 Change in fat-free mass (kg)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 0.61 (0.37) 22 0.6 (0.32) 0.01 [ -0.19, 0.21 ]
2 At 3 months
Kriemler 2013 15 -0.3 (1.2) 10 0 (0.7) -0.30 [ -1.05, 0.45 ]
3 At 6 months
Kriemler 2013 15 -0.4 (1.1) 10 -0.7 (1.8) 0.30 [ -0.95, 1.55 ]
4 At 1 month after discharge
Selvadurai 2002 22 0.69 (0.41) 22 0.65 (0.36) 0.04 [ -0.19, 0.27 ]
5 At 6 months off training
Kriemler 2013 15 -0.3 (1.5) 8 -1.2 (1.5) 0.90 [ -0.39, 2.19 ]
6 At 18 months off training
Kriemler 2013 12 -0.7 (1.4) 8 -1.2 (1.4) 0.50 [ -0.75, 1.75 ]
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Analysis 1.24. Comparison 1 Aerobic training versus no physical training, Outcome 24 Change in body fat
(%).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 24 Change in body fat (%)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 15 0.6 (1.3) 10 -1 (1.7) 1.60 [ 0.36, 2.84 ]
2 At 6 months
Kriemler 2013 15 1.1 (1.3) 10 -0.3 (2.7) 1.40 [ -0.40, 3.20 ]
3 At 6 months off training
Kriemler 2013 15 1.2 (1.8) 8 0.2 (3.6) 1.00 [ -1.66, 3.66 ]
4 At 18 months off training
Kriemler 2013 12 1.3 (2.6) 8 0.1 (3.5) 1.20 [ -1.64, 4.04 ]
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Analysis 1.25. Comparison 1 Aerobic training versus no physical training, Outcome 25 Annual rate of
change of ideal weight for height (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 25 Annual rate of change of ideal weight for height (%)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schneiderman-Walker 2000 30 0.48 (2.52) 35 -0.04 (2.75) 0.52 [ -0.76, 1.80 ]
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Analysis 1.26. Comparison 1 Aerobic training versus no physical training, Outcome 26 Change in triceps
skinfold thickness (mm).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 26 Change in triceps skinfold thickness (mm)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 0.3 (1.3) 17 -0.09 (1) 0.39 [ -0.39, 1.17 ]
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Analysis 1.27. Comparison 1 Aerobic training versus no physical training, Outcome 27 Change in arm
muscle circumference (cm).
Review: Physical exercise training for cystic fibrosis
Comparison: 1 Aerobic training versus no physical training
Outcome: 27 Change in arm muscle circumference (cm)
Study or subgroup Aerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Hommerding 2015 17 0.06 (0.4) 17 -0.1 (0.2) 0.16 [ -0.05, 0.37 ]
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Analysis 2.1. Comparison 2 Anaerobic training versus no physical training, Outcome 1 Change in VO2 peak
during maximal exercise (ml/min per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 1 Change in VO2 peak during maximal exercise (ml/min per kg BW)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 0.73 (5.89) 22 -1.22 (6.15) 100.0 % 1.95 [ -1.61, 5.51 ]
Subtotal (95% CI) 22 22 100.0 % 1.95 [ -1.61, 5.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 At 1 month after discharge
Selvadurai 2002 22 2.25 (6.25) 22 2.65 (6.02) 100.0 % -0.40 [ -4.03, 3.23 ]
Subtotal (95% CI) 22 22 100.0 % -0.40 [ -4.03, 3.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 At 3 months
Klijn 2004 11 1.5 (2.6) 9 -2.45 (10.3) 70.4 % 3.95 [ -2.95, 10.85 ]
Kriemler 2013 11 7.5 (12.8) 10 -1.84 (12.1) 29.6 % 9.34 [ -1.31, 19.99 ]
Subtotal (95% CI) 22 19 100.0 % 5.54 [ -0.25, 11.34 ]
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.061)
4 At 6 months
Kriemler 2013 8 6.22 (13.7) 10 -11.48 (11.1) 100.0 % 17.70 [ 5.98, 29.42 ]
Subtotal (95% CI) 8 10 100.0 % 17.70 [ 5.98, 29.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.0031)
5 At 6 months off training
Kriemler 2013 8 2.24 (13.6) 8 -9.35 (12.1) 100.0 % 11.59 [ -1.02, 24.20 ]
Subtotal (95% CI) 8 8 100.0 % 11.59 [ -1.02, 24.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
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(. . . Continued)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
6 At 18 months off training
Kriemler 2013 8 1.9 (13.8) 7 -7.36 (12.9) 100.0 % 9.26 [ -4.26, 22.78 ]
Subtotal (95% CI) 8 7 100.0 % 9.26 [ -4.26, 22.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 2.2. Comparison 2 Anaerobic training versus no physical training, Outcome 2 Change in FEV1 (%
predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 2 Change in FEV1 (% predicted)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 10.09 (7.43) 22 4.51 (6.9) 5.58 [ 1.34, 9.82 ]
2 At 1 month after discharge
Selvadurai 2002 22 9.8 (7.81) 22 4.72 (7.15) 5.08 [ 0.66, 9.50 ]
3 At 3 months
Kriemler 2013 11 3.19 (7.2) 10 -7.92 (6.7) 11.11 [ 5.16, 17.06 ]
4 At 6 months
Kriemler 2013 11 8.51 (10.8) 10 -11 (10.1) 19.51 [ 10.57, 28.45 ]
5 At 6 months off training
Kriemler 2013 11 0.26 (12) 8 -15.83 (12.4) 16.09 [ 4.95, 27.23 ]
6 At 18 months off training
Kriemler 2013 11 4.87 (11.5) 8 -12.14 (12) 17.01 [ 6.27, 27.75 ]
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Analysis 2.3. Comparison 2 Anaerobic training versus no physical training, Outcome 3 Change in HRQoL.
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 3 Change in HRQoL
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 month after discharge
Selvadurai 2002 22 0.02 (0.1) 22 -0.01 (0.12) 0.03 [ -0.04, 0.10 ]
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Analysis 2.4. Comparison 2 Anaerobic training versus no physical training, Outcome 4 Change in HRQoL
physical function (CF questionnaire).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 4 Change in HRQoL physical function (CF questionnaire)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Klijn 2004 11 88.4 (9) 9 87.1 (17.9) 1.30 [ -11.55, 14.15 ]
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Analysis 2.5. Comparison 2 Anaerobic training versus no physical training, Outcome 5 Change in peak
power during WAnT (W).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 5 Change in peak power during WAnT (W)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Klijn 2004 11 66.9 (23.8) 9 -3.4 (53.7) 70.30 [ 32.50, 108.10 ]
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Analysis 2.6. Comparison 2 Anaerobic training versus no physical training, Outcome 6 Change in mean
power during WAnT (W).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 6 Change in mean power during WAnT (W)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Klijn 2004 11 36.6 (11.8) 9 -6.7 (29.9) 43.30 [ 22.56, 64.04 ]
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Analysis 2.7. Comparison 2 Anaerobic training versus no physical training, Outcome 7 Change in mean
power during WAnT (W per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 7 Change in mean power during WAnT (W per kg BW)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 12 -0.05 (0.9) 10 0.58 (0.7) -0.63 [ -1.30, 0.04 ]
2 At 6 months
Kriemler 2013 11 -0.03 (0.8) 10 -0.33 (0.7) 0.30 [ -0.34, 0.94 ]
3 At 6 months off training
Kriemler 2013 11 -0.66 (0.9) 8 -0.51 (0.9) -0.15 [ -0.97, 0.67 ]
4 At 18 months off training
Kriemler 2013 11 -1.31 (1.4) 8 -1.41 (0.9) 0.10 [ -0.94, 1.14 ]
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Analysis 2.8. Comparison 2 Anaerobic training versus no physical training, Outcome 8 Change in lower
limb strength (Newton metres).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 8 Change in lower limb strength (Newton metres)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 18.32 (7.02) 22 -6.3 (6.1) 24.62 [ 20.73, 28.51 ]
2 At 1 month after discharge
Selvadurai 2002 22 15 (7.21) 22 -4.23 (6.25) 19.23 [ 15.24, 23.22 ]
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Analysis 2.9. Comparison 2 Anaerobic training versus no physical training, Outcome 9 Change in peak work
capacity during maximal exercise (W).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 9 Change in peak work capacity during maximal exercise (W)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Klijn 2004 11 11 (14) 9 -2 (5) 13.00 [ 4.11, 21.89 ]
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Analysis 2.10. Comparison 2 Anaerobic training versus no physical training, Outcome 10 Change in peak
work capacity during maximal exercise (W per kg body weight).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 10 Change in peak work capacity during maximal exercise (W per kg body weight)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 11 -0.69 (0.4) 10 -0.19 (0.4) -0.50 [ -0.84, -0.16 ]
2 At 6 months
Kriemler 2013 11 -0.04 (0.4) 10 -0.35 (0.3) 0.31 [ 0.01, 0.61 ]
3 At 6 months off training
Kriemler 2013 11 -0.11 (0.4) 8 -0.21 (0.4) 0.10 [ -0.26, 0.46 ]
4 At 18 months off training
Kriemler 2013 11 -0.23 (1.1) 7 -0.23 (0.6) 0.0 [ -0.79, 0.79 ]
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Analysis 2.11. Comparison 2 Anaerobic training versus no physical training, Outcome 11 Change in lactate
during maximal exercise (mmol/L).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 11 Change in lactate during maximal exercise (mmol/L)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Klijn 2004 11 1.8 (1.4) 9 -1.6 (2.9) 3.40 [ 1.33, 5.47 ]
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Analysis 2.12. Comparison 2 Anaerobic training versus no physical training, Outcome 12 Change in peak
oxygen saturation during maximal exercise (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 12 Change in peak oxygen saturation during maximal exercise (%)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 -1.57 (0.4) 22 -1.9 (0.56) 0.33 [ 0.04, 0.62 ]
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Analysis 2.13. Comparison 2 Anaerobic training versus no physical training, Outcome 13 Change in FVC (%
predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 13 Change in FVC (% predicted)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 2.45 (4.18) 22 2.28 (4.22) 0.17 [ -2.31, 2.65 ]
2 At 3 months
Kriemler 2013 11 1.8 (6.6) 10 -5.57 (6.2) 7.37 [ 1.89, 12.85 ]
3 At 6 months
Kriemler 2013 11 6.2 (8.3) 10 -7.85 (7.8) 14.05 [ 7.16, 20.94 ]
4 At 1 month after discharge
Selvadurai 2002 22 2.37 (4.09) 22 2.31 (4.29) 0.06 [ -2.42, 2.54 ]
5 At 6 months off training
Kriemler 2013 11 -2.1 (9.9) 8 -15.76 (10.4) 13.66 [ 4.38, 22.94 ]
6 At 18 months off training
Kriemler 2013 11 1.24 (10.2) 8 -12.39 (10.6) 13.63 [ 4.13, 23.13 ]
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Analysis 2.14. Comparison 2 Anaerobic training versus no physical training, Outcome 14 Change in RV/TLC
(%).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 14 Change in RV/TLC (%)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 11 -4.27 (4.7) 10 2.15 (5.6) -6.42 [ -10.87, -1.97 ]
2 At 6 months
Kriemler 2013 10 -6.37 (7.8) 10 8.49 (7) -14.86 [ -21.36, -8.36 ]
3 At 6 months off training
Kriemler 2013 11 1.08 (7.2) 8 7.94 (7.3) -6.86 [ -13.47, -0.25 ]
4 At 18 months off training
Kriemler 2013 11 -0.18 (6.3) 8 4.59 (6.5) -4.77 [ -10.61, 1.07 ]
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Analysis 2.15. Comparison 2 Anaerobic training versus no physical training, Outcome 15 Change in total
physical activity (counts per min).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 15 Change in total physical activity (counts per min)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 13 -104 (116) 9 -121 (116) 17.00 [ -81.59, 115.59 ]
2 At 6 months
Kriemler 2013 14 -30 (78) 9 -47 (98) 17.00 [ -58.95, 92.95 ]
3 At 6 months off training
Kriemler 2013 14 -88 (96) 8 -98 (138) 10.00 [ -98.04, 118.04 ]
4 At 18 months off training
Kriemler 2013 12 22 (163) 7 -83 (142) 105.00 [ -34.90, 244.90 ]
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Analysis 2.16. Comparison 2 Anaerobic training versus no physical training, Outcome 16 Change in
moderate to vigorous physical activity (hours per week).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 16 Change in moderate to vigorous physical activity (hours per week)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 13 -1.1 (1.8) 9 0.3 (1.8) -1.40 [ -2.93, 0.13 ]
2 At 6 months
Kriemler 2013 14 -0.4 (1.2) 8 -0.6 (2.4) 0.20 [ -1.58, 1.98 ]
3 At 6 months off training
Kriemler 2013 14 -1.5 (1.8) 8 -0.4 (1.6) -1.10 [ -2.56, 0.36 ]
4 At 18 months off training
Kriemler 2013 12 0.3 (3) 7 -0.8 (1.3) 1.10 [ -0.85, 3.05 ]
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Analysis 2.17. Comparison 2 Anaerobic training versus no physical training, Outcome 17 Change in physical
activity (MJ/day).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 17 Change in physical activity (MJ/day)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 18 12.27 (2.2) 16 11.62 (2.29) 0.65 [ -0.86, 2.16 ]
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Analysis 2.18. Comparison 2 Anaerobic training versus no physical training, Outcome 18 Change in weight
(kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 18 Change in weight (kg)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 2.76 (0.7) 22 1.03 (0.58) 1.73 [ 1.35, 2.11 ]
2 At 1 month after discharge
Selvadurai 2002 22 2.65 (0.73) 22 1 (0.66) 1.65 [ 1.24, 2.06 ]
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Analysis 2.19. Comparison 2 Anaerobic training versus no physical training, Outcome 19 Change in BMI
(kg/m2).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 19 Change in BMI (kg/m
2
)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 15 0.2 (0.6) 10 -0.3 (0.5) 0.50 [ 0.07, 0.93 ]
2 At 6 months
Kriemler 2013 15 0.3 (0.6) 10 -0.4 (0.5) 0.70 [ 0.27, 1.13 ]
3 At 6 months off training
Kriemler 2013 15 0.7 (1) 8 -0.4 (0.6) 1.10 [ 0.45, 1.75 ]
4 At 18 months off training
Kriemler 2013 12 0.9 (1.3) 8 -0.4 (0.9) 1.30 [ 0.34, 2.26 ]
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Analysis 2.20. Comparison 2 Anaerobic training versus no physical training, Outcome 20 Change in fat-free
mass (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 20 Change in fat-free mass (kg)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At hospital discharge
Selvadurai 2002 22 2.4 (0.46) 22 0.6 (0.32) 1.80 [ 1.57, 2.03 ]
2 At 3 months
Kriemler 2013 11 0.7 (1.6) 10 0 (0.7) 0.70 [ -0.34, 1.74 ]
3 At 6 months
Kriemler 2013 11 0.8 (1.5) 10 -0.7 (1.8) 1.50 [ 0.08, 2.92 ]
4 At 1 month after discharge
Selvadurai 2002 22 2.36 (0.47) 22 0.65 (0.36) 1.71 [ 1.46, 1.96 ]
5 At 6 months off training
Kriemler 2013 11 0.8 (2.6) 8 -1.2 (1.5) 2.00 [ 0.14, 3.86 ]
6 At 18 months off training
Kriemler 2013 11 2 (3.3) 8 -1.2 (1.4) 3.20 [ 1.02, 5.38 ]
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Analysis 2.21. Comparison 2 Anaerobic training versus no physical training, Outcome 21 Change in body fat
(%).
Review: Physical exercise training for cystic fibrosis
Comparison: 2 Anaerobic training versus no physical training
Outcome: 21 Change in body fat (%)
Study or subgroup Anaerobic Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Kriemler 2013 11 0.2 (1.7) 10 -1 (1.7) 1.20 [ -0.26, 2.66 ]
2 At 6 months
Kriemler 2013 11 0.5 (2.5) 10 -0.3 (1.2) 0.80 [ -0.85, 2.45 ]
3 At 6 months off training
Kriemler 2013 11 2.2 (1.9) 8 0.5 (2.1) 1.70 [ -0.14, 3.54 ]
4 At 18 months off training
Kriemler 2013 11 1.8 (2.6) 8 0.7 (3.3) 1.10 [ -1.65, 3.85 ]
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Analysis 3.1. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
1 Change in VO2 peak during maximal exercise (ml/min per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 1 Change in VO2 peak during maximal exercise (ml/min per kg BW)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -2.1291667 (1.42954146) -2.13 [ -4.93, 0.67 ]
2 At 3 - 6 months
Hebestreit 2010 2.04 (1) 2.04 [ 0.08, 4.00 ]
3 At 6 months off training
Hebestreit 2010 0.7 (1.18) 0.70 [ -1.61, 3.01 ]
4 At 12 - 18 months off training
Hebestreit 2010 3.73 (1.23) 3.73 [ 1.32, 6.14 ]
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Analysis 3.2. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
2 Change in FEV1 (% predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 2 Change in FEV1 (% predicted)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 8 -1.25 (4.0620192) 6 -0.5 (4.9699095) -0.75 [ -5.62, 4.12 ]
2 At 3 months
Rovedder 2014 19 -6 (16.1) 22 -2 (7.3) -4.00 [ -11.86, 3.86 ]
3 At 3 - 6 months
Hebestreit 2010 22 -2.1 (8.4) 13 -4.1 (11.8) 2.00 [ -5.31, 9.31 ]
4 At 6 months off training
Hebestreit 2010 18 -6 (12.5) 12 -4.9 (8.7) -1.10 [ -8.69, 6.49 ]
5 At 12 - 18 months off training
Hebestreit 2010 20 -5.5 (10.1) 13 -9.1 (12.2) 3.60 [ -4.37, 11.57 ]
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Analysis 3.3. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
3 Annual change in FEV1 (mL).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 3 Annual change in FEV1 (mL)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 months
Moorcroft 2004 107 (92.34) 107.00 [ -73.98, 287.98 ]
-500 -250 0 250 500
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Analysis 3.4. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
4 Change in subjective health perception (CFQ-R).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 4 Change in subjective health perception (CFQ-R)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 9.91 (4.6) 9.91 [ 0.89, 18.93 ]
2 At 6 months off training
Hebestreit 2010 -2.31 (6.71) -2.31 [ -15.46, 10.84 ]
3 At 12 - 18 months off training
Hebestreit 2010 9.89 (4.72) 9.89 [ 0.64, 19.14 ]
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Analysis 3.5. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
5 Change in Quality of Life: CFQ-R.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 5 Change in Quality of Life: CFQ-R
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical Functioning at 12 weeks
Beaudoin 2017 8 1.625 (1.767767) 6 1.67 (5.1639778) -0.04 [ -4.35, 4.27 ]
2 Vitality at 12 weeks
Beaudoin 2017 8 0.375 (1.3024702) 6 0 (0.8944272) 0.38 [ -0.78, 1.53 ]
3 Emotional state at 12 weeks
Beaudoin 2017 8 -1 (1.4142136) 6 0.17 (1.602082) -1.17 [ -2.78, 0.45 ]
4 Eating disturbances at 12 weeks
Beaudoin 2017 8 -0.125 (0.3535534) 6 0 (0) Not estimable
5 Treatment burden at 12 weeks
Beaudoin 2017 8 -0.5 (1.7728105) 6 0 (1.4142136) -0.50 [ -2.17, 1.17 ]
6 Health perception at 12 weeks
Beaudoin 2017 8 1 (1.5118579) 6 1.5 (1.2247449) -0.50 [ -1.93, 0.93 ]
7 Social limitations at 12 weeks
Beaudoin 2017 8 -0.875 (2.3566017) 6 0.5 (1.2247449) -1.38 [ -3.28, 0.53 ]
8 Body image at 12 weeks
Beaudoin 2017 8 -0.375 (0.9161254) 6 0.17 (1.4719601) -0.54 [ -1.88, 0.80 ]
9 Role limitations at 12 weeks
Beaudoin 2017 8 -0.125 (1.9594095) 6 -0.67 (1.2110601) 0.54 [ -1.13, 2.21 ]
10 Weight problems at 12 weeks
Beaudoin 2017 8 -0.25 (0.8864053) 6 0 (0) Not estimable
11 Respiratory symptoms at 12 weeks
Beaudoin 2017 8 0.25 (3.105295) 6 0.83 (2.4832774) -0.58 [ -3.51, 2.35 ]
12 Digestion symptoms at 12 weeks
Beaudoin 2017 8 0.5 (0.9258201) 6 -0.83 (2.1369761) 1.33 [ -0.49, 3.16 ]
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Analysis 3.6. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
6 Change in peak power during WAnT (W per kg body weight).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 6 Change in peak power during WAnT (W per kg body weight)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 22 -0.26 (0.95) 14 0.18 (0.7) -0.44 [ -0.98, 0.10 ]
2 At 6 months off training
Hebestreit 2010 18 0.16 (2.39) 12 0.59 (2.52) -0.43 [ -2.23, 1.37 ]
3 At 12 - 18 months off training
Hebestreit 2010 19 0.72 (1.96) 13 0.35 (0.99) 0.37 [ -0.66, 1.40 ]
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Analysis 3.7. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
7 Change in mean power during WAnT (W per kg body weight).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 7 Change in mean power during WAnT (W per kg body weight)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 22 -0.28 (0.65) 14 -0.06 (0.46) -0.22 [ -0.58, 0.14 ]
2 At 6 months off training
Hebestreit 2010 18 -0.22 (0.84) 12 -0.14 (1.36) -0.08 [ -0.94, 0.78 ]
3 At 12 - 18 months off training
Hebestreit 2010 19 -0.18 (0.67) 13 -0.35 (0.75) 0.17 [ -0.34, 0.68 ]
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Analysis 3.8. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
8 Change in muscle strength (all limbs) (1RM test).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 8 Change in muscle strength (all limbs) (1RM test)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Right upper limb at 3 months
Rovedder 2014 19 1 (1.7) 22 0 (0.9) 1.00 [ 0.15, 1.85 ]
2 Left upper limb at 3 months
Rovedder 2014 19 1.2 (2.2) 22 -0.2 (1) 1.40 [ 0.33, 2.47 ]
3 Right lower limb at 3 months
Rovedder 2014 19 2.1 (2) 22 1 (3.2) 1.10 [ -0.51, 2.71 ]
4 Left lower limb at 3 months
Rovedder 2014 19 2.4 (1.9) 22 0.8 (2.8) 1.60 [ 0.15, 3.05 ]
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Analysis 3.9. Comparison 3 Combined aerobic and anaerobic training versus no physical training, Outcome
9 Change in muscular strength - leg press (kg; 1 RM test).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 9 Change in muscular strength - leg press (kg; 1 RM test)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 33.2625 (32.9724533) 8 6 14 (16.9989411) 19.26 [ -7.33, 45.85 ]
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Analysis 3.10. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 10 Change in Muscular Strength - Chest press (kg; 1 RM test).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 10 Change in Muscular Strength - Chest press (kg; 1 RM test)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 8 6.7875 (8.1723292) 6 3.65 (8.3753806) 3.14 [ -5.64, 11.91 ]
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Analysis 3.11. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 11 Change in Muscular Strength - Latpull down (kg; 1 RM test).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 11 Change in Muscular Strength - Latpull down (kg; 1 RM test)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 8 2.85 (6.2953498) 6 0.9 (2.359661) 1.95 [ -2.80, 6.70 ]
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Analysis 3.12. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 12 Change in Muscular Strength - Biceps curl (kg; RM test).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 12 Change in Muscular Strength - Biceps curl (kg; RM test)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 8 1.2125 (1.9995982) 5 2.3 (1.8261982) -1.09 [ -3.20, 1.03 ]
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Analysis 3.13. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 13 Change in Muscular Endurance - Number of push ups.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 13 Change in Muscular Endurance - Number of push ups
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 9.4285714 (10.517559) 7 4 2.25 (3.5939764) 7.18 [ -1.37, 15.73 ]
-100 -50 0 50 100
Favours No Physical Training Favours Combined Training
142Physical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.14. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 14 Change in Muscular Endurance - Number of sit ups.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 14 Change in Muscular Endurance - Number of sit ups
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 4.5714286 (9.1807252) 7 6 -1.5 (6.0249481) 6.07 [ -2.26, 14.41 ]
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Analysis 3.15. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 15 Change in Muscular Endurance - Flexibility (cm).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 15 Change in Muscular Endurance - Flexibility (cm)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -3.4285714 (18.3312769) 7 6 -1.47 (2.0314199) -1.96 [ -15.64, 11.71 ]
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Analysis 3.16. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 16 Change in Muscular Endurance - hand grip strength (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 16 Change in Muscular Endurance - hand grip strength (kg)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -6.125 (15.1510254) 8 5 -0.2 (7.8549348) -5.93 [ -18.48, 6.63 ]
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Analysis 3.17. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 17 Change in peak work capacity during maximal exercise (W per kg BW).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 17 Change in peak work capacity during maximal exercise (W per kg BW)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 0.25 (0.11) 0.25 [ 0.03, 0.47 ]
2 At 6 months off training
Hebestreit 2010 0.19 (0.11) 0.19 [ -0.03, 0.41 ]
3 At 12 - 18 months off training
Hebestreit 2010 0.37 (0.11) 0.37 [ 0.15, 0.59 ]
-1 -0.5 0 0.5 1
Favours No Physical Training Favours Combined Training
Analysis 3.18. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 18 Change in functional exercise capacity.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 18 Change in functional exercise capacity
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6MWT distance (m) at 3 months
Rovedder 2014 19 -7 (39.8) 22 -6.2 (37.5) -0.80 [ -24.59, 22.99 ]
2 6MWT distance (% predicted) at 3 months
Rovedder 2014 19 -1.2 (5.9) 22 -3.1 (9.9) 1.90 [ -3.01, 6.81 ]
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Analysis 3.19. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 19 Change in peak heart rate during 6MWT (beats/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 19 Change in peak heart rate during 6MWT (beats/min)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Rovedder 2014 19 -0.4 (20.7) 22 -5.1 (24.6) 4.70 [ -9.17, 18.57 ]
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Analysis 3.20. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 20 Annual change in peak heart rate (beat/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 20 Annual change in peak heart rate (beat/min)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 -8.2 (3.78) -8.20 [ -15.61, -0.79 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 -1.4 (4.49) -1.40 [ -10.20, 7.40 ]
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Analysis 3.21. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 21 Annual change in VE (L/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 21 Annual change in VE (L/min)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 -2.5 (1.84) -2.50 [ -6.11, 1.11 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 -3.3 (1.58) -3.30 [ -6.40, -0.20 ]
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Analysis 3.22. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 22 Change in peak ventilation (VE) during maximal exercise.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 22 Change in peak ventilation (VE) during maximal exercise
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -0.8125 (10.6988274) 8 6 5.93 (9.4852299) -6.74 [ -17.35, 3.87 ]
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Analysis 3.23. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 23 Annual change in lactate (mmol/l).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 23 Annual change in lactate (mmol/l)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 -0.83 (0.36) -0.83 [ -1.54, -0.12 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 -0.32 (0.42) -0.32 [ -1.14, 0.50 ]
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Analysis 3.24. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 24 Change in RR during 6MWT (breaths/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 24 Change in RR during 6MWT (breaths/min)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Rovedder 2014 19 -0.3 (5) 22 0.7 (9.5) -1.00 [ -5.56, 3.56 ]
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Analysis 3.25. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 25 Annual change in RR (breaths/min).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 25 Annual change in RR (breaths/min)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 -0.8 (2.09) -0.80 [ -4.90, 3.30 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 1.5 (2.35) 1.50 [ -3.11, 6.11 ]
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Analysis 3.26. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 26 Annual change in RER.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 26 Annual change in RER
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 0.02 (0.02) 0.02 [ -0.02, 0.06 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 0 (0.02) 0.0 [ -0.04, 0.04 ]
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Analysis 3.27. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 27 Change in oxygen saturation (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 27 Change in oxygen saturation (%)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At rest (at 3 months)
Rovedder 2014 19 -0.1 (1.3) 22 -1 (2.1) 0.90 [ -0.15, 1.95 ]
2 During 6MWT (at 3 months)
Rovedder 2014 19 1.3 (5.4) 22 -1.3 (2.9) 2.60 [ -0.11, 5.31 ]
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Analysis 3.28. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 28 Change in Borg breathlessness score.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 28 Change in Borg breathlessness score
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At rest (at 3 months)
Rovedder 2014 19 0.1 (0.4) 22 0.1 (0.8) 0.0 [ -0.38, 0.38 ]
2 During 6MWT (at 3 months)
Rovedder 2014 19 -0.4 (2.1) 22 -0.3 (1.8) -0.10 [ -1.31, 1.11 ]
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Analysis 3.29. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 29 Annual change in Borg breathlessness score.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 29 Annual change in Borg breathlessness score
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 0 (0.51) 0.0 [ -1.00, 1.00 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 -0.9 (0.51) -0.90 [ -1.90, 0.10 ]
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Analysis 3.30. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 30 Change in Borg fatigue score.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 30 Change in Borg fatigue score
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At rest (at 3 months)
Rovedder 2014 19 0.02 (0.8) 22 0 (0.9) 0.02 [ -0.50, 0.54 ]
2 During 6MWT (at 3 months)
Rovedder 2014 19 -0.9 (2.6) 22 -0.3 (1.2) -0.60 [ -1.87, 0.67 ]
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Analysis 3.31. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 31 Annual change in Borg muscle effort.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 31 Annual change in Borg muscle effort
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Constant load bicycle ergometry (at 1 year)
Moorcroft 2004 -0.3 (0.61) -0.30 [ -1.50, 0.90 ]
2 Constant load arm ergometry (at 1 year)
Moorcroft 2004 0.3 (0.66) 0.30 [ -0.99, 1.59 ]
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Analysis 3.32. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 32 Change in FVC (% predicted).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 32 Change in FVC (% predicted)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 3.29166667 (3.90382266) 3.29 [ -4.36, 10.94 ]
2 At 3 months
Rovedder 2014 -3.3 (4.3) -3.30 [ -11.73, 5.13 ]
3 At 3 - 6 months
Hebestreit 2010 0.5 (2.45) 0.50 [ -4.30, 5.30 ]
4 At 6 months off training
Hebestreit 2010 2.71 (3.61) 2.71 [ -4.37, 9.79 ]
5 At 12 - 18 months off training
Hebestreit 2010 6.06 (2.87) 6.06 [ 0.43, 11.69 ]
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Analysis 3.33. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 33 Annual change in FVC (mL).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 33 Annual change in FVC (mL)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 year
Moorcroft 2004 213 (107.14) 213.00 [ 3.01, 422.99 ]
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Analysis 3.34. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 34 Change in RV/TLC (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 34 Change in RV/TLC (%)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 22 1.7 (10.8) 13 2.6 (6.8) -0.90 [ -6.73, 4.93 ]
2 At 6 months off training
Hebestreit 2010 18 1.5 (12.2) 12 3.7 (12.7) -2.20 [ -11.33, 6.93 ]
3 At 12 - 18 months off training
Hebestreit 2010 20 2.2 (11.2) 13 7.1 (13.4) -4.90 [ -13.68, 3.88 ]
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Analysis 3.35. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 35 Change in Total Energy Expenditure (k/cal).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 35 Change in Total Energy Expenditure (k/cal)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -57.75 (224.277093) 8 6 51.17 (246.784454) -108.92 [ -360.20, 142.37 ]
-200 -100 0 100 200
Favours No Physical Training Favours Combined Training
Analysis 3.36. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 36 Change in the Number of Steps.
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 36 Change in the Number of Steps
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -181.25 (2216.17597) 8 6 -70.67 (1880.76534) -110.58 [ -2260.72, 2039.56 ]
-1000 -500 0 500 1000
Favours No Physical Training Favours Combined Training
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Analysis 3.37. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 37 Change in Physical Activity (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 37 Change in Physical Activity (%)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 8 10.775 (7.8683362) 6 -9.08 (21.3615933) 19.86 [ 1.92, 37.80 ]
-100 -50 0 50 100
Favours No Physical Training Favours Combined Training
Analysis 3.38. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 38 Change in vigorous physical activity (hours per week).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 38 Change in vigorous physical activity (hours per week)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 - 6 months
Hebestreit 2010 1.05 (0.87) 1.05 [ -0.66, 2.76 ]
2 At 6 months off training
Hebestreit 2010 2.08 (2) 2.08 [ -1.84, 6.00 ]
3 At 12 - 18 months off training
Hebestreit 2010 1.63 (0.82) 1.63 [ 0.02, 3.24 ]
-10 -5 0 5 10
Favours No Physical Training Favours Combined Training
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Analysis 3.39. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 39 Change in body weight (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 39 Change in body weight (kg)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -0.19375 (1.0155778) 8 6 0.07 (1.6397886) -0.27 [ -1.76, 1.22 ]
2 At 3 - 6 months
Hebestreit 2010 22 1.1 (1.8) 15 0 (2.6) 1.10 [ -0.42, 2.62 ]
3 At 6 months off training
Hebestreit 2010 19 1.5 (4) 12 1.3 (3.6) 0.20 [ -2.52, 2.92 ]
4 At 12 - 18 months off training
Hebestreit 2010 20 1.8 (6) 13 1.8 (5) 0.0 [ -3.78, 3.78 ]
-10 -5 0 5 10
Favours No Physical Training Favours Combined Training
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Analysis 3.40. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 40 Change in BMI (kg/m2).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 40 Change in BMI (kg/m
2
)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 0.0975 (0.36056214) 0.10 [ -0.61, 0.80 ]
2 At 3 - 6 months
Hebestreit 2010 0.4 (0.29) 0.40 [ -0.17, 0.97 ]
3 Annual change
Moorcroft 2004 0.54 (0.32) 0.54 [ -0.09, 1.17 ]
4 At 6 months off training
Hebestreit 2010 0 (0.4) 0.0 [ -0.78, 0.78 ]
5 At 12 - 18 months off training
Hebestreit 2010 -0.1 (0.52) -0.10 [ -1.12, 0.92 ]
-2 -1 0 1 2
Favours No Physical Training Favours Combined Training
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Analysis 3.41. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 41 Change in sum of four skinfolds (mm).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 41 Change in sum of four skinfolds (mm)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3-6 months
Hebestreit 2010 -1.19 (1.92) -1.19 [ -4.95, 2.57 ]
2 At 6 months off training
Hebestreit 2010 -5.68 (2.63) -5.68 [ -10.83, -0.53 ]
3 At 12-18 months off training
Hebestreit 2010 -7.1 (3.2) -7.10 [ -13.37, -0.83 ]
-20 -10 0 10 20
Favours No Physical Training Favours Combined Training
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Analysis 3.42. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 42 Change in body fat (%).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 42 Change in body fat (%)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -1.2125 (0.59535029) -1.21 [ -2.38, -0.05 ]
2 At 3 - 6 months
Hebestreit 2010 1.3 (1.86) 1.30 [ -2.35, 4.95 ]
3 At 6 months off training
Hebestreit 2010 -0.5 (2.18) -0.50 [ -4.77, 3.77 ]
4 At 12 - 18 months off training
Hebestreit 2010 2.2 (3.11) 2.20 [ -3.90, 8.30 ]
-10 -5 0 5 10
Favours Combined Training Favours No Physical Training
Analysis 3.43. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 43 Change in fat-mass (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 43 Change in fat-mass (kg)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -0.166875 (0.7830502) 8 6 0.93 (0.5642264) -1.09 [ -1.80, -0.39 ]
-4 -2 0 2 4
Favours Combined Training Favours No Physical Training
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Analysis 3.44. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 44 Change in fat-free mass (kg).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 44 Change in fat-free mass (kg)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -0.05425 (1.2397642) 8 6 0.09 (1.3893653) -0.15 [ -1.55, 1.26 ]
2 At 3 - 6 months
Hebestreit 2010 20 0.3 (9.2) 13 -0.6 (7.3) 0.90 [ -4.76, 6.56 ]
3 At 6 months off training
Hebestreit 2010 17 2 (3.7) 8 1.3 (3.1) 0.70 [ -2.08, 3.48 ]
4 At 12 - 18 months off training
Hebestreit 2010 17 -1.9 (9.6) 12 -0.5 (5.3) -1.40 [ -6.86, 4.06 ]
-20 -10 0 10 20
Favours No Physical Training Favours Combined Training
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Analysis 3.45. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 45 Change in metabolic parameters (HbA1c (%)).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 45 Change in metabolic parameters (HbA1c (%))
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -0.000875 (0.0021671) 8 4 0 (0.0023805) 0.00 [ -0.01, 0.00 ]
-0.01 -0.01 0 0.01 0.01
Favours Combined Training Favours No Physical Training
Analysis 3.46. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 46 Change in metabolic parameters (Glucose AUC).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 46 Change in metabolic parameters (Glucose AUC)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -5.46375 (5.1223626) 8 6 0.13 (8.8479484) -5.59 [ -13.51, 2.33 ]
-20 -10 0 10 20
Favours Combined Training Favours No Physical Training
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Analysis 3.47. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 47 Change in metabolic parameters (Total Insulin AUC).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 47 Change in metabolic parameters (Total Insulin AUC)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 -8.2157143 (33.5157803) 8 6 11.81 (29.0755983) -20.02 [ -52.90, 12.85 ]
-100 -50 0 50 100
Favours Combined Training Favours No Physical Training
Analysis 3.48. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 48 Change in metabolic parameters (Insulin Sensitivity Index).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 48 Change in metabolic parameters (Insulin Sensitivity Index)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 weeks
Beaudoin 2017 0.0158657 (0.0168878) 8 6 -0.01 (0.0204161) 0.02 [ 0.00, 0.04 ]
-0.1 -0.05 0 0.05 0.1
Favours No Physical Training Favours Combined Training
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Analysis 3.49. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 49 Change in Plasma Glucose (mmol/L).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 49 Change in Plasma Glucose (mmol/L)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 0 minutes
Beaudoin 2017 8 0.00688 (0.494866) 6 -0.43 (0.959988) 0.44 [ -0.41, 1.28 ]
2 After 30 minutes
Beaudoin 2017 -1.747143 (1.585357) 7 6 0.21 (1.407727) -1.96 [ -3.58, -0.33 ]
3 After 60 minutes
Beaudoin 2017 7 -1.79 (1.662117) 6 0.07 (2.360004) -1.86 [ -4.11, 0.40 ]
4 After 90 minutes
Beaudoin 2017 -2.074286 (1.144871) 7 6 -0.38 (4.11534) -1.69 [ -5.09, 1.71 ]
5 After 120 minutes
Beaudoin 2017 -2.34125 (1.258371) 8 6 0.9 (3.816525) -3.24 [ -6.41, -0.06 ]
-4 -2 0 2 4
Favours Combined Training Favours No Physical Training
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Analysis 3.50. Comparison 3 Combined aerobic and anaerobic training versus no physical training,
Outcome 50 Change in Plasma Insulin (µU/mL).
Review: Physical exercise training for cystic fibrosis
Comparison: 3 Combined aerobic and anaerobic training versus no physical training
Outcome: 50 Change in Plasma Insulin ( U/mL)
Study or subgroup Combined Training No Physical Training
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 0 minutes
Beaudoin 2017 -0.377143 (1.371631) 7 6 1.72 (4.001887) -2.10 [ -5.46, 1.26 ]
2 After 30 minutes
Beaudoin 2017 -6.120286 (4.26804) 7 6 7.78 (5.728133) -13.90 [ -19.47, -8.33 ]
3 After 60 minutes
Beaudoin 2017 -4.277714 (6.741404) 7 6 8.12 (10.45679) -12.39 [ -22.14, -2.65 ]
4 After 90 minutes
Beaudoin 2017 7 3.01829 (22.92715) 6 -3.18 (19.84514) 6.20 [ -17.05, 29.45 ]
5 After 120 minutes
Beaudoin 2017 -1.291143 (13.68341) 7 6 -3.52 (15.81846) 2.23 [ -13.98, 18.45 ]
-20 -10 0 10 20
Favours Combined Training Favours No Physical Training
A D D I T I O N A L T A B L E S
Table 1. Study results for Santana-Sosa 2012
Variable Group Pre-training Post-training Detraining P value (group x
time)
Comments
Age (mean (SE))
years
Intervention 11 (3) - - -
Control 10 (2) - - -
Sex (% boys) Intervention 55 - - -
Control 64 - - -
VO2 peak (mean
(95% CI)) ml/
min per kg body
weight
Intervention n.a. 3.9 (1.8 to 6.1) -3.4 (-5.7 to 1.7) 0.036 Significantly
higher in controls
at baseline (P = 0.
023).
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Table 1. Study results for Santana-Sosa 2012 (Continued)
Data were pre-
sented in a fig-
ure in the original
publication.
Control n.a. -2.2 (-5.3 to 0.1) -0.7 (-4.4 to 5.9)
Leg press (mean
(95% CI)) kg
Intervention n.a. 24.9 (14.3 to 34.
4)
-1.0 (-4.1 to 3.3) < 0.001 Data are reported
in a figure in the
original publica-
tion.
Significantly
higher in controls
at baseline (P = 0.
014).Control n.a. n.a. n.a.
Bench press
(mean (95% CI)
) kg
Intervention n.a. 10.5 (7.0 to 14.0) -1.2 (-3.6 to 3.0) < 0.001 Significantly
higher in controls
at baseline (P = 0.
007).
Data presented in
a figure in the
original publica-
tion.Control n.a. n.a. n.a.
Seated row
(mean (95% CI)
) kg
Intervention n.a. 12.7 (9.2 to 16.0) -0.2 (-3.6 to 3.2) < 0.001 Significantly
higher in controls
at baseline (P = 0.
009).
Data presented in
a figure in the
original publica-
tion.Control n.a. n.a. n.a.
Oxygen satura-
tion at peak exer-
cise (mean (SE))
Intervention 94.9 (0.9)% 95.6 (0.8)% 94.5 (1.2)% n.a.
Control 95.7 (0.5)% 96.4 (0.4)% 96.1 (0.5)%
FEV1 (mean
(SE)) litres
Intervention 1.87 (0.24) 1.94 (0.23) 1.90 (0.25) 0.769
Control 1.77 (0.17) 1.87 (0.15) 1.79 (0.19)
FVC (mean (SE)
) litres
Intervention 2.41 (0.24) 2.49 (0.25) 2.56 (0.29) 0.920
Control 2.29 (0.19) 2.36 (0.20) 2.40 (0.24)
PImax (mean
(SE)) cm H2O
Intervention 64.0 (5.5) 69.8 (6.8) 75.2 (6.2) 0.797
Control 61.5 (6.9) 72.2 (7.2) 76.4 (7.5)
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Table 1. Study results for Santana-Sosa 2012 (Continued)
HRQoL score -
children’s report
(median (range))
Intervention 696 (495 - 741) 719 (550 - 734) - 0.257 HRQoL was as-
sessed before and
after the interven-
tion.
P value for com-
parison pre versus
post-training.Control 649 (578 - 768) 638 (461 - 791) -
HRQoL score
- parents’ report
(median (range))
Intervention 896 (688-1011) 889 (811 - 973) - 0.143 HRQoL was as-
sessed before and
after the interven-
tion.Control 911 (842 - 1028) 978 (684 - 1059) -
Weight (mean
(SE)) kg
Intervention 39.9 (3.5) 40.5 (3.4) 41.4 (3.4) 0.723
Control 34.0 (2.6) 35.1 (2.8) 36.2 (3.0)
BMI (mean (SE)
) kg/m²
Intervention 18.4 (1.0) 18.3 (0.7) 18.5 (0.7) 0.959
Control 17.2 (0.8) 17.1 (0.8) 17.4 (0.9)
Fat-free mass
(mean (SE)) %
Intervention 78.1 (2.7) 79.4 (2.8) 78.8 (2.9) 0.115
Control 81.1 (2.5) 80.9 (2.1) 81.1 (2.2)
Body fat (mean
(SE)) %
Intervention 21.9 (2.7) 20.6 (2.8) 21.2 (2.9) 0.115
Control 18.9 (2.5) 19.1 (2.1) 18.9 (2.2)
Compliance
with
physical training
(mean (SE)) %
Intervention - 95.1 (7.4) - -
-
73%
of children com-
pleted all training
sessions.Control - - -
Adverse effects Intervention - - - - No adverse effects
occurred during
training or maxi-
mal exercise test-
ingControl - - -
BMI: body mass index
CI: confidence interval
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
HRQoL: health-related quality of life
n.a.: not applicable
PImax : maximum inspiratory mouth pressure
SE: standard error
VO2 peak: peak oxygen consumption
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Table 2. Study results for Santana-Sosa 2014
Variable Group Pre-training Post-training Detraining P value (group x
time)
Comments
Age (mean (SE))
years
Intervention 11 (1) - - -
Control 10 (1) - - -
Sex (% boys) Intervention 60 - - -
Control 60 - - -
VO2 peak (mean
(95% CI) ml/
min per kg body
weight
Intervention n.a. 6.9 (3.4 to 10.5) -1.5 (-2.7 to -0.4) < 0.001 Significantly
higher in controls
at baseline (P = 0.
034).Control n.a. n.a. n.a.
Leg press (mean
(SE)) kg
Intervention 62.5 (6.5) 89.5 (9.3) 88.6 (9.2) < 0.001 Significantly
higher in controls
at baseline (P = 0.
046).Control 45.2 (4.7) 43.9 (5.1) 43.9 (5.4)
Bench press
(mean (SE)) kg
Intervention 26.4 (2.7) 38.4 (3.2) 35.9 (2.9) < 0.001
Control 23.2 (2.9) 21.6 (3.2) 21.7 (3.6)
Lateral row
(mean (SE)) kg
Intervention 30.5 (3.6) 43.0 (4.2) 35.9 (2.9) < 0.001
Control 23.2 (3.0) 22.0 (3.1) 21.7 (3.6)
Oxygen satura-
tion at peak exer-
cise (mean (SE))
%
Intervention 94.7 (0.7) 94.5 (0.7) 93.1 (0.8) n.a.
Control 96.4 (0.4) 96.2 (0.5) 96.1 (0.6)
FEV1 (mean
(SE)) L
Intervention 1.65 (0.19) 1.74 (0.23) 1.69 (0.24) 0.486
Control 1.57 (0.26) 1.55 (0.26) 1.59 (0.26)
FVC (mean (SE)
) L
Intervention 2.23 (0.27) 2.34 (0.29) 2.28 (0.28) 0.156
Control 1.90 (0.33) 1.85 (0.32) 1.92 (0.32)
PImax (mean
(SE)) cm H2O
Intervention 68.3 (6.3) 107.6 (8.4) 103.2 (8.1) < 0.001
Control 69.5 (9.7) 71.8 (10.0) 66.7 (9.4)
HRQoL score
(median (min -
max))
Intervention 629 (505 - 701) 688 (609 - 791) - 0.071 HRQoL was as-
sessed before and
after the interven-
tion.
168Physical exercise training for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Study results for Santana-Sosa 2014 (Continued)
Control 636 (626 - 745) 638 (626 - 737) -
Weight (mean
(SE)) kg
Intervention 36.4 (3.1) 37.8 (3.2) 38.3 (3.1) 0.342
Control 31.5 (4.6) 32.4 (4.7) 32.7 (4.5)
Fat-free
mass (mean (SE)
) % of total
Intervention 81.6 (1.3) 82.6 (1.0) 82.5 (1.0) 0.001
Control 82.9 (1.8) 82.8 (1.8) 82.5 (1.9)
Body fat (mean
(SE)) % of total
Intervention 18.4 (1.3) 17.4 (1.2) 17.5 (1.1) 0.023
Control 17.1 (1.8) 17.2 (1.8) 17.5 (1.9)
Compliance
with
physical training
(mean (SE)) %
Intervention - 97.5 (1.7) - 70%
of children com-
pleted all training
sessions.Control - - -
Adverse effects Intervention - - - No adverse effects
occurred
during training or
exercise testingControl - - -
CI: confidence interval
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
HRQoL: health-related quality of life
n.a.: not applicable
PImax : maximum inspiratory mouth pressure
SE: standard error
VO2 peak: peak oxygen consumption
Table 3. HRQoL results for Rovedder 2014
Health-related quality of life Exercise group (n = 19) Control group (n = 22) P value
HRQoL scale - physical (me-
dian (interquartile range))
6.1 (-4 to 8) 2.4 (-10 to 13) 0.742
HRQoL scale - body image
(median (interquartile range))
3.3 (-11 to 22) 3.0 (-2 to 11) 0.915
HRQoL scale - digestive (me-
dian (interquartile range))
-1.0 (-4 to 0) -0.5 (0 to 0) 0.953
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Table 3. HRQoL results for Rovedder 2014 (Continued)
HRQoL scale - respiratory (me-
dian (interquartile range))
3.8 (0 to 11) -4.7 (-1 to 7) 0.925
HRQoL scale - emotional (me-
dian (interquartile range))
1.2 (-6 to 6) -4.3 (-13 to 6) 0.458
HRQoL scale - social (median
(interquartile range))
-1.1 (-11 to 5) -1.7 (-5 to 11) 0.822
HRQoL scale - food (median
(interquartile range))
-0.3 (-11 to 6) -2.0 (-11 to 0) 0.913
HRQoL scale - treatment (me-
dian (interquartile range))
-2.0 (-11 to 0) -2.5 (-11 to 11) 0.850
HRQoL scale - vitality (median
(interquartile range))
-1.2 (-16 to 8) 2.6 (-8 to 10) 0.579
HRQoL scale - health (median
(interquartile range))
1.7 (-11 to 16) -3.0 (-11 to 0) 0.382
HRQoL scale - weight (median
(interquartile range))
4.6 (0 to 33) 12.1 (0 to 11) 0.410
HRQoL scale - social role (me-
dian (interquartile range))
0.8 (-8 to 8) 1.8 (-2 to 0) 0.935
SF-36 - functional capacity
(median (interquartile range))
2.8 (-10 to 15) 2.0 (-11 to 10) 0.916
SF-36 - physical aspects (me-
dian (interquartile range))
11.8 (-25 to 50) 6.8 (-6 to 31) 0.705
SF-36 - pain (mean (median
(interquartile range))
-7.2 (-28 to 11) 8.0 (7 to 17) 0.100
SF-36 - general health (median
(interquartile range))
3.7 (-5 to 10) -3.5 (-11 to 5) 0.197
SF-36 - vitality (median (in-
terquartile range))
1.2 (-15 to 20) 7.5 (-1 to 21) 0.416
SF-36 - social aspects (median
(interquartile range))
15.2 (0 to 33) 21.2 (0 to 66) 0.989
SF-36 - emotional aspects (me-
dian (interquartile range))
4.7 (-12 to 37) 4.5 (-12 to 25) 0.914
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Table 3. HRQoL results for Rovedder 2014 (Continued)
SF-36 - mental health (median
(interquartile range))
-0.8 (-12 to 12) 0.9 (-9 to 13) 0.752
Pre-post changes in HRQoL measured by the CFQ and the SF-36
CFQ: Cystic Fibrosis Questionnaire
HRQoL: health-related quality of life
SF-36: Medical Outcomes Study-36 Item Short-Form Health Survey
WH A T ’ S N E W
Last assessed as up-to-date: 19 October 2017.
Date Event Description
1 November 2017 Amended Formatting issues resolved
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2002
Date Event Description
19 October 2017 New citation required but conclusions have not
changed
Despite the inclusion of two new studies our conclu-
sions remain the same
19 October 2017 New search has been performed A search of the Cystic Fibrosis and Genetic Dis-
orders Review Group’s Cystic Fibrosis Trials Regis-
ter identified 38 new references which were poten-
tially eligible for inclusion in the review. There was
one additional reference to an already included study
(Schneiderman-Walker 2000) and six additional refer-
ences to five already excluded studies (Amelina 2006;
delCorralNunez-Flores 2011;Kuys 2011; Lima 2014;
Salonini 2015). Six references to two new studies has
been included (Beaudoin 2017; Douglas 2015) and
seven references to five new studies are listed as ’Await-
ing classification’ (Housinger 2015; Johnston 2004;
Lorenc 2015; Mandrusiak 2011; Oliveira 2010). One
studywith two references is ongoing (Hebestreit 2016)
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and a total of 16 references to 13 new studies have been
excluded (Bieli 2017; Bongers 2015; Calik-Kutukcu
2016; Chang 2015; Dwyer 2017; Giacomodonato
2015; Haynes 2016; Kriemler 2016; Ozaydin 2010;
Patterson 2004; Shaw 2016; Vallier 2016; Wheatley
2015).
A search of clinicaltrials.gov identified 11 addi-
tional studies. Five studies were added to ’Await-
ing classification’ (NCT00609050; NCT00792194;
NCT02552043; NCT03100214; NCT03109912)
, one study was added under ongoing studies (
NCT02700243) and five studies were excluded (
NCT02277860; NCT02715921; NCT02821130;
NCT03117764; NCT02875366).
A search of the WHO ICTRN identified three addi-
tional studies; one is listed as awaiting classification
(ACTRN12617001009303) and twohave been added
under ongoing studies (Donadio 2017; Gupta 2017).
From this update we have stated a minimum duration
of the intervention as being at least two weeks
15 June 2015 New citation required but conclusions have not
changed
Two authors from the original review have stepped
down at this update and a new team of authors have
taken on the review
The title of the reviewhas been changed from ’Physical
training for cystic fibrosis’ to ’Physical exercise train-
ing for cystic fibrosis’ as the new team felt this better
reflected the content of the review
Despite the inclusion of new studies and data in this
update of the review, the conclusions remain the same
15 June 2015 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders
Group’s Cystic Fibrosis Register identified 32 new ref-
erences which were potentially eligible for inclusion in
this review
Three new studies (one reference each) were included
(Rovedder 2014; Santana-Sosa 2012; Santana-Sosa
2014). Two studies previously listed as excluded have
been reassessed and moved to included studies with
two new references each (although one paper referred
to both studies) (Hebestreit 2010; Kriemler 2013).
One study has been moved from ’Awaiting classifica-
tion’ to included studies with an additional two refer-
ences (Hommerding 2015).
Onewas an additional reference to an already excluded
study (Kuys 2011).
A total of 14 new studies (20 references) were ex-
cluded (Alarie 2012; Amelina 2006; Asher 1982;
Balfour 1998; del Corral Nunez-Flores 2011; Dwyer
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2008; Gruet 2012; Lima 2014; Lowman 2012;
Petrovic 2013; Rand 2012; Reix 2012; Salonini 2015;
Vivodtzev 2013).
One study (one reference) has been listed as ’Awaiting
classification’ until we are able to obtain further infor-
mation (Almajan 2011).
22 May 2012 Amended Contact details updated.
7 March 2011 New search has been performed A total of two new references were identified in a search
of the Group’s CF Trials Register. One study was ex-
cluded as it compared Nintendo Wii exercise train-
ing to an existing exercise programme and hence did
not meet the inclusion criteria (Kuys 2011). The other
study did meet the inclusion criteria but outlined in
its abstract that recruitment was ongoing and for this
reason it has been listed as an ongoing study; results
will be included in the review once the study has been
completed (Phillips 2008a)
In addition some amendments were made to the Back-
ground in order to incorporate updated guidelines and
a relevant survey
19 January 2009 Amended The fourth primary outcome ’mortality’ was moved to
Secondary outcomes in line with Cochrane Collabo-
ration guidance to limit the number of primary out-
comes to three
5 January 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any references to trials which are po-
tentially eligible for inclusion in this review
12 November 2008 Amended Converted to new review format.
14 November 2007 Amended The generic inverse variance method has been used
to analyse data which were previously not able to be
presented in the ’Statistical Analysis’.
The ’Synopsis’ has been replaced by a new ’Plain Lan-
guage Summary’
14 November 2007 New search has been performed The search identified 11 new references. Of these, two
were additional references to already excluded stud-
ies (Albinni 2004; Edlund 1986). The remaining nine
studies did not fulfill the inclusion criteria; four of
these studies which seemed eligible from the title, have
been excluded on the basis of trial design and are
listed under ’Excluded studies’ (Acquino2006; Balestri
2004; Orenstein 2004; Stanghelle 1998).
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The study which was previously listed as ’Awaiting
assessment’ has been moved to the list of excluded
studies after correspondence with the study authors
(Hebestreit 2003)
13 November 2007 New citation required and conclusions have changed Substantive amendment
25 May 2005 New search has been performed A further article has been included (Klijn 2004).
The full paper of the trial by Moorcroft (Moorcroft
2004) has also been included. Following publication
of this paper, the details about the published abstracts
of this trial, previously listed in the ’Characteristics of
included studies’ table, under Dodd 1998 and Moor-
croft 2000 have been listed under Moorcroft 2004
We contacted authors of trials already included in the
review regarding confirmation of data and requests for
additional data. Their responses have been included in
section detailing the search strategy
One trial has been moved from the ’Studies awaiting
assessment’ section to the ’Excluded studies’ section of
the review (Tuzin 1998)
One trial has been added to the section ’Studies await-
ing assessment’ section (Hebestreit 2003). The authors
have been contacted and have indicated that this study
is in preparation for publication
31 July 2003 Amended The presentation of the data inMetaView has been re-
formatted
31 July 2003 New search has been performed The full paper of the Selvadurai trial has now been
included, previously only the abstract of this trial was
included in the review (Selvadurai 2002)
A further two trials added to the ’Excluded studies’
section of the review (Barry 2001; Kriemler 2001)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Post hoc changes for the 2017 update
Summary of findings tables have been added in line with Cochrane guidance.
It was stipulated that the duration of each included study duration should be at least two weeks, which is the typical length of (drug)
treatment for pulmonary exacerbations where people with CF may also take part in in-hospital exercise training. Moreover, from
an exercise physiology perspective, less than two weeks of structured exercise are unlikely to elicit meaningful changes in the chosen
outcomes measures.
We added the lung clearance index (LCI) derived from multiple-breath washout to secondary outcomes “4. Additional indices of
pulmonary function and respiratory muscle strength”. The LCI is a relatively new and much examined pulmonary function outcome
measure and included in many clinical studies including exercise training interventions.
We also added the diffusing capacity for carbon monoxide (DLCO) and the diffusing capacity for nitric oxide (DLNO) to secondary
outcomes “4. Additional indices of pulmonary function and respiratory muscle strength”. Non-invasive measurement of the pulmonary
diffusing capacity can provide novel physiological insights into the exercise training effects on pulmonary function beyond the much
examined FEV1, derived from spirometry.
Post hoc changes for the 2015 update
The title of the review has been changed from ’Physical training for cystic fibrosis’ to ’Physical exercise training for cystic fibrosis’ as
the new team felt this better reflected the content of the review.
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The fourth primary outcome ’mortality’ was moved to secondary outcomes in line with Cochrane guidance to limit the number of
primary outcomes to three. For this update, primary and secondary outcome measures were changed as follows:
Primary outcomes
We limited the primary outcome measures to:
1. Exercise capacity by peak oxygen uptake (VO2 peak)
2. Pulmonary function by forced expiratory volume in one second (FEV1)
3. Health-related quality of life (HRQoL).
In CF, VO2 peak and FEV1 are strong predictors of mortality, objectively measurable and are often used as primary outcomes in
studies of physical exercise training. The outcome measure HRQoL is important participant-reported outcome measure and is related
to physical fitness in people with CF. None of the other primary outcomes from previous reviews has been shown to be of predictive
value in CF and they should be considered explorative endpoints. All previous primary outcomes for pulmonary function are now
integrated under the secondary outcome number 4 “Additional indices of pulmonary function and respiratory muscle strength” and
exercise capacity variables including effort, oxygenation and fatigue are integrated into the secondary outcome number 3 “ Additional
indices of exercise capacity”.
Secondary outcomes
We removed the secondary outcomes “Symptom scores”, “Compliance with other treatment, such as chest physiotherapy, nutritional
regimens” and “Cost evaluation”. These outcomes are of unclear relevance, difficult to measure reliably and are rarely reported in
physical training studies. We added the secondary outcome “Physical activity” because it is an important outcome in exercise training
studies. The outcome “Measures of bone mineral density and diabetic control” was separated into “Bone health” and “Diabetic control”
because these outcomes are unrelated and should be studied and reported separately. The outcome “Weight” was removed as a separate
outcome and is now integrated within the outcome “Body composition” which comprises all measures of nutrition including body
weight, body fat and fat-free mass. The secondary outcome “Number of acute exacerbations, intravenous antibiotic courses and time
off work or school” was separated as “Acute exacerbations (a) number of exacerbations; (b) time to first exacerbation” and “Antibiotic
use (including oral, intravenous or inhaled antibiotics)”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Exercise Therapy; ∗Exercise Tolerance; Cystic Fibrosis [∗rehabilitation]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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